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Background: Oral cavity cancer (OCC) is the most frequent of all head and neck (HN) 
cancers, and has distinct survival outcomes compared to other sites. The oral tongue is the 
most common site of cancer in the oral cavity. About 90% of these are squamous cell 
carcinomas (SCC), and they can be very aggressive with a high mortality rate. The treatment 
of these cancers is based on the tumor (T), lymph node (N), and metastasis (M) classification, 
although tumors with the same TNM classification may act differently in aggressiveness. 
Treatment of oral cavity (OC)SCC is preferentially surgery when the tumor is regarded as 
resectable, with additional neck-dissection for many of them. For some patients, postsurgical 
radiotherapy (RT) is added, and chemotherapy can be used in a palliative setting. Today there 
are no established histopathological or molecular markers in use to differentiate between 
those who will benefit from additional neck-dissection, or RT, when no lymph node 
metastases primarily are suspected. Such additional markers would be useful for 
supplementing the commonly used TNM classification in treatment decisions. Objective: The 
goal of this PhD-project was to collect clinical and histopathological information for a 
national cohort of OCSCC in the period 2005-2009, the Norwegian oral cancer (NOROC) 
study, to assess survival and prognostic factors. We explored whether high-risk Human 
Papilloma Virus (HPV) was present in oral tongue (OT)SCC, and assessed the prognostic 
value of different tumor growth patterns of these cancers. Methods: Clinical information was 
retrieved from the patients’ electronic hospital files. Histologic sections were reexamined. 
Data from the national Cause of Death Registry was used to calculate overall and disease-
specific survival. Statistical evaluation was performed to determine correlations, and find 
independent and significant predictors of survival. Results: We identified 643 patients with 
OCC, 535 of these were primary treatment-naïve OCSCC. Age at time of diagnosis, and low-
stage disease correlated with higher survival outcome. We did not detect high-risk Human 
Papilloma Virus in the OTSCC. Tumor depth of invasion shifted many of the tumors to a 
higher T-status. Tumor differentiation, tumor budding, and lymphocytic infiltrate were the 
most important histopathologic prognosticators. Conclusions: Histopathological variables 
such as tumor budding, tumor differentiation, and lymphocytic infiltration, can add significant 
prognostic information to aid clinicians in treatment decisions and follow up, especially for 





Bakgrunn: Munnhulekreft er den hyppigst forekommende kreftformen i hode- og 
halsområdet. Munnhulekreft kan vokse aggressivt, og har lav overlevelsesprosent, nesten 
halvparten av pasientene dør i løpet av de første fem år etter behandling. Behandlingen 
avgjøres basert på pasientens generelle helsetilstand, men mest av alt med bakgrunn i 
klassifiseringen av kreftsykdommen, en såkalt TNM-klassifisering. T står for svulststørrelse, 
N for spredning til lokale lymfeknuter og M for fjernspredning. Sykdom med samme 
klassifisering kan ha forskjellig forløp. Munnhulekreft behandles først og fremst ved kirurgi, i 
tillegg kan det gis strålebehandling og i sjeldnere tilfeller kjemoterapi. Vi har så langt ingen 
veletablerte histopatologiske eller molekylære markører til bruk for å differensiere mellom 
behandlingsmodaliteter for munnhulekreft. Målsetting: Vårt mål var å etablere en nasjonal 
kohort av munnhulekreft. Vi reklassifiserte patologiske vevsprøver fra pasienter med kreft i 
den mobile tunge. Vi ønsket å undersøke om høyrisiko humant papillomavirus (HPV) er 
tilstede i tungekreft. Vi ønsket også å undersøke om ulike aspekter ved vekstmønster i disse 
kreftsvulstene er av prognostisk verdi. Metode: Dette doktorgradsprosjektet er basert på en 
retrospektiv innsamling av datamateriale fra pasienter som fikk påvist og behandlet 
munnhulekreft i Norge i årene 2005-2009, og reklassifisering av tilgjengelige 
histopatologiske prøver. Studien fikk navnet NOROC, Norwegian Oral Cancer study. Vi 
innhentet data fra Dødsårsaksregisteret for å kunne beregne overlevelse. Forskjellige 
statistiske metoder ble brukt for å undersøke sammenheng mellom variabler og 
overlevelsesanalyser. Resultat: Vi har beskrevet en stor kohorte med munnhulekreft fra 
Norge, og fant 643 tilfeller der munnhulekreft var satt med ICD-10-diagnose. 535 av disse var 
førstegangs tilfeller av kreft i munnhulen. Median alder for diagnosen var 67 år, fem års total 
overlevelse var 47%, fem års sykdoms-spesifikk overlevelse var 52%. Vi fant at yngre alder, 
små svulster med lav sykdomsutbredelse (N0) korrelerte med høyere overlevelse. Vi fant ikke 
høyrisiko HPV i vårt materiale av tungekreft. For vekstmønster fant vi at dybdevekst forskjøv 
mange av tumorene til høyere klassifisering. Tumor budding, differensieringsgrad sammen 
med lymfocytt infiltrat, de siste to i en kombinert histo-skår, kan være med som supplement 
til TNM-klassifiseringen. Konklusjon: Vi har demonstrert at histopatologiske variabler som 
tumor budding, differensieringsgrad og lymfocytt infiltrat, kan tilføre viktig informasjon. 
Dette kan brukes til å predikere for aggressivitet i tumor og bidra sammen med TNM-






















Oral cavity cancer (OCC) is one of the most common subsites of head and neck (HN) cancers. 
In all treatment of cancer, the patients should be able to know what disease they are facing, by 
receiving current and correct information. Clinicians and patients need to decide upon 
treatment based on the most updated knowledge and most likely outcome, and the patient has 
to provide consent for treatment from this perspective. Consequently, there is a need for 
continuous research in epidemiology, diagnosis, management protocols, and outcomes for all 





HN cancers constitute 2-5% of all cancers in the world (1). Lip and OCC, when joined 
together, are the most common subtypes of HN cancers, and these comprised 354,864 new 
cases worldwide in 2018, 2% of all cancers. Oropharyngeal (oral pharynx) cancer comprised 
92,887 new cases the same year, 0.5% of all cancers (1). These subsites should not be merged 
as they are different entities.  
In 2012, the global incidence of oral cancer was estimated at 275,000 per year, and the 
incidence is steadily rising worldwide, according to global cancer statistics in 2018. Lip and 
OCC rank as the 18th most common of all cancers with 354,864 new cases, and rank as the 
16th most frequent of deadly cancers in the world, with 177,384 deaths in 2018 (1). In 
general, men are at higher risk for having OCC than women (1). Median age for OCC is in 
the mid-sixties, but for oropharyngeal cancer, especially the human papillomavirus (HPV)-
positive oropharyngeal cancer, the median age is ten years younger (2-4). Some studies report 
patients with oral tongue cancer to be younger than patients with other cancers of the oral 
cavity (5, 6). 
The numbers of HN cancers have been rising in Norway, as well as globally (1, 7, 8). In the 
latest annual surveys from the Cancer Registry of Norway (CRN), OCC has been recorded 
without merging that with cancer of the lip or base of tongue (oropharyngeal part). The 
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cancers are classified to their anatomical location according to the International Statistical 
Classification of Diseases and Related Health Problems 10th Revision (ICD-10) diagnosis 
(9). Previously the national cancer registry tended to merge oral cavity and oropharyngeal 
sites; the number of new cases by primary sites and sex, from the CRN, for 2008 and 2018, is 
shown in Figure 1 (7, 8).  
 
 
Figure 1 Estimates of head and neck cancers in Norway in 2008 and 2018. From "Cancer in 
Norway", 2008 and 2018 (with permission, and available from 
https://www.kreftregisteret.no/globalassets/) (7, 8). 
 
In Norway, the total number of patients with new cases of OCC (ICD-10; C02-C06) was 181 
in 2008 (although this number includes C01, an oropharyngeal site), and 244 in 2018 (7, 8). 
The oral tongue is the most common site for OCC, comprising up to 50% of the cases (2, 10, 
11).  
Cancers occurring in different anatomical sites often have distinct etiologies and different 
treatment options, resulting in different survival outcomes. HN cancers are often presented 
and discussed as one type of cancer although the term includes different entities of cancer 
(12). It is important to describe precisely the sub-cohort of HN cancer patients when 
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estimating the most probable outcome. Oral cavity cancer and oropharyngeal cancer are two 
distinct cancer sites with different etiology, treatment, and survival outcome (13). In earlier 
investigations, data from oral tongue cancer (oral cavity site) and base of tongue cancers 
(oropharyngeal site) have often been combined and called tongue cancers or oral cancers, 
without being distinguished, and these studies are hampered by bias with respect to both risk 
factors and survival outcomes (14-16). In other reports, OCC incidence is presented together 
with cancer in the lip, and global cancer statistics combine these two locations in their 
presentations (1). Lip cancers tend to act like non-melanoma skin cancers and are for the most 
part less aggressive than cancers of the oral cavity (1, 17, 18). As a consequence, it is 
important to describe cohorts with validated oral cavity sites that are not merged with other 
HN sites in order to have reliable information. 
In most countries, studies on patients with OCC report a five-year survival rate around 50% 
(4, 12, 18). In 2019, the Surveillance, Epidemiology, and End Results (SEER) program 
database in the U.S., published a five-year relative survival rate of 53% for the floor of mouth, 
and 66% for tongue, for the years 2009-2015 (19). It is difficult to compare different reports, 
as many merge anatomical sites, or do not specify precisely the anatomical sites they are 
describing, and there is no consistency in reporting survival as relative survival, overall 
survival (OS), or disease-specific survival (DSS). In some cases, differences in reporting 
cancer cohorts occur regardless of treatment options, and some studies report survival of the 
patients treated in curative intent, and exclude those with metastasized cancer, and this will 
also preclude any proper comparison of cohorts (2, 20). The anatomical regions are nowadays 
better clarified by the World Health Organization (WHO), and one should describe cohorts 
according to this resource (21).  
Squamous cell carcinomas (SCC) are the most common malignancy in the oral cavity, 
representing 90% of the cases. Less common are verrucous carcinomas, adenocarcinomas, 
melanomas, lymphomas, and sarcomas (21).  
In this thesis, we present the Norwegian Oral Cancer (NOROC) study, in which we focus on 
SCC of the oral cavity, with both clinical data and histopathological data, documenting 
diagnosis, treatment choices, and follow-up. All this in order to present a homogeneous 




1.2 Anatomy and classification of tumors 
 
The oral cavity consists of the oral tongue, floor of the mouth, hard palate, buccal mucosa 
including the retromolar areas, and upper and lower alveolus and gingiva (gum), as shown in 
Figure 2 a-b. With respect to discussing locations and management of OCC, the designation 
“oral tongue” is applied to the mobile/anterior two-thirds of the tongue. The remaining 
posterior one-third is the base of the tongue and considered as part of the oropharynx (22). 
 
Figure 2 Oral cavity anatomy: a) oral tongue, buccal mucosa, and hard palate; b) floor of 
mouth, and gingiva and alveolar mucosa. Photographs: IH Bjerkli. 
 
Tumors and cancers are classified by anatomical location according to ICD-10 with an 
alphanumeric code, possibly with an eventual fourth character. ICD-10 diagnoses applied to 
cancer in oral cavity are C02-C06 (9), but do not include C05.1 (soft palate) and C05.2 
(uvula), as these are regarded oropharyngeal sites. C02.4 (tongue-tonsils) should also be 
exclusively used for oropharyngeal cancers (22). The ICD-10 diagnoses for OCC are shown 




Table 1. ICD-10 diagnoses and anatomical sites of oral cavity cancer. 
ICD-10 diagnosis Anatomical site of oral cavity cancer 
C02 Oral part of tongue 
C03 Upper and lower gum 
C04 Floor of mouth 
C05 Hard palate 
C06 Buccal mucosa 
 
The anatomical extent of disease is classified in the TNM system. The TNM system describes 
the extent of the primary tumor (T); for head and neck cancers, the extent (absence or 
presence) of cervical (regional) lymph node metastasis (N); and the absence or presence of 
distant metastases (M). The TNM classification and staging of disease (I-IV) are described 
according to TNM Union for International Cancer Control (IUCC) and American Joint 
Committee on Cancer (AJCC) (17, 21-23). The simplicity of the TNM system promotes 
clinical utility, but the prognostic outcome can be difficult to determine in patients with oral 
cavity squamous cell carcinoma (OCSCC) (24). 
The TNM system has been revised on an irregular basis, but in 2017 a new classification was 
introduced (22, 24). In the new TNM 8th edition, for OCC, tumor dimension now including 
depth of invasion (DOI), is a standard assessment in the T classification. Cervical lymph 
nodes surgically removed will be described with or without extranodal extension (22). For the 
oropharyngeal cancers, HPV-status was included. The categories in the former TNM in use 
for the years 2005-2009, and those in the new 8th edition of TNM classification for OCC, are 










Table 2. TNM classification and stage for oral cavity cancer and the changes in the 
classification between 5th and 8th editions. Adapted from «TNM Atlas, 5th Edition» (23) and 
«TNM Classification of Malignant Tumours, 8th Edition» (22). 
  TNM 5th edition TNM 8th edition (if changed) 
Primary tumor (T) classification, size and extent 
TX Primary tumor cannot be assessed   
T0 No evidence of primary tumor   
T1 Size ≤2 cm in greatest dimension and 5mm or less in depth of invasion (DOI) 
T2 Size > 2cm<4 cm in greatest dimension Size≤2cm and DOI 5-10mm, or size >2 
cm<4cm and DOI≤10mm 
T3 Size >4 cm in greatest dimension or DOI >10 mm 
T4a/b Tumor invades adjacent tissue   
Cervical node (N) metastasis classification 
NX Regional lymph nodes cannot be assessed   
N0 No regional lymph node assessment   
N1 Metastsis in a single ipsilateral node,  and without extranodal extension 
≤3 cm in greatest dimension 
N2 a) Metastasis in a single ipsilateral>3 cm< 6cm a) and no extranodal extension 
b) Ipsilateral, multiple ≤6 cm b) and no extranodal extension 
c) Bilateral, contralateral≤6cm c) and no extranodal extension 
N3 >6 cm a) and no extranodal extension 
b) Any N with extranodal extension 
Distant metastasis (M) classification 
MX Distant metastasis cannot be assessed considered to be inappropriate to use 
M0 No distant metastasis   
M1 Distant metastasis   
Stage of disease on basis of TNM classification 
Stage I T1 N0 M0   
Stage II T2 N0 M0   
Stage III T1-T2 and N1 M0   
  T3 and N0-N1 M0   
Stage 
IVA T1-T3 N2 M0   
  T4a N0-2 M0   
Stage 
IVB Any T N3 M0   
  T4b any N M0   
Stage 
IVC Any T any N M1   
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The use of the TNM classification system guides in the choice of treatment and provides a 
rough prediction of probable outcome. Moreover, the TNM system of classification facilitates 
treatment evaluation and the exchange of information between clinicians, supports cancer 
control activities, and contributes to standardize cancer research. For these reasons, it is 
important that the classification system remains stable, in order to evaluate factors 
contributing to long-term survival outcomes in a population (22).  
 
1.3 Etiology of oral cavity cancer 
  
Globally, there are large geographical variations in incidence of HN and cancer of the oral 
cavity (1). Cultural habits, such as betel nut quid chewing and eating areca nuts, increase the 
OCC incidence in South and South East Asia (4, 25, 26). Cigarette (tobacco) smoking and 
excessive alcohol consumption are major risk factors (27-29) . We also know there is a 
synergistic effect of smoking and alcohol consumption (28). Poor dental health status has also 
been considered to be a risk factor, although reports are inconsistent (30, 31). On the other 
hand, other factors like consuming vegetables and fruits might forestall development of 
cancer (29, 32).  
Viruses (oncoviruses) play a role in some HN cancers; especially documented is the Epstein-
Barr virus in nasopharyngeal cancer, and HPV in laryngeal and oropharyngeal cancers (17). 
In the last decade, high-risk HPV has been established as playing an important  role in 
oropharyngeal cancers, and this has therefore been implemented in the new TNM 
classification (22). Some studies have reported a small proportion of OCC presenting as 
HPV-positive (33, 34). HPV detection and confirmation can be done by several methods (35, 
36). We lack larger studies on high-risk HPV in OCC where the anatomical locations for the 
tumors are precisely described.  
The risk of recurrence or second primary tumors is present for the patients (37, 38). Genetic 
factors influence the initiation and progression of cancers, but the molecular mechanisms 
remain uncertain; several biological concepts have been described by Hanahan and colleagues 




1.4 Diagnosing oral cavity cancer 
 
1.4.1 Clinical and radiological considerations 
  
Early detection is important to improve the likelihood of good survival outcomes (2, 12, 40). 
The most common clinical manifestations of OCC are pain or numbness, wounds not healing, 
dental-symptoms, and cervical lymph node presentation (palpable lumps or mass) (21).  
Patients can present with their signs and symptoms to the general practitioner, an ear-nose-
throat /HN-specialist, or a dentist or dental hygienist. In Norway, patients with suspected HN 
cancer are referred to one of the four university clinics in the country, either Oslo University 
Hospital–Rikshospitalet in Oslo, Haukeland University Hospital in Bergen, St. Olavs 
University Hospital in Trondheim, or University Hospital of North Norway (UNN), Tromsø. 
The patients are clinically examined, documented by radiological imaging such as ultrasound, 
computed tomography (CT) scan, orthopantomogram (OPG), and sometimes magnetic 
resonance imaging (MRI) and positron emission tomography (PET)-CT (41, 42). CT is the 
most-used imaging modality for OCSCC in the Nordic countries (43). The clinical and 





Nearly 90% of the cancers of the oral cavity are SCC, originating from within the epithelial 
(mucosal) lining (21). The SCC in the HN region is heterogenous in histopathologic 
presentation, clinical appearance, and response to treatment. Samples, such as biopsies, and 
fine needle aspiration cytology (FNAC), are examined histologically for signs of pathology 
by a clinical pathologist. The histopathological verification forms the pathological (p)TNM 
classification (22). Histopathological confirmation of the clinico-radiological diagnosis is the 
foundation for tumor classification and further treatment decisions.  
OCSCC are further classified according to morphological evaluation, although grading alone 
does not correlate well with prognosis (21). WHO distinguishes three morphological grades 
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divided into well, moderately, and poorly differentiated (grade I-III). Within a tumor, the 
degree of differentiation varies as well (21).  
Within the same TNM classification, individual differences in clinical outcome is present, 
especially for the lower stages. Low-stages (early-stages) tumors are stage I and stage II 
(T1N0M0 and T2N0M0, in TNM 8th edition, with tumor size <4cm and/or DOI ≤ 10 mm, 
with no lymph node or distant metastasis) of OCSCC (44).  
Tumor budding (TB) has been proposed as a possible additional variable for colorectal cancer 
(22, 45), and some have argued that this characteristic may also be of value for appraising 
OCSCC evaluation (46, 47). In fact, before DOI was introduced into the new TNM 
classification, some studies also suggested applying a combined TB and DOI score (BD 
score) as a prognostic indicator (48, 49). 
Guidelines for recognizing patterns of the invasive front of the tumor and histologic risk 
models have been proposed by Anneroth and coworkers in 1987, Bryne and coworkers in 
1998, and by Brandwein-Gensler and coworkers in 2005 (50-52). These latter classifications 
have been tried in later studies, but with only moderate success, as differentiating high-risk 
tumors and low-risk tumors is very challenging (44, 53-55). Proposed histopathological risk-
parameters of tumors are: WHO differentiation grade, worst pattern of invasion (WPOI), 
degree of keratinization, nuclear polymorphism, perineural invasion, lymphocyte infiltration, 
and vascular infiltration (17, 21, 50-52). Some of the different histopathological growth 
pattern assessments presented in literature over recent years are shown in Table 3.   
Table 3. Histopathological risk-parameters often presented in literature. 
Histopathological variables References 
Tumor depth of invasion (DOI)  (22) 
Tumor budding (TB)  (45, 46) 
Tumor budding and depth of invasion score  (48) 
WHO differentiation, whole tumor  (17, 21) 
WHO differentiation, worst pattern  (52) 
Degree of keratinization, whole tumor  (50) 
Degree of keratinization, tumor front  (51) 
Nuclear polymorphism, whole tumor  (50) 
Nuclear polymorphism, tumor front  (51) 
Perineural infiltration  (52) 
Lymphocytic infiltrate  (52) 
Worst pattern of invasion (WPOI)  (52) 
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Several studies have tried to adapt to these oral cancer risk-parameters in histopathology. 
However, few studies have been large enough, or based strictly on one anatomical site, to 
allow conclusive results. Different pathologists notice different patterns (inter-rater) and they 
will not always agree with themselves (intra-rater). The reproducibility between pathologists 
has potential for improvement with respect to inter-rater and intra-rater agreement (53, 56). 
 
1.5 Treatment options and treatment complications 
 
Multidisciplinary team (MDT) meetings are central in all cancer treatment and care (57, 58). 
The treatment options of today require accurate tumor classification and staging as well as 
additional molecular details. As a consequence, an increasing number of procedures for 
diagnosing and staging of cancer in patients is needed to determine any treatment decision 
(59). Today, treatment requires involvement of experts within different medical disciplines, 
and specialists from these disciplines meet in MDT.  
For many cancers, a range of innovative surgical and medical treatments have been developed 
over recent decades. Examples include minimal invasive surgery techniques, stereotactic 
radiation therapy (RT), numerous chemotherapeutics, and involvement of targeting therapies 
and immune-therapies, all broadening the choice of treatment for most cancer types (60).  
For OCC, the most common choice of treatment is still surgery of the primary site when the 
tumor is regarded resectable, with or without surgical neck dissection (61). Additional 
postoperative RT may be given (62). In some of the cases, RT is given before surgery to 
decrease the size and extent of the tumor (59, 63-65). A more advanced stage of disease 
(≥stage III) will, for some patients, lead to additional medical treatment with chemotherapy or 
combined radiochemotherapy. Chemotherapy alone is for the most part used for metastasizing 
disease and in a palliative setting (66, 67). The treatment in many cases leads to some sequela, 
depending on the size of the tumor and the extent to which the patient has had neck dissection 
surgery, reconstructive surgery, and postoperative RT.  
As many as one-fifth of patients with low-stage tumors might experience neck node 
metastasis and recurrence within 1-3 years (68, 69). Two options are discussed for treatment 
of the neck in clinically node-negative (N0) OCSCC. One is elective neck dissection, and the 
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other is wait-and-see. In some cases for low-stage diseases, clinicians might suggest watchful 
waiting rather than neck dissection surgery (70-72). A patient with a small tumor and a N0-
status in the neck region does not necessarily need neck dissection or postoperative RT, but 
early-stage node-negative OCSCC, that later develops regional metastasis, has poor prognosis 
(70, 71).  
Complications of OCC treatment are associated with physical and psychological debility. 
Some patients feel socially inhibited due to a changed facial appearance and disfiguring scars, 
or because of persistent speech, swallowing, or tracheostomy difficulties. Xerostomia is 
common and can cause poorer dental health. Alterations in taste, malnutrition, and trismus are 
other complications. Moreover, a late complication of RT is induced osteoradionecrosis of the 
mandible, and some report an increased risk of ischemic stroke many years after RT (73). The 
patients may perceive themselves as altered, and many are not able to work again, part-time 
or full-time. Any impact on quality of life will be a cost for the individual as well as for 
society (74-76). 
There is no established tumor growth pattern or biomarker profile to identify patients with 
occult neck metastasis that would allow for more individualized treatment, especially for the 
patients with low-stage disease (77). If such a diagnostic tool were available, we could predict 
aggressiveness of the tumor and limit treatment-related adverse effects. Due to the severe 
side-effects of the treatment, it is important to reduce overtreatment of OCC patients. In the 
absence of a national guideline for treatment of HN cancers in Norway, the Danish Head and 
Neck Cancer Group (DAHANCA) and the U.S. National Comprehensive Cancer Network 
(NCCN) guidelines have been used (59, 63). 
Many previous studies that describe treatment and survival outcome of patients with OCC 
have not been consistent in reporting the anatomy and ICD-10 diagnosis or the actual 
treatment given. Some studies only included a small number of patients, and in some studies 
different anatomical sites have been merged (12, 78). In several studies, SCC of the 
oropharynx may be presented as part of the oral cavity and vice versa (13, 16). This 
predicament makes discussions of etiology and survival outcome inconclusive. To better 
understand OCC and answer our own and our patients’ questions, it was considered important 
to describe a cohort of solely primary OCC, that is, squamous cell carcinomas, since they 
make up 90% of oral cancer patients. We wanted to provide a more precise description of 
epidemiology, etiology, treatment, and survival outcome in a national cohort that is 
 
12 
comparable to other studies. Only in this manner can we describe and argue for the choice of 
treatment and give prognostic outcomes to both our patients and our colleagues. A transparent 
cohort would be valuable for future studies to adhere to the Reporting Recommendations for 




















2 Aims of the thesis  
2.1 Purpose of the thesis in general 
 
The general aim was to establish a large cohort of oral cavity squamous cell carcinomas with 
a broad overview concerning clinical and histopathological characteristics. All this in order to 
find characteristics with prognostic value. The specific aims of my PhD-work were: 
1. To establish a national, multicenter cohort of patients strictly limited to OCSCC, 
excluding other HN cancer sites; 
2. To describe this cohort with respect to clinical and histopathological characteristics, 
and to calculate survival data;  
3. To determine if high-risk HPV is present in oral tongue (OT) SCC;  
4. To assess prognostic value of various morphological tumor traits that have previously 
been suggested as prognostic markers for OCSCC.  
Our contributions fulfilling the stated aim of this thesis are presented in four separate articles, 
each with different research aims. 
 
2.2 Aims of the included papers 
  
• In Paper I we wanted to characterize a retrospective, multicenter cohort of solely 
OCSCC from all four health regions in Norway. We aimed to find clinical 
characteristics that significantly influenced survival, which we could compare with 
other cohorts. 
• In Paper II we aimed to determine if high-risk HPV was found in a cohort with 
OTSCC. 
• In Paper III we wanted to explore how depth of tumor invasion and tumor budding in 
OTSCC can impact survival outcomes.  
• In Paper IV we aimed to describe how different high-risk histopathological patterns, 



























3 Materials and methods 
 
This section provides an overview of the patient material retrieved retrospectively as the basis 
for the NOROC study, a collaborative multi-center study in Norway, outlining methods used. 
In Norway, treatment of HN cancer is centralized to the four university hospitals. The 
Institutional Review Board (IRB) of the Northern Norwegian Regional Committee for 
Medical Research Ethics (REK Nord) approved the NOROC study in 2013, with an 
expansion in 2015, and an extension in 2019. The protocol numbers are REK Nord 2013/1786 
and 2015/1381 (Appendices I, II, III and IV). Ethical and methodological considerations are 
summarized in chapter 5.  
 
3.1 The web-based case report form 
 
The main build-up of the case report form (CRF), was developed in cooperation with the 
clinicians and pathologists of the NOROC group. Data collection was enabled by a web-based 
data collection system developed and administered by The Unit of Applied Clinical Research 
(AKF), Faculty of Medicine and Health Sciences, Norwegian University of Science and 
Technology, Trondheim, Norway (82). The web-based CRF was administered on different 
servers, all situated in Norway. To be able to record, the person had to log in with a personal 
ID and a two-step message-access control code (double-authentication). Each of the four 
university hospitals had one clinician and one pathologist with access to record data into the 
CRF, a total of eight persons. The vast majority of the recording of clinical data was made by 
the PhD-candidate (IHB) as a clinician, supplemented by the other clinicians at the other 
hospitals. Four different pathologists were responsible for the histopathological re-assessment 







3.2 Data collecting process 
 
3.2.1 Extracting clinical data from the patient cohort 
 
Electronic health records (EHR) have been introduced in hospitals in many countries and, for 
Norwegian hospitals, from the beginning of 2000. Digitalized journals were implemented in 
Norway from 2002, but the latter were only fully available from 2005. After the introduction 
of EHR, we could search for the diagnoses electronically, and we did not have to find and 
store large collections of health records on paper (83). The time span 2005–2009 was chosen 
for data collection because we wanted to have a minimum of 500 patients and to have a 
minimum of a five-year follow-up in 2015; hence the last year for diagnosis had to be 2009. 
The collection of clinical data was achieved between August 2015 and February 2017.  
The inclusion criteria were that patients had to be diagnosed with OCSCC (ICD-10 C02-C06) 
in the time span 1 January 2005–31 December 2009, documented in the EHRs. Exclusion 
criteria were: any reservation about research recorded in the EHR, the cancer not being in the 
oral cavity but in a neighboring site (like C05.1, C05.2, or in the tongue-tonsil C02.4), cancers 
other than SCC, recurrent cancer or second primary from a cancer before 2005, or any record 
of previous cancer treatment. 
The ICD-10 diagnoses were matched with the pathologists’ archive for patient tumors with 
coding T51 (mouth) and T53 (tongue). These are codes in the pathologists’ archive called the 
Systematized Nomenclature of Medicine (SNOMED) (84). Some patients did not have the 
correct diagnosis in the EHR, and some were registered twice with different codes within the 
oral cavity or twice in different hospitals. We found 643 patients with OCC (ICD-10; C02-
C06). The NOROC study focused on SCC, so therefore we excluded other histopathological 
diagnoses such as verrucous carcinoma, malignant melanoma, adenoid cystic carcinoma, 
lymphomas, and sarcomas. When all diagnoses, clinical data, and available histopathological 
samples were assessed, we ended up with 535 unique primary treatment-naïve OCSCC, as 
described in Paper I. When we extracted the strictly oral tongue cancers from the original 
643, we found a total of 273 patients that had OTSCC; 34 of these were recurrences or second 
primaries. Those of the 273 patients with OTSCC available for tissue microarray (TMA) 
technique (n=146), formed the cohort for Paper II. When focusing on the primary treatment-
naïve OTSCC, we ended up with 239 patients. Those of the 239 patients who were primary 
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treatment-naive and treated in curative intent eligible for histopathological reassessment 




Figure 3 Flow-chart outlining the number of patients and available histopathological samples 
in the NOROC cohort presented in Papers I-IV. 
 
Rikshospitalet in Oslo is the national referral hospital. When a patient was located in EHRs at 
both the Rikshospitalet and another university hospital (registered twice), the case was 
excluded from one of the hospital’s CRF in order to be registered as a single patient at a 
single hospital. Most cases were recorded in the CRF belonging to the hospital that completed 
the follow-up. The proportion of patients in each of the four different hospitals is shown in 
Figure 4. 
643
• ORAL CAVITY CANCER→ 
535 primary treatment-
naïve squamous cell 
carcinomas (Paper I)
273
• ORAL TONGUE  SQUAMOUS 
CELL CARCINOMAS→146 




NAÏVE  ORAL TONGUE 
SQUAMOUS CELL 
CARCINOMA→150 available 
for histopathological          
reinvestigation            





Figure 4 Percentage and number of patients diagnosed with primary OCSCC at the four 
university hospitals in Norway, 2005-2009. 
 
We retrieved clinical data such as gender, age, county, treating hospital, cigarette smoking, 
alcohol consumption, medication, comorbidity, ICD-10 diagnosis, treatment of surgery, 
radiation therapy and chemotherapy, follow-up, residual disease, recurrence of disease, 
second primary, and survival at fold-in date. See Appendix V for details.  
 
3.2.2 HPV assessment 
 
HPV analysis can be done by several methods: immunohistochemistry (IHC) for tumor 
suppressor protein (p)16, and HPV in situ hybridization (ISH) for both DNA and mRNA (35). 
To be able to explore high-risk HPV in OTSCC, we used TMAs (85, 86). This is a method to 
analyze huge amounts of molecular analyses of, in this case, DNA, RNA, and p16, in so-
called micro-matrices shown in Figure 5.  
University Hospital of North Norway, 11% (n=56)
St.Olavs University Hopsital, 12% (n=67)
Haukeland University Hospital, 17% (n=90)




Figure 5 Tissue microarrays of oral tongue squamous cell carcinoma: a) overview H&E-
stained TMAs; b) example of one pan-keratin stained TMA block (EA1EA3). Photographs: T 
Søland. 
 
TMAs were designed from formalin-fixed, paraffin-embedded tissue blocks from OTSCC 
samples. We used a fully automated TMA machine (Ventana). The p16 IHC, the HPV DNA 
ISH, and the HPV RNA ISH, were all performed on TMAs. In situ hybridization is used to 
map and order (in this case) DNA and RNA to localize a specific DNA or RNA in a section 
of tissue. For details regarding methodology, consult Paper II. 
 
3.2.3 Extracting histopathological data 
 
The histopathological re-evaluation was fully discussed among the NOROC collaborating 
pathologists before beginning the task and documenting into the CRF. The pathologists also 
had a more detailed written worklist corresponding to the pathology part in the CRF, shown 
in Appendix VI. The collaborating pathologists had workshops prior to histopathological 
assessment. The histological re-evaluation for the OTSCC was done on available 
Hematoxylin and Eosin (H&E)-stained tissue sections and the pathologists were blinded for 





3.2.4 Depth of tumor invasion and tumor budding  
 
Depth of tumor invasion or just depth of invasion is the depth the tumor invades into the 
tissue. The DOI was implemented for the T-status for OCC in the 8th edition of TNM in 2017 
(22). This was also described by the International Consortium for Outcome Research in 2014 
(24), and is also explained in Appendix VI. The pathologists re-evaluated the OTSCC and 
included the new DOI in the available H&E-slide sections.  
Tumor budding is suggested as a new risk parameter for OTSCC (46). TB is a microscopic 
finding defined as the presence of isolated single tumor cells or small clusters of tumor cells, 
of four or fewer tumor cells at the invasive tumor front (47, 87), as shown in Figure 6. More 
details are explained in Paper III. 
 
 
Figure 6 H&E-stained section of OTSCC with tumor budding; green arrowheads indicating 







3.2.5 Histopathological assessment of risk-patterns 
 
Oral cavity SCC is for the most part described with the WHO differentiation of the whole 
tumor in the reports from the pathologists to the clinicians (21). Bryne and coworkers in 1998 
and Brandwein-Gensler and coworkers in 2005, introduced assessment of histopathological 
risk-patterns in oral cancer (51, 52, 88). The additional histopathological information includes 
the WHO differentiation for worst pattern, nuclear polymorphism in the whole tumor, nuclear 
polymorphism at tumor front, keratinization of the whole tumor, keratinization in tumor front, 
lymphocyte infiltrate, perineural infiltration, and WPOI. A recent work by Steigen and 
coworkers (2020) provides an overview of the variables (56), which is shown in Paper IV. 
Details about grading are shown in Appendix IV. In Paper IV we also describe a less 
complex scoring model with fewer options, as previously shown to increase inter-rater and 
intra-rater agreement (56). All the histopathological variables assessed and presented in this 
thesis are listed below in Table 4.  
 
Table 4. The various variables in oral tongue squamous cell carcinomas considered in this 
thesis. 
Variable  Score Paper 
High-risk HPV Present or not II 
Depth of tumor invasion (DOI) <5mm, 5-10mm, and >10mm III 
Tumor budding (TB) Low-high (2-tier) or  
low-intermediate-high (3-tier) 
III 
Tumor budding and depth of 
invasion score 
Low-high (2-tier) or  
low, intermediate, and high (3-tier) 
III 
WHO differentiation, whole tumor Well-moderately-poor IV 
WHO differentiation, worst pattern Well-moderately-poor IV 
Degree of keratinization, whole 
tumor 
Highly-moderately-minimal-no keratinization IV 
Degree of keratinization, tumor 
front 
Highly-moderately-minimal-no keratinization IV 
Nuclear polymorphism, whole 
tumor 
Little-moderately-abundant-extreme IV 
Nuclear polymorphism, tumor front Little-moderately-abundant-extreme IV 
Perineural infiltration No nerves-at invasive front-in tumor center IV 
Lymphocytic infiltrate Marked-moderate-little/none IV 
Worst pattern of invasion (WPOI) Pushing-Infiltrating-small groups-marked-tumor 





3.3 Data from the Cancer Registry of Norway 
 
This study also uses data from the CRN. To be able to verify whether we had found the 
majority of patients diagnosed and treated for OCC, we contacted the CRN in October 2015 
to obtain the total number of patients diagnosed with OCC (ICD-10, C02-C06) recorded in 
their registry between 2005–2009. The data presented in this thesis are those selected by the 
author from that official public document of the CRN. Data was provided according to current 
regulations; Legal Authority Cancer Registry § 3-4(1).  
 
3.4 Data from Norwegian Cause of Death Registry 
 
Cause of death was acquired from Norwegian Cause of Death Registry. In this manner we 
could calculate overall survival and disease-specific survival (89).  
 
3.5 Statistical analyses 
 
In this thesis, the following statistical methods have been performed by using the IBM 
Statistical Package for the Social Sciences (SPSS) version 25-26 for Windows (SPSS, Inc., 
Chicago, IL, USA). Descriptive data with range, mean, median, and frequencies, were used to 
characterize the cohort in the four included papers. Chi-square was used to describe 
association among variables (90). Spearman bivariate correlation (2-tailed) including 
bootstrapping was used to identify correlation between variables (91). To avoid risk of bias 
from sparse-data, the variables with few data were excluded from these calculations (92). The 
Log-Rank (Mantel Cox) univariate survival analysis, giving Kaplan-Meier survival curves, 
was used to carry out a survival plot where all patients were censored at death or at follow-up 
after five years (93). When statistical variables were significant in univariate analysis, they 
were entered onto Cox regression multivariate analyses to assess their independent value as a 
prognostic factor of survival in the presence of other variables (90). For survival evaluation in 
multivariate analyses, Cox regression allowed us to describe significance, hazard ratio (HR), 
 
23 
and 95% confidence interval (CI) after bootstrapping. Collinearity was evaluated with linear 













































4 Summary of results 
This is a summary of the papers in the present thesis. Paper I is based on the clinical 
characteristics of the oral cavity cancer patients in the NOROC study. Paper II is based on 
tissue microarrays assessment of high-risk HPV in oral tongue cancer. In Paper III and 
Paper IV, we focus on the different histopathological patterns in oral tongue squamous cell 
carcinomas and their association with survival outcomes. 
 
4.1 Paper I 
Characteristics and prognosis of primary treatment-naïve oral cavity squamous cell 
carcinoma in Norway, a descriptive retrospective study. Bjerkli IH, Jetlund O, Karevold 
G, Karlsdóttir Á, Jaatun E, Uhlin-Hansen L, Rikardsen OG, Hadler-Olsen E, Steigen SE. 
PLoS One. 2020 Jan 16;15(1): e0227738. doi: 10.1371/journal.pone.0227738. eCollection 
2020. 
In Paper I, we outline a large and retrospective study of primary OCSCC from all four 
university hospitals in Norway, the NOROC study. We describe the incidence of the cancer at 
the different anatomical sites of the oral cavity, together with descriptive data such as gender, 
age, smoking, alcohol consumption, treatment of choice, follow-up, and five-year survival 
outcomes. The patients in the NOROC study form the basis of the other papers in this thesis. 
All patients were diagnosed in the years 2005–2009, and validated against comparable 
cohorts.  
• We identified 535 patients with primary treatment-naïve squamous cell carcinomas 
from the years 2005–2009. 
• The male: female ratio was 1.2. Median age at diagnosis was 67 years, the range from 
24 to 101 years. Men were eight years younger at diagnosis compared to women, 
median of 64 years and 72 years, respectively. 
• Forty-five percent of the cases were oral tongue cancer. 
• Age at time of diagnosis, tumor-status and node-status significantly influenced 
survival, but there was no gender difference in survival.  
• The five-year disease-specific survival for the whole cohort was 52%. Patients treated 
with curative intent had a 62% five-year DSS.  
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4.2 Paper II 
High-risk human papilloma virus was not detected in a Norwegian cohort of oral 
squamous cell carcinoma of the mobile tongue. Søland TM, Bjerkli IH, Georgsen JB, 
Schreurs O, Jebsen P, Laurvik H, Sapkota D. Manuscript submitted for publication. 
In Paper II, we wanted to describe to what extent high-risk HPV was present in OTSCC. 
Tissue microarrays of tumor tissue from 146 Norwegian OTSCC patients were assessed for 
presence of high-risk HPV. We compared different and independent approaches for HPV 
detection. We used DNA and RNA in situ hybridization assays and immunohistochemistry to 
evaluate the expression of HPV surrogate marker p16. We hypothesized that high-risk HPV 
infection is uncommon in OTSCC.  
• We did not identify any transcriptional active HPV in these cases. 
• None of the tumors were positive for either high-risk HPV DNA or for E6/E7 mRNA 
by in situ hybridization. 
• Only two cases showed strong and uniform p16 in more than 70% of the cells (both 
cytoplasmic and nuclei staining). 
• The main conclusion was that high-risk HPV is an unlikely causative factor in 
OTSCC.  
 
4.3 Paper III 
Tumor budding score predicts lymph node status in oral tongue squamous cell 
carcinoma and should be included in the pathology report. Bjerkli IH, Laurvik H, 
Nginamau ES, Søland TM, Costea D, Hov H, Uhlin-Hansen L, Hadler-Olsen E, Steigen SE. 
Manuscript submitted for publication. 
In Paper III, 150 cases of H&E-stained slide sections from OTSCC treated in curative intent 
were described. Survival outcome was compared with clinical and histopathological variables 
to evaluate their prognostic significance. We elucidated the prognostic value of the TNM 8th 
edition pT classification, including DOI, as well as lymph node status, TB, and a combined 
TB and DOI score, and whether these could supplement treatment decision.  
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• Tumors shifted to a higher T-status when classified according to the TNM 8th edition 
pT compared to the older pT. This indicates that DOI significantly complements T 
classification for prognostication. 
• The age at diagnosis, TNM 8th edition pT classification, N-status, TB, DOI in a 3-tier 
category, and the combined TB and DOI scores, all significantly influenced prognosis 
in univariate analyses. 
• A high TB score was associated with lymph node metastasis. For tumors with low TB 
score 22.5% had lymph node metastases, whereas for tumors with high TB score, 
42.8% had lymph node metastases. 
• The 8th edition T-status and TB in a 3-tier category were independent variables of 
five-year DSS in multivariate analyses. 
• Tumor budding was associated with lymph node metastases, and can be used as a 
supplement to TNM classification in treatment decision for low-stage tumors. 
 
4.4 Paper IV 
A combined histo-score based on tumor differentiation and lymphocytic infiltrate is a 
robust prognostic marker for mobile tongue cancer. Bjerkli IH, Hadler-Olsen E, 
Nginamau ES, Laurvik H, Søland TM, Costea D, Uhlin-Hansen L, Steigen SE. Manuscript 
submitted for publication. 
In Paper IV, we determined whether tumor histopathological differentiation and other 
histopathologic high-risk assessments, when made less complex through fewer options, can 
help in predicting survival outcome for oral tongue cancer and thereby supplement treatment 
decisions. 
• One-hundred and fifty H&E-stained sections of OTSCC treated in curative intent were 
available for re-investigation; 77 of these were low-stage tumors (T1-2, N0M0). 
• Five-year disease-specific survival for the whole cohort was 65%, and for the low-
stage tumors, five-year DSS was 83%. 
• For the whole cohort, lymph node status and risk-patterns including differentiation of 




• The WHO whole tumor differentiation correlated with survival outcome following the 
traditional grading, but also when made less complex, both for the whole cohort and 
for low-stage diseases.  
• Lymphocytic infiltration can be scored with fewer options, to increase reproducibility 
(inter-rater and intra-rater agreeability), without losing prognostic value.  
• A histo-score combining WHO differentiation and lymphocytic infiltration identified a 
group of low-stage tumors with a five-year DSS worse than the high-stage tumors, and 





















The general objective of this thesis has been to gain knowledge about cancer of the oral cavity 
from a cohort of strict OCSCC where the clinical and histopathological registration has been 
done in a structured manner. We present a large and well-controlled group of cases. As there 
may be differences in risk factors and clinical course of OCSCC from different oral sub-sites, 
we performed separate and more extensive analyses on the OTSCC, which comprised almost 
half of the cohort. Our retrospective study has not interfered with any choice of treatment or 
survival outcomes, insofar as the patients included had had their treatment 10-15 years ago.  
This section will first address the ethical considerations of this research, emphasizing issues 
regarding the patient cohort. Then methodological and statistical considerations specific to 
this thesis will be addressed. The findings from the four papers will then be comprehensively 
discussed and related to other findings from the literature.  
 
5.1 Ethical considerations 
 
The Declaration of Helsinki was developed by the World Medical Association (WMA) in 
1964, and has been updated several times (94). The declaration is a statement of ethical 
principles for medical research when it involves human subjects, and also covers human 
material and research data. The principle of informed consent is essential. 
Originally this research was planned as a multicenter-study with two Norwegian university 
hospitals and one Finnish university hospital, but inasmuch as we found it difficult to collect 
clinical data in an unrelated foreign language, we shifted to a multicenter-study comprising 
the four university hospitals in Norway, naming it the NOROC study. 
For the NOROC study, a passive consent procedure was utilized. The NOROC study and 
approach for consent was approved by the IRB of the REK Nord (Appendix I and Appendix 
II). Approval from one of the four regional IRBs gives validated approval for the other 
national health regions. Patients alive at the retrospective inclusion date received a written 
informal consent letter informing them about the study (Appendix III). The patients were 
given the opportunity to decline participation (opt-out). Deceased patients and those who did 
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not opt-out were included in the analyses, except for three patients with written statements in 
the EHR about not participating in research; these were excluded at the outset.  
This patient group is a vulnerable patient group having high mortality risk, with location of 
cancer in a part of the body that is important to vital functions and social life. Confidentiality 
of patient information is mandatory. Individual data such as information about burden of 
disease may have implications, for example, for the right to insurance; thus confidentiality is 
essential (95).  
The study was planned retrospectively and approved in 2013/2014, five to ten years after the 
patients had had their cancer diagnosed and treated. The patients still alive were informed that 
they could withdraw from the NOROC study without concern. The letter was sent to patients 
when inclusion started between August 2015 and February 2017. We found the latest 
addresses given in the EHR; addresses are updated once or twice a year. No letters were 
returned from either patients or postal services. Three patients contacted the principal 
investigator by telephone to confirm they were agreeing to participate. One of them said, “do 
whatever you want, because this is very important research for our group of patients”, and 
another said, “you can do what you want at any time, and there is no need to inform me more 
about further research on my case”. My own experience with patients suggests that the 
majority of patients are very positive to research. None of the living patients contacted us to 
opt-out. As this was a retrospective study, many years after primary treatment, this study did 
not interfere with their treatment or outcome in any way. All data are kept anonymous, and 
the study register will be terminated when the time-period for the IRB approval closes, the 
study was given an extension in 2019 (Appendix IV).  
If we had been obliged to have the patients to opt-in to the project, we could have been facing 
many patients not responding for several reasons, given their advanced age and perhaps not 
able to focus on an illness they survived many years ago. We would then only have had the 
clinical data and histopathological data of those not alive, and the analyses of five-year OS 
and DSS would not have been valid for all the patients with the cancer. With the consent 
approach we were given, we could gain insight into the patients who have survived, with both 
clinically and histopathological data, not only from those deceased. With our procedure, 
clinical data of all patients were available regardless of outcome or available tumor samples. 
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5.2 Methodological considerations 
 
The study was conducted in collaboration with the four university hospitals in Norway, and 
with some of their most experienced clinicians and pathologists diagnosing and treating oral 
cavity cancer patients in Norway. All clinical and histopathological information was collected 
into a web-based CRF.  
 
5.2.1 Web-based case report form 
 
We considered other web-based collection systems, but for the security of data, we chose a 
national administration in Trondheim; AKF, with the servers situated in Norway and with a 
two-step authentication for the recorders (82).  
The study register is a method of structuring the recording of patient data. The CRF was 
prepared to organize the clinical and histopathological data used for the NOROC study and 
the papers in this thesis. A basic CRF was prepared from knowledge at that time (2014), with 
a prospective model as guide, as there were few retrospective models to be found (27, 96). 
Previous studies from our group in Tromsø had collected clinical data such as gender, age, 
smoking, drinking, TNM stage, treatment, and survival outcome (34). We now wanted to 
collect more detailed data if these were available, but still anonymized, especially about 
treatment, follow-up, and histopathological variables in a broader manner.  
We discussed and then designed a CRF with five main sections in addition to the first page 
with anonymized identification. Those five main sections were: basic patient data, ICD-10 
diagnosis, histopathological information, treatment, and follow up (Appendix V). To some 
extent the sections were detailed, but given that members in the research group had different 
medical backgrounds, we focused on several objectives. We wanted to explore whether it was 
possible to record these data retrospectively. The recording was documented in the de-
identified CRF. The information from the CRF was then uploaded as a SPSS file for 
statistical analyses. No birthdate or identification number is available in the CRF or in the 
SPSS file; a key list was held by one of the co-investigators.  
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The CRF was found to be functional for annotation and sufficiently nuanced by the clinicians 
and pathologists recording into it. We did not do a pilot, but from AKFs all-around 
experience, they had created a test session page that one should try out before adding patients 
in to the main CRF. The researcher who carried out the majority of data-collection into the 
CRF, as well as the other clinicians, had extensive experience in the diagnosing, surgical 
treatment, and follow-up of this patient group. Histopathological assessment was done by 
experienced clinical pathologists at each hospital. 
When several professionals are collaborating, a CRF will naturally have to include questions 
that not all are equally familiar with. It is important to have standardized methods for 
collecting data, and to have systematic ways to evaluate the results as well. Among clinicians 
and pathologists, some of the questions and answers could be misunderstood from the original 
context, and one could also miss out on some questions due to fatigue during the collection 
process, but we did not find this a significant problem. 
It was not possible to find and record all details into the CRF from the EHR. The EHR 
records are tools for diagnosis and treatment, and not designed for research (83, 97, 98). To 
use EHR directly as a study-register for research is difficult because of the variable quality of 
the details, since the documentation accumulates as a running record (83, 97, 98). That is why 
a CRF can be constructed in a manner that requires us to carefully read through the EHR and 
assess data in a systematic manner. Presently, compared to 10-15 years ago, assessments in 
the EHRs are more standardized; for example, patient symptom-burden is recorded with 
Edmonton Symptom Assessment System-revised version (ESAS-r) and patient performance 
status as Eastern Cooperative Oncology Group (ECOG) (99-101). As NOROC was a 
retrospective study, many of the details we wanted to assess were not fully available in the 
EHR, underlining how difficult it can be to find the information needed for a retrospective 
study. A prospective study could ask specific questions and use standardized questionnaires, 
and patients would answer directly; however, patients may not answer honestly, or not 
respond at all, particularly concerning smoking and drinking habits (102). 
The data recording was done by reading the EHR and re-classifying the available 
histopathological samples, not by searching codes for diagnosis, histopathology, or 
procedures. Our CRF decreased the number of misclassifications, and enabled us to describe 
which treatment had been given and not just what was planned for. It is important to have a 
CRF that is built to assess crucial clinical data. 
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5.2.2 The tissue microarrays and H&E-slide section assessment 
 
Histopathological evaluation of tumors into many variables is time-consuming, and in our 
work, we limited the workload to this point by including squamous cell carcinomas of the oral 
tongue. We had hoped to be able to evaluate histopathological samples from all registered 
OTSCC patients, but some lacked material in the archives. This resulted in a lower number of 
samples available for TMA and the other histopathological re-evaluations. In addition, some 
of the samples were excluded because of reduced quality of the collected sample-slides, or 
fragmented or shallow resections, or biopsies inappropriate for further assessments.  
TMAs were used to explore high-risk HPV in the OTSCC. TMA has the advantage of 
examining many samples at the same time (less time-consuming), and for a lower cost. A 
TMA disadvantage is that only a small part of the tumor is examined, and that might not be 
representative of the whole tumor. The question is also whether one should choose material 
from the middle of the tumor or at the tumor front. The number of harvested cores needs to 
ensure representability for the whole tumor. Two or three cores have been said to be 
representative, and TMA is well accepted as a method (85, 86).  
With full section H&E-stained slides, the pathologists normally look at one or a few slides 
that are harvested to be most representative for the tumor, and both the central and the 
peripheral parts can be evaluated, so that arguments about TMA being limited to small 
samples are less of a concern.  
We wanted to explore the histopathological DOI and TB on the available H&E-stained tissue 
sections available on the OTSCC in our cohort (22, 24, 45). The pathologists also re-
evaluated the parameters suggested in the risk-model: WHO differentiation grade, WPOI, 
degree of keratinization, nuclear polymorphism, perineural invasion, lymphocytic infiltration, 
and vascular infiltration (50-53, 88). This has been verified in other studies, but 
differentiating between high-risk and low-risk tumors is challenging, with poor 
reproducibility among pathologists (44, 53). The pathologist evaluates one slide at a time, and 
this is obviously time-consuming. A less complex categorization might be less time-
consuming, and also seems to be of greater value with respect to better inter-rater and intra-
rater agreeability (56). 
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Many pathologists welcome analyzing software that could diminish subjective results in the 
future. Digital pathology in the future, represented by new bio-imaging analysis platforms 
such as QuPath, might prove to analyze histopathological slides with a high grade of 
reproducibility. Such a system is time-consuming for importing and standardizing the data-
input, but the system will then score the tumors in the same manner (103). 
 
5.3 Statistical considerations 
 
With 535 primary treatment-naïve patients in our cohort, the study was sufficient according to 
a-priori power calculation. But because there are so many different variants of tumor stage, 
etiological factors, and treatment, sub-grouping is sometimes important to control for known 
risk-factors, and such sub-groups could become small and thus be potential sources of bias. 
Statistical tests will always be debated and can be misinterpreted (104). We decreased the risk 
of sparse-data bias by excluding variables with fewer than five cases (92). The Chi-square test 
was used to test relationships between variables (90). The Spearman bivariate correlation (2-
tailed), including bootstrapping at 95% CI was used to identify correlation between 
parameters. By bootstrapping we also decreased the bias of small sample size. When the 
cohort contains few individuals of a variable, and correlation is calculated, bootstrapping 
decreases the bias of small samples by calculating imagined samples from the cohort several 
times (105-107). In 2-tailed correlation (bivariate), cases with missing values are excluded 
pairwise. We used Spearman correlation because it does not require normal distributed data, 
and we can use Spearman correlation to analyze nonlinear relationship; thus we do not have 
to worry about extreme outliers in the cohort (91). 
Log-Rank univariate survival analyses were used to give Kaplan-Meier curves for estimates 
of survival. It is easy to calculate, and gives a non-parametric estimate of the survival 
function. One can only calculate one variable, commonly used to compare two (or a few 
more) study populations within the same variable. It is easily applicable to small, medium, 
and large samples. When a patient dies within (in our calculations) five years, it is censored at 
the time of death. One limitation is that one should have >50% uncensored observations. The 
program gives the median survival time, and does not control for covariates; for that we then 
have to do multivariate analyses (93).  
 
35 
Multivariate analyses are means to control for confounding factors in univariate analyses. 
Only variables significant on univariate analyses were included into the multivariate tests. We 
tested independent variables for collinearity with linear regression when we suspected they 
could be correlated, and thus excluded them from the multivariate calculation (90). Cox 
regression analyses for survival allowed us to describe significance, HR, and 95% CI after 
bootstrapping for multivariate variables (90).  
 
5.4 Discussions of main findings 
 
The thesis is based on a newly established, large Norwegian cohort of patients with OCSCC. 
The NOROC cohort represents the majority of patients treated for OCSCC in all four health 
regions in the country during 2005-2009. To our knowledge, there are no previous studies 
aiming to include all patients treated with OCSCC in Norway, with a five-year follow-up. In 
Paper I, we describe the clinicopathological variables of the cohort and survival outcome. 
We explored the available OTSCC for high-risk HPV in Paper II, and re-investigated them 
histopathologically in Paper III and Paper IV. 
The characterization of this cohort is important for clinicians in Norway. It is crucial to know 
the characteristics of our patients to be able to compare them with other cohorts. It is also of 
great impact for further studies on prognostic biomarkers to be able to report in a rigorous 




According to the CRN, the number of patients classified according to ICD-10 with label C02-
C06 in the years of 2005–2009 was 788, or 158 patients annually.  We found 643 unique 
patients, and of these 535 were primary treatment-naïve oral cavity cancers (annually, 107 
patients). In 2018 (the last reports from CRN), the average annual number of new cases in 
oral cavity cancer (C02-C06) was 220 (male 123, female 97), so the annual incidence is 
increasing (7).  
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Four hundred unique patients were identified by searching for the relevant ICD-10 codes in 
the EHRs at Rikshospitalet. Patients treated at Haukeland, St. Olavs, and UNN were first 
identified by searching the hospitals’ pathology archives for cancers with topographic 
SNOMED coding T51 and T53, which were subsequently matched with the relevant ICD-10 
codes recorded in the EHR. Three hundred and eighty unique patients were found in the latter 
three hospitals, but screening of the files showed that 115 patients (30.3%) had been 
incorrectly coded and did not have oral cancer. The majority (91 patients) of these had 
oropharyngeal cancer, accounting for 24% of the 380 identified patients.  
The total number of patients we identified with primary OCSCC was 535. If we calculate that 
25-30 % of the patients recorded in the CRN during these years could be misclassified, the 
numbers of patients would be reduced from 788 to about 575, and we found 535 primary 
treatment-naïve patients. Some patients may have had histopathological diagnoses other than 
squamous cell carcinoma, and some patients with small tumors might have been treated at 
local hospitals. Also, patients with cancer at an advanced stage treated without curative intent 
might not have been transferred to the university hospital but treated palliatively at a local 
hospital. Given this background, we think we have documented a representative group of 
patients.  
The 535 primary OCSCC found in this cohort included 322 patients (60.2%) from 
Rikshospitalet, 90 patients (16.8%) from Haukeland, 67 patients (12.5%) from St. Olavs, and 
56 patients (10.5%) from UNN, respectively, as previously shown in Figure 4. This correlated 
well with the division between Health Regions of Norway: Rikshospitalet in Oslo should have 
had 58%, but actually had 60% of the patients. This correlates with the demographic pattern 
in Norway (2007 and today), and considering that Rikshospitalet in Oslo is a tertiary referral 
hospital (108). 
For cancers of the oral cavity, the male: female ratio has been reported to be 1.4–1.8 (7, 20, 
109), but the ratio tends towards no gender difference with a recent report from Finland 
having the male: female ratio of 0.9 (2).  We found a ratio of 1.2. in Paper I. The numbers we 
had from the CRN were 433 men and 355 women, also giving a male: female ratio of 1.2. 
In our cohort we found a median age 67 years. The ages reported from CRN corresponded to 
that median age (7). The median age from a Danish cohort reported retrospectively in 2017 
was 63 years (20). From a Finnish study the median age of OTSCC was 66 years (2). In a 
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recent Spanish and Swedish report for HN cancers, the mean age at diagnosis was 64 and 67 
years, respectively (40, 110). Our Norwegian cohort is therefore in line with other cohorts in 
Europe. We found the younger age-groups to present better five-year DSS, than older age 
groups (>70 years of age) (p=0.001). We did not have many young patients; only 13 patients 
(2.4%) were under 40 years. Other reports have found a larger proportion of younger patients 
with oral cancer —in Finland as high as 8-10%; a U.S. study reporting median age for 
OCSCC of 35 years (2, 111); and worldwide, increasing trends of younger patients with oral 
tongue cancers have been reported (6). This suggests that there might be different etiology in 
different countries as found in a U.S. report (109). 
The median survival follow-up time after primary treatment (major surgery or definitive 
radiation therapy with or without chemotherapy) in our cohort was 48 months; 53% of the 
patients deceased within 5 years. Median follow-up at 48 months confirms the high rate of 
death during the first five years. Cause-specific survival/DSS is defined as the percentage of 
patients in a study or treatment group who have not died from a specific disease in a defined 
period of time (89). We used the phrase DSS in our studies and not disease-free survival 
(DFS). For both DSS and DFS, the period of time usually begins at the time of diagnosis or at 
the start of treatment and ends at the time of death. DFS was not considered, as this is defined 
as the length of time after a new, primary treatment of cancer and the period the patient 
survives without signs or symptoms of that particular cancer (or disease). Measuring DFS is 
largely used to evaluate how a new treatment works in a clinical trial and should be restricted 
to that use (89). We found the OS to be 47% and the DSS to be 52% in Paper I. Relative 
survival for HPV-unrelated oral tongue cancer was reported to be 57% in Germany, and in the 
same report the U.S. had 64% relative survival (112). For OCC (not including tongue and 
lingual tonsils), the Northern Europe five-year age-standardized relative survival was 
estimated to be 50% (12). We believe the five-year OS and DSS rates we found are reliable. 
 
5.4.2 Anatomy and classification of tumors 
 
When reading the EHR, we could verify what diagnoses the patients had, comparing the given 
diagnosis to the surgical documentation, and in some we corrected the diagnosis in the CRF 
accordingly. This led to exclusion of some patients, mostly oropharyngeal cancer documented 
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as tongue cancer, or very few maxillary cancers with breakthrough to hard palate documented 
improperly as hard palate cancer (a neighboring anatomical site). 
In the NOROC study we included patients diagnosed with OCSCC between 1 January 2005–
31 December 2009. Therefore, patients had originally been classified according to an older 
TNM edition (23). We based our anatomic classification in the CRF on the latest TNM 
edition, in which the description of anatomical location is improved (22). The relevant ICD-
10 codes were C02-C06, referring to cancers of the oral cavity. We excluded lip cancers, and 
ICD-10 codes C05.1 and C05.2, which are regarded as oropharyngeal sites. C02.4 for tongue-
tonsils was seldom used, but it also reflects an oropharyngeal anatomical site, and should be 
exclusively used for oropharyngeal cancers. In this way we present a homogenous cohort 
regarding anatomical sites. The numbers we obtained from the CRN indicated C02 to be 
40.6%, C03–25.6%, C04–19%, C05–2.7%, and C06 to be 12.1%. In the NOROC cohort we 
found quite similar numbers: C02–44.9%, C03–20%, C04–19%, C05–1.3%, and C06 to be 
14.8%. Hence, our cohort appears consistent, corroborating a previous cohort in Northern 
Norway (34), and oral cavity cancers in the U.S. (113). Today the anatomical regions are 
better clarified by the WHO and in TNM 8th edition, and we recommend describing cohorts 
according to these resources (21, 22). It is important to verify the diagnoses by reading the 
clinical presentation recorded in the EHR, and not only base the search for patients for 
inclusion in a cohort according to recorded ICD-10 diagnosis or a SNOMED-code. In this 
way, we have decreased the number of misclassifications. 
Histopathological cancer types other than SCC were excluded. In Papers I, III, and IV we 
excluded patients with second primaries or previous cancer treatment to focus on the primary 
treatment-naïve SCC, and to decrease the bias of previous treatment interfering with 
development of new cancer.  
The patient’s TNM score reported to the CRN was found in the EHR, and the staging was 
done in the CRF according to which TNM was recorded in the EHR. Some lacked T, N, or M, 
and were registered in the EHR with TX, NX, and/or MX. These were few, only 22 of 535 
patients ended up with unknown staging. The same trend of some unknown stages is 
described in Cancer in Norway 2018 (7). 
In our cohort for Paper I, T1 constituted 20.6%, T2–32.2%, and T4 as much as 33.3%. N0-
status made up 61.3% of the patients. A total of 42.1% of the tumors were stage I and stage II, 
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which is in line with data from a Swedish HN cohort where stage I and stage II tumors 
accounted for 43.1% (40). In a German/U.S. report of HPV-unrelated oral tongue cancer, 44% 
of the Germany patients versus 62% for the U.S. patients were stage I and II tumors (112). 
This might reflect an earlier awareness of oral cancer in the U.S., but our cohort seems in line 
with other European cohorts. 
In Paper III and Paper IV, the re-evaluation of T-status including DOI increased the T-status 
of many of the tumors. Those who remained T1, improved survival outcome compared to the 
former T1, likewise for T2. We confirmed an upregulation of T with the implementation of 
DOI from previous TNM editions, as others have described (24, 114). 
The N-status correlated with survival outcome. N0 disease is associated with better survival 
outcome than N+. In Paper I, we showed that patients with N0 disease had a five-year OS of 
59% and five-year DSS of 65%; these were the five-year survival outcomes for all 
documented patients regardless of the T-status or treatment. In Paper III and Paper IV, 
patients with N0 disease had a five-year DSS of 82% and N+ five-year DSS of 38% 
(p<0.001). These findings of better survival with N0-status, is in line with other work on this 
matter (115-117).  
Tumor-status together with node-status (stage of disease) influenced survival. There was no 
gender difference in tumor or node-status. Patients with low-stage disease (stage I and stage 
II; T1-T2, N0M0) at time of diagnosis had better survival outcome, as shown in Papers I, III, 
and IV. In Paper I, we found five-year DSS for T1–73%, T2–62%, N0–65%, Stage I–80.2%, 
and Stage II–67.7% (all p≤0.001). In Paper III and Paper IV, patients treated in curative 
intent were investigated. Here we found five-year DSS to be 88% for pT1, 64% for pT2 and 
pT3 (p=0.006), and five-year DSS for pN0 to be 82% (p<0.001). In Paper IV, low-stage 
disease had a five-year DSS of 83% and high-stage disease a five-year DSS of 45% 
respectively (p<0.001). This is in line with other studies showing low-stage tumors to have 








When presenting etiological factors for OCC, the following are often discussed: smoking, 
alcohol, the synergy of these last two, level of education, socioeconomic status, and high-risk 
HPV. A disadvantage of collecting data retrospectively is that clinicians tend to document 
such data differently. In part of the basic patient-data, we discovered that it was difficult to 
specify etiological factors such as level of education, family history of cancer, smoking, and 
drinking habits, as these are not consistently documented in the patient journal.  
In as many as 35% of the EHRs, the documentation of smoking and drinking was lacking; our 
results in Paper I have to be considered with this in mind. In another retrospective study from 
our group, and also in other retrospective and prospective studies, smoking and alcohol data 
can be missing for up to 30% of the participants (34, 102, 111). We cannot specify smoking 
and drinking habits in detail, nor smoking in pack-years, as this was not a standard of 
documenting amount of smoking during 2005-2009. 
For dental status we found 20% to have good dental status, 50% in need of treatment, 21% 
edentulous, and 9% without unknown dental status, in Paper I. Older people were more often 
edentulous. Patients with oral tongue cancer had better dental status than patients with other 
oral cavity cancer sites. For survival, five-year DSS was 69% for those with good dental 
status, whereas those in need of dental treatment had 55% five-year DSS, whereas those 
edentulous had five-year DSS of 29% (p<0.001). Good oral hygiene may reduce the risk of 
HN cancer (13, 31, 119), and oral hygiene may as well reflect socioeconomic status. 
We wanted to explore and document the presence of high-risk HPV in our cohort of OTSCC 
in Paper II. One of the research-questions based on the OTSCCs assumed that high-risk HPV 
has no role in OTSCCs. There were several reasons to explore whether these SCC contained 
high- risk HPV. First of all, to explore the presence or absence of high-risk HPV in oral 
tongue cancer. Secondly, to know if HPV could impact further sample staining, infiltration, or 
other growth patterns. And finally, this was also to indicate whether or not we had 
homogeneous material, not biasing future research.  
There are many available screening test for detecting high-risk HPV (36). We used the most 
recommended detection and confirmation analyses for high-risk HPV (35). p16 is a surrogate-
marker for HPV. p16 protein can be upregulated by HPV, but it can also be present because 
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of other sources by contamination (120). With HPV DNA ISH, we cannot be sure if this is in 
the patient samples, or if it might be present by contamination, and we cannot determine 
whether this is virus replication. Also, with HPV RNA ISH (mRNA), we are exploring 
whether we have an active transcription process; there are few other studies so far that have 
done this in their samples (35).  
In Paper II, we present both second primaries and primary oral tongue squamous cell 
carcinomas, to find whether there was any difference in high-risk HPV presentation between 
primary cancer and recurrent or second primary disease. There was none. We found no 
positive samples for high-risk HPV, and so have concluded that our material is not biased by 
high-risk HPV, and high-risk HPV will therefore not bias further staining and assessment of 
infiltration or other growth patterns in future work on the NOROC cohort. Our results are 
supporting a study from 2017 from Jansen and coworkers, that found no HPV-related oral 
tongue cancers in Germany or in the U.S. (112). For biomarkers, many clinicians ask for 
HPV-status, not only for oropharyngeal cancers, but also for oral tongue cancers; to our 
knowledge this is not necessary as a standard.  
Within the five-year follow-up time, 18% of the patients had recurrence within three years. 
Second primaries, a new OCC more than three years after first presence of OCC, was the case 
for 10.5% of the patients. There are various definitions of second primaries, but second 
neoplasms after an HN index tumor is decreasing ultimate survival (121).  
We wanted to explore whether we could document the patients’ body mass index (BMI), but 
in many patient charts we might have been able to document either weight or height, but not 
both. This can also be lacking in prospective studies (102). Another drawback in the CRF was 
the lack of documentation of physical performance status (often reported according to 
Karnofsky performance status scale, ECOG-scale, or WHO scale) of the patients (122). The 
patient’s physical performance could absolutely influence treatment decision and survival 
outcome. Patients with low performance status are more likely to have low survival outcome 
(40). By reading the EHR, we recognized that it was not a tradition in 2005–2009 to specify 
the patient’s physical performance status; it was neither documented nor vaguely described, 
and it would have been difficult to register in this retrospective study. In a new prospective 




5.4.4 Histopathological growth pattern findings 
 
As part of the NOROC project, dedicated and experienced pathologists have now reassessed 
available histopathological oral tongue samples; other sites will be pursued later. The 
reassessment has reclassified one of the oral tongue cancer patients from SCC to verrucous 
carcinoma, thereby excluding this patient from statistical analyses. By reading the EHR, we 
found that the patient had had the appropriate treatment given the histopathological result, but 
due to this, this case was first included into the CRF on the basis of the ICD-10 diagnosis in 
Paper I, written before the histopathological re-evaluation. However, by histopathological re-
evaluation, we then excluded this case from the other statistical analyses. 
As part of this project we also wanted to explore whether histopathological 
patterns/morphological characteristics in OTSCC could be used to predict tumor 
aggressiveness. Hypothetically such characteristics may allow more personalized treatment, 
especially for low-stage tumors. In Paper III and Paper IV, histopathological growth pattern 
and survival outcome were explored.  
Tumor thickness and DOI are used by many pathologists without further description (123). 
Tumor thickness can be reported as actual tumor thickness (TA) or reconstructed tumor 
thickness (TR), ad modum Woolgar from 1995 (Appendix V). The NOROC pathologists used 
TR to describe DOI in Paper III.  
When integrating DOI into the T classification in the re-evaluation from an older TNM 
version to our newer TNM classification, we found that DOI provided complementary 
prognostic value for the classification. Tumors generally shifted to a higher T-status as 
described in Paper III. This is in line with other reports documenting that DOI generally 
upregulates the T-size (10, 24, 124). As a consequence of this, the five-year OS and DSS for 
those staying low-stage tumors improves (10, 124). 
Tumor budding has been recommended to be an additional prognostic factor to the TNM 
classification in grading of colorectal cancer, and also to supplement the T classification of 
OTSCC (45, 46). A recent work by Shimizu and colleagues found TB to be a prognostic 
marker for low-stage OCSCC, together with mode of invasion (125). We found TB to be 
significant in univariate analyses. High budding-score was associated with a higher degree of 
lymph node metastases. In this way, TB predicts aggressiveness of the tumor, and can be of 
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important relevance, together with the TNM classification, as a supplement in treatment 
decision. A high TB score has been shown to correlate with lymph node (N+) involvement 
and recurrence of disease in other studies (126, 127). Our findings could also support a 
recommendation that low-stage tumors with high TB score could have neck dissection. 
Other research questions were to investigate whether histopathological risk-patterns of the 
tumors can predict the aggressiveness of OTSCC (50-52), and we addressed this in our Paper 
IV. For the whole cohort, lymph node status and risk-patterns such as differentiation of the 
whole tumor, perineural infiltration, and lymphocytic infiltrate, were found to associate with 
survival. A recent work from Sinha and coworkers in 2018 also found WPOI, lymphocytic 
host response, and perineural invasion, to be histologic factors that could indicate a more 
aggressive treatment for some low-stage OCSCC (128). Wagner and colleagues found that 
Bryne’s tumor histologic differentiation grading system was a useful method to predict 
survival outcome, where the well differentiated (grade I) had the highest survival outcome 
(129). Lymphocytic infiltrate, also called lymphocytic host response in the risk model, is 
histopathologically quantified as the density of lymphocytes at the tumor front (53, 130). 
High density of lymphocytic infiltration, has for a long time been considered as a positive 
prognostic sign (52, 53, 131). Also, we found that the WHO differentiation grading of whole 
tumor together with lymphocytic infiltration in a combined histo-score, was significant 
predictor for survival. In this work, we found that this combined histo-score of differentiation 
and lymphocytic infiltration as a combined variable can be used as a supplement into the 
TNM classification when assessing tumor aggressiveness. We could use this combined score 
especially when deciding whether a low-stage tumor should have additional neck dissection 





Since 1 May 2015, we have had fast-track on diagnosing and startup of treatment of HN 
cancer patients in Norway. The goal is that a minimum of 80% of the patients should be 
diagnosed and commence treatment within 28 days (132). In the NOROC study we could not 
always determine the point when the patient was referred to the hospital until given treatment, 
because the referral letter was not always documented and filed in the EHR. We tried to 
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calculate time from first mention of referral or annotation in the EHR until start of treatment, 
and 52% of the patients had started treatment within 4 weeks, additionally 32% had started 
treatment within 8 weeks, 3% started the treatment 9 weeks or more after referral, and for 13 
% we could not specify when they had been referred. Today, all corresponding letters from 
general practitioners, dentists, or other specialists are documented in the EHR the same day as 
they are received electronically; this was not the case in 2005–2009. 
Most of the patients’ data had been documented in MDT meetings (58). Today this is routine. 
It was a positive finding that this was also the standard in 2005–2009 as shown in Paper I. 
Treatment procedure was not registered based on procedure codes in our CRF, but by reading 
through the EHRs as to what had actually been the treatment. For treatment assessment, 
planned treatment and actual treatment were not always aligned. Patients could deteriorate 
during treatment. Postoperative RT ended up as definitive RT without post RT surgery. It was 
necessary to read the surgical report to assess what surgical treatment had been given, not just 
trusting the codes and headlines, especially when defining what type of dissection of the neck 
the patients had. We tried to assess RT given, but to some extent it was difficult to find this, 
because at some hospitals the RT given is recorded in another file system, or the patients were 
given the RT at an oncological hospital, not the same one where they had the diagnosis or 
surgery treatment. We also discovered that split-course RT was missed when uploaded as a 
SPSS file for statistical analyses, because the answer option in the CRF was set as a single 
number without allowance for using combinations.    
There were no great differences in treatment between the four hospitals. At one hospital, there 
was a slight tendency to give more preoperative RT to the patients, but the difference was not 
statistically significant. The cohort is uniform when we consider survival outcome from 
different hospitals. For the patients given preoperative RT, we only had the diagnostic biopsy. 
We did not have or include eventual resections if they had preoperative RT, to avoid 
influencing the histopathological assessment with bias from the actual given RT.  
Chemotherapy was given in few cases, and in combination with RT with or without surgery, 
altogether only 44 patients (8%). This is quite in line with recent Swedish study that reported 
12% given chemoradiotherapy (but for all HN cancer types) (40). 
In our cohort in Paper I, we documented that 11% of the patients were given palliative 
treatment; this is in line with that recent Swedish study, though it includes all sites of HN 
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cancers, reporting 9% for palliative treating (40). This is also in line with the knowledge that 
most patients with this type of cancer usually present with local or regional cancer, seldom 
with metastasized cancer (112). 
Concerning the follow-up time, we wanted to assess whether patients had many complications 
after treatment, but these were often not specified in the EHR. To some extent clinicians had 
asked the patients about complications and documented them, but this was not the standard. 
It is important to diagnose and treat OCC at an early stage, and screening of premalignant 
lesions might prevent development of oral cancer. Public awareness is important, and each 
year there is one month focusing on oral cancer in the UK (Mouth Cancer Action Month, 
November 2020) (133). In the U.S., the 8-Step Oral Cancer Screening has been introduced to 
reduce people’s risk of oral cancer, and April is Oral Cancer Awareness Month (134). In 
Norway, 16 September 2020 is «Munn-og halskreftdagen 2020» (postponed to November 








































With this thesis and cohort of patients, we have contributed to increased knowledge about one 
type of cancer for different specialty fields of medicine, especially the clinical and 
histopathological fields. We have described a large, Norwegian cohort of OCSCC where the 
inclusion criteria have been strict enough to exclude tumors at the base of the tongue, an 
oropharyngeal localization, and other neighboring sites. We have clarified the role of HPV in 
OTSCC, and have presented histopathological growth patterns that might supplement the 
TNM classification in choice of treatment for OTSCC, especially for the low-stage tumors. 
In Paper I, we presented a national cohort of primary treatment-naïve OCSCC comparable to 
other cohorts. This can be used as a standard cohort for future research on 
biomarkers/proteomics following the REMARK guidelines. We found that younger age-
groups (< 70 years of age) and low-stage tumors had better five-year survival. We stated in 
Paper II that we had a homogenous cohort with no detection of high-risk HPV in OTSCC. 
The implementation of DOI to the T-status according to the newest TNM classification 
shifted many of the tumors to a higher T-status as shown in Paper III. N0-status gave higher 
survival outcome compared to N+ status, and tumor budding can be used as a supplement to 
guide in treatment planning for low-stage tumors. Some of the high-risk histopathologic 
patterns as described in Paper IV, also when made less complex with fewer options, can 
indicate degree of aggressiveness and therefore guide in treatment planning. In our work a 
combined histo-score (WHO differentiation grade of whole tumor combined with 
lymphocytic infiltrate) identified a subgroup of patients with lower five-year DSS than high-
stage disease, although they were diagnosed with low-stage disease. This histo-score could be 
a promising variable to be added to the TNM classification for treatment planning. From our 
research, especially for low-stage OTSCC, we may recommend TB, tumor differentiation and 
lymphocytic infiltrate (in a combined histo-score), as additional factors supplementing the 
TNM classification in treatment decisions and follow-up. In less aggressive tumors and a 





























7 Future perspectives 
There is no common consensus in Norway about how we collect clinical and 
histopathological data, except for the short reports we send to the CRN. Here we have 
established a study-registry with a web-CRF, with a fairly homogenous cohort of OCSCC 
patients. The work in conducting the CRF was necessary to develop a platform for data 
collection. Information could not have been taken directly from the diagnosis codes or the 
treatment codes; we had to validate both diagnosis and treatment. A national guideline for 
diagnosing, treatment, and follow-up of HN cancers in Norway was published recently in 
May 2020 (136). We could recommend that all patients be treated according to mutual 
treatment decisions, in national or Nordic clinical trials. We must seek the advantages of a 
common way of documenting the clinical and histopathological variables and to constitute 
data through time, in order to establish evidence-based knowledge. Part of the CRF has 
already been implemented in another project on dental health care and HN cancer. 
For the future, we would present more clinical perspectives concerning choice of treatment 
for the patients. The calculations in the statistical file (SPSS) are necessarily time-consuming, 
and many details need to be rearranged within the statistical file to get variables to use in 
calculations for future research. In our CRF and associated SPSS documents, there is further 
material for continuing research from a clinical point of view. We will also proceed with 
further biomarker-studies, both looking into overall growth pattern and on protein and 
transcriptional level, with bioinformatics, proteomics, and nanotechnology of the tumors, to 
inspect for the presence or absence of certain markers in the tumors of those who survive or 
not (137-140). Our work has had as a future goal that henceforth studies on biomarkers will 
be reported according to the REMARK-guidelines, and that we can hope to find prognostic 
markers for the clinical management of patients allowing for personalized treatment (79-81). 
This collaboration worked well; it is important to have a principal investigator who has a 
broad knowledge about different aspects of epidemiology and the disease, both clinical and 
histopathologic. To gain further insight into clinical appearance, treatment, and tumor 
samples, we could recommend collaboration in a prospective study with an updated CRF, one 
where the new general data protection regulation would be implemented (141). In the pipeline 
of the present NOROC collaboration, other papers on details in clinical appearance, 
evaluation of biomarkers, and proteomics are in progress. All of this will allow us to explore 
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Incidence of oral cavity squamous cell carcinomas is rising worldwide, and population char-
acterization is important to follow for future trends. The aim of this retrospective study was to
present a large cohort of primary oral cavity squamous cell carcinoma from all four health
regions of Norway, with descriptive clinicopathological characteristics and five-year survival
outcomes.
Materials and methods
Patients diagnosed with primary treatment-naïve oral cavity squamous cell carcinomas at
all four university hospitals in Norway between 2005–2009 were retrospectively included in
this study. Clinicopathological data from the electronic health records were compared to sur-
vival data.
Results
A total of 535 patients with primary treatment-naïve oral cavity squamous cell carcinomas
were identified. The median survival follow-up time was 48 months (range 0–125 months)
after treatment. The median five-year overall survival was found to be 47%. Median five-
year disease-specific survival was 52%, ranging from 80% for stage I to 33% for stage IV
patients. For patients given treatment with curative intent, the overall survival was found to
be 56% and disease-specific survival 62%. Median age at diagnosis was 67 years (range
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24–101 years), 64 years for men and 72 years for women. The male: female ratio was 1.2.
No gender difference was found in neither tumor status (p = 0.180) nor node status (p =
0.266), but both factors influenced significantly on survival (p<0.001 for both).
Conclusions
We present a large cohort of primary treatment-naïve oral cavity squamous cell carcinomas
in Norway. Five-year disease-specific survival was 52%, and patients eligible for curative
treatment had a five-year disease-specific survival up to 62%.
Introduction
Oral cavity cancer (OCC) is the most common subtype of head and neck (HN) cancer [1], and
includes cancers in the mobile tongue (anterior 2/3 of the tongue), floor of mouth, buccal and
labial mucosa, upper and lower gingiva and alveolar mucosa, retromolar trigone, and hard pal-
ate [2–4]. The mobile tongue is the most common site for OCC, accounting for up to 50% of
the cases [5–7].
In 2012 the global incidence of OCC was estimated to 275 000 [1], and is steadily rising
worldwide. According to global cancer statistics in 2018, the estimated incidence of OCC
together with lip location was found to be around 355 000 [8]. However, there is geographical
variation; as many as 25% of all cancers in high-risk countries in South-East Asia are oral carci-
noma [8, 9]. In Europe, the incidence is higher in Southern and Central/Eastern parts com-
pared to Northern and Western parts [9–11]. For cancer of the tongue, there is a trend of
increasing incidence in the Nordic countries as well as in the United States [5, 12–14]. The
now recognized importance of HPV infection in developing oropharyngeal cancer has stressed
the importance of distinguishing OCC from oropharyngeal cancers [1, 15]. HPV has been
found to be uncommon in OCC [16, 17]. The incidence of oropharyngeal cancers was esti-
mated globally to be around 93 000 cases in 2018 [8].
Squamous cell carcinoma (SCC) accounts for more than 90% of malignant neoplasms of
the oral cavity [11, 15, 18], and is classified by the TNM system according to primary tumor
size (T), regional lymph node spread (N), and distant metastasis (M) [3, 4].
Tobacco smoking, betel chewing, and excessive alcohol drinking are major risk factors,
though the habit of betel nut chewing is a factor mainly in Asia [9, 18–20]. Poor dental health
is also considered to be a risk factor [20–23]. Some patients experience recurrence or risk of
second primary tumors [24–27].
Primary surgery is the preferred treatment for oral cavity squamous cell carcinoma
(OCSCC) in most institutions when the tumor is regarded resectable, with or without recon-
struction and neck dissection. Postoperative adjuvant radiation therapy (RT) is often neces-
sary, whereas chemotherapy is seldom used, except sometimes for advanced stages [28–34].
The treatment should be decided by a multidisciplinary team (MDT) [35]. In lack of a national
treatment protocol for HN cancer, management of OCSCC in Norway usually follows the pro-
tocol published by the Danish Head and Neck Cancer Group (DAHANCA) [34].
Five-year survival rate for OCSCC is approximately 50% for most countries [9, 11, 36].
Despite earlier detection and more treatment options, survival rate has not improved more
than three to five percent over the last decades [11, 15]. The Surveillance, Epidemiology, and
End Result program (SEER) database has published five-year relative survival rate of 66% for
tongue, and 53% for the floor of mouth in the period 2009–2015 [37].
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The epidemiological and survival data for OCC are hampered with uncertainty as many
studies report results from small patient cohorts, often selected from a single or a referral hos-
pital, or a small region. Furthermore, some studies include only patients treated with curative
intention, or unfortunately merge patients with cancers of various subsites of the HN region
[5–7, 12, 16].
The aim of this retrospective study was to present a large cohort of OCSCC, from all four
health regions of Norway, with descriptive clinicopathological characteristics and five-year
survival outcomes. All patients were diagnosed with primary treatment-naïve OCSCC in the
period 2005–2009, and the results were evaluated against comparable cohorts.
Materials and methods
Data collection process
The Norwegian Oral Cancer (NOROC) study is a retrospective study that includes patients
diagnosed with primary treatment-naïve OCSCC in the four university hospitals in Norway
between January 1st 2005 through December 31st 2009. In Norway, management of OCC is
centralized to university hospitals of Rikshospitalet (Oslo), Haukeland (Bergen), St. Olavs
(Trondheim) and North Norway (Tromsø), where Rikshospitalet in Oslo (The National Hos-
pital) also is regarded as a tertiary referral hospital. Patients were identified by searching for
the relevant International Statistical Classification of Diseases and Related Health Problems
10th Revision (ICD-10) codes in the electronic health records (EHR) of these hospitals, as well
as by searching the pathology archives for cancers with topographic systematically organized
computer-processable collection of medical terms providing codes (SNOMED) coding T51
and T53. The patients diagnosed during this period were classified according to TNM 5th Edi-
tion 2005 UICC [3].
We included patients with the relevant ICD-10 classification codes C02-C06 [38], which
refer to cancers in the buccal and labial mucosa, upper and lower gingiva and alveolar mucosa,
hard palate, mobile tongue, and floor of mouth. We excluded ICD-10 codes C05.1 and C05.2
which are regarded as oropharyngeal sites, and cancer of the external upper or lower lip (ver-
milion), because these almost exclusively arise in the lower lip and are more likely to act as
skin cancer [15]. Tumors with different histopathology than SCC were also excluded, as well
as patients with HN second primaries or previous cancer treatment. Approximately 27% of the
patients had been incorrectly coded; the majority of these had oropharyngeal cancer, and were
excluded.
Extracting clinical data
Anonymized clinical data were recorded in a web-based Case Report Form (CRF). The last
day of follow-up was June 1st 2015 when all patients had been followed throughout a minimum
of five years after end of treatment. The patient EHRs were screened from date of diagnosis
until date of death, or from date of diagnosis until last day of follow-up. Recording was done
by experienced clinicians (IHB, OJ, GK, EJ and ÁK). Relevant patient data, ICD-10 diagnosis,
TNM classification, treatment, and follow-up were registered. Since these patients were diag-
nosed between 2005–2009, the stage classification was done according to AJCC 6th edition
2002 [15].
In the TNM classification system, the term TX, NX, and MX can be used in cases where the
primary tumor, regional lymph nodes, or distant metastasis cannot be assessed [3, 4, 15]. For
this reason, some tumors lacked T, N, or M status. However, a T4 tumor could be staged with-
out knowledge of the N and M status, since it automatically classifies as a stage IV tumor. This
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was also true with N status�N2, and M1. In this study we pooled stage IVA, IVB, and IVC
into Stage IV.
The study was approved by the Institutional Review Board of Northern Norwegian
Regional Committee for Medical Research Ethics (REK Nord) giving validated approval for all
four hospitals (Protocol number REK Nord; 2013/1786 and 2015/1381). REK Nord waved the
need for the patients still alive to have the opportunity to opt-out when they were informed
about the project. The information-consent letter was approved by REK Nord before being
sent out to the patients still alive. This study was planned retrospectively and approved in
2014, five to ten years after the patients had had their diagnosis and treatment. Patients were
informed they could withdraw from the study without concern. The letter was sent to patients
when the inclusion stage of research commenced between August 2015 and February 2017.
The patient information-consent letter was sent to those still alive giving them the option to
opt-out of the study. This was executed by the principal investigator, who received the list over
patients still alive from one of the co-investigators who was the only one with access to the
patient’s identifying data. The address used was the latest address given in the EHR. No letters
were returned from patients or postal services. Three patients contacted the principal investi-
gator to confirm they were agreeing to participate, no one contacted to opt-out. Cause of death
was acquired from Norwegian Cause of Death Registry.
Categorical grouping
Patients were divided into groups based on age at time of diagnosis; 51–60 years, 61–70 years,
and 71–80 years. Those younger than 50 and older than 80 were few and thus pooled in a
younger (�50 years) and an older (�81 years) age group. We also organized the patients
according to an indicator called Integrated Risk Factor (IRF) based on extent of tobacco and
alcohol consumption as previously described by Rikardsen et al. [16].
Patients with alcohol consumption recorded as seldom in the EHRs were classified as “light
drinkers” (� 1 times weekly), whereas those with consumption denoted as current, moderate,
heavy, or former alcoholic abuse were classified as “drinkers” (> 1 times weekly or daily) [39,
40]. Based on information from the EHR, dental status was categorized as good (no dental treat-
ment needed), need of dental therapy before start of treatment, or edentulous [41]. Cancer treat-
ment described in the EHR was categorized into different groups/combinations of treatment
modalities. Palliative treatment and treatment vaguely described, were pooled. Level of educa-
tion was poorly described in the EHRs and could not be used to describe socioeconomic status.
Statistical analyses
The correlation between gender and different variables was evaluated using Spearman bivari-
ate correlation (2-tailed) and bootstrapping at 95% confidence interval (CI), as shown in
Tables 1–3. For evaluating survival, Cox regression allowed us to report significance, hazard
ratio (HR), and 95% CI after bootstrapping as shown in Tables 4 and 5. Results were consid-
ered to be significant at p<0.05. For survival the variables significant in univariate analysis
were analyzed for multicollinearity (VIF), applying linear regression, testing independent vari-
ables against a dependent variable. VIF values<2 were regarded to indicate no multicollinear-
ity. The variables with limited data (few in number), were excluded from calculations because
of risk of sparse-data bias [42–44]. Kaplan-Meier (Log Rank) was used to construct survival
analyses plot. For survival analysis the definitions used were overall survival (OS) and disease-
specific survival (DSS); the latter was equivalent to cause-specific survival [45]. All statistical
analyses were performed with IBM Statistical Package for the Social Sciences (SPSS) version
25.
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Results
Our study identified 646 patients with cancer in the oral cavity, of which 111 were excluded as
specified in the flowchart in Fig 1, giving a final cohort of 535 patients diagnosed with primary
treatment-naïve OCSCC.
The male: female ratio was 1.2, and the median survival follow-up time from end of primary
treatment till death or last day of follow-up was 48 months (range 0–125 months).
Clinicopathological characteristics
The clinicopathological characteristics are given in Table 1.
Table 1. Clinicopathological characteristics of 535 primary oral cavity squamous cell carcinomas 2005–2009.
Male n (%) Female n (%) (rs) (CI 95%) p
Variable 294 (55) 241 (45)
Age, median (range) 64 (25–101) 72 (24–96)
Age groups
�50 31 (10.5) 19 (7.9)
51–60 72 (24.5) 36 (14.9)
61–70 108 (36.7) 55 (22.8) 0.245 (0.162–0.325) <0.001
71–80 54 (18.4) 66 (27.4)
>80 29 (9.9) 66 (27.0)
Primary site
Mobile tongue 142 (48.3) 98 (40.7)
Gingival/alveolar 46 (15.6) 61 (25.3)
Floor of mouth 69 (23.5) 33 (13.7) 0.062 (-0.026–0.147) 0.154
Cheek/bucca/retromolar 35 (11.9) 44 (18.3)
Hard palate 2 (0.7) 5 (2.1)
Tumor status
T1 65 (22.1) 46 (19.1)
T2 100 (34.0) 73 (30.3)
T3 29 (9.9) 29 (12.0) 0.059 (-0.030–0.141) 0.180
T4 92 (31.3) 85 (35.3)
Unknown� 8 (2.7) 8 (3.3)
Lymph node status
N0 186 (63.3) 143 (59.3)
N1 34 (11.6) 23 (9.5)
N2 53 (18.1) 56 (23.2) 0.050 (-0.039–0.136) 0.266
N3�� 4 (1.4) 1 (0.4)
Unknown� 17 (5.8) 18 (7.5)
Stage of disease
Stage I 61 (20.7) 40 (16.6)
Stage II 75 (25.5) 51 (21.2)
Stage III 35 (11.9) 28 (11.6) 0.089 (-0.004–0.172) 0.043
Stage IV 112 (38.1) 111 (46.1)
Unknown� 11 (3.7) 11 (4.6)
� Unknown data were not included in the calculations.
��Not included in calculations because of risk of sparse-data bias.
rs = Spearman rank correlation, rho.
https://doi.org/10.1371/journal.pone.0227738.t001
Characteristics and prognosis of oral cavity squamous cell carcinomas in Norway
PLOS ONE | https://doi.org/10.1371/journal.pone.0227738 January 16, 2020 5 / 16
Median age at time of diagnosis for the whole cohort was 67 years (range 24–101 years)
with few patients younger than 40 and older than 90 (13 and 11 cases, respectively). The
median age at time of diagnosis for men was 64 years (range 25–101 years) compared to 72
years for women (range 24–96 years).
In 97% of the cases TNM staging was complete, and 93% of the cases were discussed in
MDT meetings. There was no significant gender difference in either T or N status, and just
slightly significant for stage.
T1 and T2 tumors constituted 53% of the cases, almost 11% were T3 tumors, and 33% were
T4. According to the AJCC staging, 43% of the patients had stage I and II disease, 12% had
stage III disease, and 42% had stage IV disease.
There was no significant gender difference in location of the primary tumor (Table 1). The
mobile tongue was the most common tumor site, accounting for almost 50% of the cases for
men and 40% for women. The second most common tumor location in men was floor of
mouth while gingiva and alveolar mucosa were more frequent in women. Cancers in the
mobile tongue were most often T1-T2 tumors, whereas gingiva and alveolar mucosa had more
T4 tumors. Tumors of the floor of mouth were most often T2 and T4. There was no correlation
between age group and location (p = 0.068, CI: 0.001–0.164). Only three patients had distant
metastasis at time of diagnose, and no calculations were performed on this variable.
Risk factors
Risk factors are listed in Table 2.
Table 2. Risk factors for 535 patients with primary oral cavity squamous cell carcinoma in Norway 2005–2009.
Male n (%) Female n (%) (rs) (CI 95%) p
Variable 294 (55) 241 (45)
Smoking
Never 41 (13.9) 82 (34.0)
Current 169 (57.5) 97 (40.2) -0.230 (-0.317–0.137) <0.001
Former 70 (23.8) 37 (15.4)
Unknown� 14 (4.7) 25 (10.4)
Alcohol comsumption
Never (Non-drinker) 12 (4.1) 36 (14.9)
�1 times weekly (Light drinker) 42 (14.3) 55 (22.8) -0.405 (-0.501–0.305) <0.001
>1 times weekly or daily (Drinker) 155 (52.7) 49 (20.3)
Unknown� 85 (28.9) 101 (41.9)
Integrated Risk Factor
Non-smoker/Non-drinker 12 (4.1) 32 (13.3)
Non-smoker/Light drinker 39 (13.3) 41 (17.0)
Smoker/Non-drinker�� 1 (0.3) 5 (2.1) -0.084 (-0.201–0.036) 0.119
Smoker/Light drinker 15 (5.1) 20 (8.3)
Smoker/Drinker 138 (46.9) 42 (17.4)
Unknown� 89 (30.3) 101 (41.9)
Dental status
Good 68 (21.4) 44 (18.3)
Needs treatment 158 (53.7) 112 (46.5) 0.119 (0.024–0.206) 0.009
Edentulous 45 (15.3) 64 (26.6)
Unknown� 28 (9.5) 21 (8.7)
� Unknown data were not included in the calculations.
��Not included in calculations because of risk of sparse-data bias.
rs = Spearman rank correlation, rho.
https://doi.org/10.1371/journal.pone.0227738.t002
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Smoking habits were recorded for 93% of the patients. There was a significantly lower pro-
portion of never-smokers among male compared to female patients (14% vs. 34%), and 58% of
the male patients were current smokers compared to 40% of female patients. Only two patients
were recorded consuming Scandinavian snuff, but both were former smokers and recorded as
such. Current smoking neither correlated with site of primary cancer (p = 0.175, CI: -0.025–
0.141), nor with T status (p = 0.909, CI: -0.093–0.085) or with N status (p = 0.628, CI: -0.064–
0.109).
Men consumed significantly more alcohol than women, with 11% of the men being heavy
drinkers compared to less than three percent (2.5%) of the women (Heavy drinkers were
included in the “drinker”-group). Alcohol consumption neither associated with site of primary
cancer (p = 0.858, CI: -0.068–0.094), nor with T status (p = 0.522, CI: -0.111–0.054) or N status
(p = 0.770, CI: -0.084–0.069). Of note, 35% of the EHR lacked information of alcohol con-
sumption, and were excluded when analyzing for known risk factors.
More men than women were classified as smokers and drinkers according to the IRF classi-
fication, but the difference was not statistically significant. IRF correlated with T status
(p = 0.001, CI: 0.067–0.237), but not with site of primary cancer (p = 0.265, CI: -0.035–0.125)
or with N status (p = 0.856, CI: -0.060–0.081).
Half of the patients needed some form of dental therapy before treatment, whereas 40% had
no need of dental treatment, of whom 20% were edentulous. The remaining 10% lacked infor-
mation on dental status. There were more edentulous patients in the older than younger age
groups (p<0.001, CI: 0.178–0.348). There was a significant correlation between dental status
and gender, but when adjusting for age this difference was no longer present (p = 0.708, CI:
-0.071–0.104). Patients with tongue cancer had significantly better dental status than patients
with cancer in other oral sites (p = 0.002, CI: 0.039–0.213). In the five-year follow-up time
recurrence was found in 95 (17.8%) of the patients within three years. Second primaries,
defined as a new OCC more than three years after first presence of OCC, was found in 56
(10.5%) of the patients.
Treatment
This study includes patients treated with both curative and palliative intention. Cancer treat-
ment as described in the EHR are listed in Table 3. Palliative treatment was to some extent
vaguely described and pooled.
For 69% (n = 386) of the patients the treatment was surgery, of whom 64% (n = 235)
received postoperative RT as shown in Table 3. Very few of the patients had RT prior to sur-
gery and there was no gender difference in this stratification of treatment (p = 0.215, CI:
-0.171–0.026). Primary RT with or without chemotherapy was reported for 16%, and palliative
treatment was effectuated for 11% (around six percent with RT, the rest with some debulking
surgery or chemotherapy, vaguely described).
There was a significant difference in use of RT between age groups (p<0.001, CI: -0.334-
-0.173). Women seemed to receive significantly less RT than men, but when adjusting for age
there was no difference in use of RT between the genders (p = 0.381, CI: -0.049–0.124). Use of
RT was significantly associated with higher T status (p = 0.008, CI: 0.027–0.207) and positive
N status (p = 0.031, CI: 0.007–0.171) but not with site of tumor (p = 0.683, CI: -0.070–0.100).
Survival
Five-year overall survival (OS) was 47% for the cohort, and disease-specific survival (DSS) was
52% (225 of 435 patients). Five-year DSS was 80% for stage I, 68% for stage II, 45% for stage
III, and 33% for stage IV (Fig 2).
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When excluding patients given palliative treatment, the five-year OS and DSS for
patients given treatment in curative intent, increased to 56% and 62%, respectively. The
five-year DSS was then 80% for stage I, 68% for stage II, 51% for stage III, and 43% for stage
IV (p<0.001, HR = 1.435, CI: 0.261–0.481). Tables 4 and 5 show calculations for five-year
OS and DSS for the whole cohort compared to clinicopathologic characteristics and risk
factors.
Age-groups, T status, N status, stage of disease, and dental status were all significantly
associated with both OS and DSS, in univariate tests at p value <0.05 level (Tables 4 and 5).
As stage is based on T status and N status, stage of disease was not included in multivariate
analyses. Age-groups, T status, and N status were all independent predictors for OS in mul-
tivariate analyses (p = 0.001, HR; 1.487, CI: 0.288–0.517, p = 0.003, HR; 1.201, CI: 0.063–
0.303 and p = 0.001, HR; 1.682, CI: 0.363–0.679). The same factors were independent
predictors of DSS.
Table 3. Treatment of 535 primary oral cavity squamous cell carcinoma patients 2005–2009.
All n (%) Male n (%) Female n (%) (rs) (CI 95%) p
Patients 535 (100) 294 (55.0) 241 (45.0)
Treatment intention
Curative 427 (79.8) 239 (81.3) 188 (78.0)
Palliative 26 (4.9) 12 (4.1)) 14 (5.8) 0.046 (-0.052–0.141) 0.329
Unknown� 82 (15.3) 43 (14.6) 39 (16.2)
Given treatment
Surgery
Surgery alone 125 (23.4) 58 (19.7) 67 (27.8)
Surgery + postop RT 235 (43.9) 147 (50.0) 88 (36.5)
Preop RT + surgery�� 4 (0.7) 2 (0.7) 2 (0.8) -0.134 (-0.240–0.034) 0.009
Surgery + pre- and postop RT�� 1 (0.2) 1 (0.3) 0
Surgery with chemo�� 0 0 0
Surgery with RT and chemo 21 (3.9) 12 (4.1) 9 (3.7)
Non-surgery
RT alone 63 (11.8) 34 (11.6) 29 (12.0)
Chemo alone�� 0 0 0
RT + chemo 23 (4.3) 12 (4.1) 11 (4.6) 0.016 (-0.194–0.241) 0.884
No treatment�� 2 (0.4) 1 (0.3) 1 (0.4)
Unknown� 3 (0.6) 2 (0.7) 1 (0.4)
Palliative 58 (10.8) 25 (8.5) 33 (13.7)
Neck surgery
No neck surgery 255 (47.7) 133 (45.2) 122 (50.6)
Elective neck 76 (14.2) 49 (16.7) 27 (11.2)
Selective neck 52 (9.7) 30 (10.2) 22 (9.1) -0.079 (-0.166–0.013) 0.094
Modified radical and radical neck 68 (12.7) 41 (13.9) 27 (11.2)
Unknown neck surgery� 84 (15.7) 41 (14.0) 43 (17.8)
� Unknown data were not included in the calculations.
��Not included in calculations because of risk of sparse-data bias.
rs = Spearmans rank correlation, rho.
RT = Radiation therapy
Chemo = Chemotherapy
https://doi.org/10.1371/journal.pone.0227738.t003
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Discussion
Our study is large, and includes a substantial number of well characterized patients with pri-
mary treatment-naïve OCSCC compared to other publications in this field. Many epidemio-
logical studies present merged data for OCC and oropharyngeal cancer [1, 15, 18]. In our
study around a quarter of the cases recorded as oral cavity cancers in the pathology archives
and EHRs were oropharyngeal cancers and thus excluded from the study population. This sug-
gests that there is a need to raise the awareness among both clinicians and pathologists of the
importance of a correct anatomical description of the cancer site in patient medical records.
Table 4. Clinicopathological characteristics and five-year overall survival and disease-specific survival.
OS DSS
OS n (%) HR (CI 95%) p DSS n (%) HR (CI 95%) p
Patients 251 (100) 225(100)
Gender
Male 137 (55) 122 (54)
Female 114 (45) 1.022 (-0.206–0.248) 0.853 103 (46) 1.009 (-0.249–0.271) 0.929
Age groups
�50 35 (70.0) 35 (72.9)
51–60 65 (57.4) 59 (60.2)
61–70 88 (54.0) 1.435 (1.299–1.586) <0.001 81 (61.4) 1.580 (0.338–0.594) 0.001
71–80 48 (40.0) 38 (41.3)
>80 18 (19.1) 12 (18.5)
Primary site
Mobile tongue 117 (48.8) 106 (54.4)
Gingiva/alveolar 49 (45.8) 44 (48.9)
Floor of mouth 50 (40.9) 1.041 (-0.046–0.121) 0.338 43 (54.4) 1.058 (-0.041–0.152) 0.228
Cheek/bucca/retromolar 33 (41.8) 30 (45.5)
Hard palate 2 (28.6) 2 (40.0)
Tumor status
T1 70 (63.1) 66 (72.5)
T2 95 (54.9) 83 (61.9)
T3 19 (32.8) 1.401 (0.232–0.437) <0.001 16 (34.0) 1.531 (0.311–0.553) <0.001
T4 60 (33.9) 53 (34.6)
Unknown� 7 (38.9) 7 (70.0)
Lymph node status
N0 193 (58.7) 174 (65.2)
N1 21 (36.8) 18 (37.5)
N2 22 (20.2) 1.825 (0.469–0.741) <0.001 22 (22.9) 1.929 (0.509–0.816) <0.001
N3�� 0 (0) 0 (0)
Nx/Unknown� 7 (50.0) 3 (51.3)
Stage of disease
Stage I 69 (68.3) 65 (80.2)
Stage II 77 (61.1) 67 (67.7)
Stage III 29 (46.0) 1.435 (0.261–0.481) 0.001 24 (45.3) 1.665 (1.356–1.729) 0.001
Stage IV 68 (30.5) 62 (32.6)
Unknown� 8 (36.4) 7 (58.3)
� Unknown data were not included in the calculations.
��Not included in calculations because of risk of sparse-data bias.
https://doi.org/10.1371/journal.pone.0227738.t004
Characteristics and prognosis of oral cavity squamous cell carcinomas in Norway
PLOS ONE | https://doi.org/10.1371/journal.pone.0227738 January 16, 2020 9 / 16
Correct coding is crucial for proper cancer statistics and treatment. One should avoid using
the ICD-10 diagnose C02.4 (tongue tonsils) as this can easily be misinterpreted as an oral loca-
tion. Tumors arising in the root of the tongue is best coded as C01 (base of the tongue) recog-
nized as an oropharyngeal location [38]. Separating oral cavity and oropharyngeal cancers is
important as they are associated with distinct risk factors and also differ in primary treatment
protocols, response to treatment, and survival rates.
The five-year DSS for our cohort was approximately 52%, which is in accordance with the
global report from the review in 2009 of Warnakulasuriya et al. [9]. The five-year OS in our
Norwegian cohort was 47%, which is somewhat higher than reported in a Danish cohort for
the period 1980–2014 (44%)[13], but lower than in a Finnish study (61%). However, the Finn-
ish study included only patients with OSCC of the tongue, treated with curative intent [5].
When we excluded patients given palliative treatment, the five-year OS and DSS increased to
56% and 62%, respectively. Although the OCSCC treatment in Norway is centralized to four
university hospitals, some patients with small T1 tumors may have been treated at local hospi-
tals without referral to the HN cancer centers, and would be missed from our cohort. Patients
with T1 tumors have significantly better survival rates than patients with more advanced
Table 5. Risk factors and five-year overall survival and disease-specific survival.
OS DSS
OS n (%) HR (CI 95%) p DSS n (%) HR (CI 95%) p
Patients 251 (100) 225 (100)
Gender
Male 137 (55) 122 (54)
Female 114 (45) 1.022 (-0.206–0.248) 0.853 103 (46) 1.009 (-0.249–0.271) 0.929
Smoking
Never 61 (49.6) 56 (52.8)
Current 125 (47.0) 0.915 (-0.234–0.055) 0.222 111 (52.4) 0.926 (-0.254–0.110) 0.372
Former 51 (47.7) 45 (51.1)
Unknown� 12 (32.4) 11 (40.7)
Alcohol comsumption
Never (Non-drinker) 18 (37.5) 14 (38.9)
�1 times weekly (Light- drinker) 49 (50.5) 0.929 (-0.203–0.052) 0.246 48 (55.8) 0.916 (-0.239–0.069) 0.242
>1 times weekly/daily (Drinker) 90 (44.1) 80 (48.5)
Unknown� 94 (50.5) 83 (56.1)
Integrated Risk Factor
Non-smoker/Non-drinker 17 (38.6) 12 (37.5)
Non-smoker/Light-drinker 46 (57.5) 0.969 (-0.067–0.006) 0.081 44 (62.0) 0.965 (-0.081–0.006) 0.091
Smoker/Non-drinker�� 3 (50.0) 3 (60.0)
Smoker/Light drinker 18 (51.4) 18 (56.3)
Smoker/Drinker 70 (38.9) 63 (43.8)
Unknown� 97 (51.1) 85 (56.3)
Dental status
Good 66 (61.7) 63 (68.5)
Needs treatment 138 (51.1) 1.218 (0.030–0.382) 0.025 124 (54.6) 1.472 (0.177–0.613) <0.001
Edentulous 31 (28.4) 24 (28.6)
Unknown� 14 (30.4) 12 (41.4)
� Unknown data were not included in the calculations.
��Not included in calculations because of risk of sparse-data bias.
https://doi.org/10.1371/journal.pone.0227738.t005
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disease, and if some T1 tumors are missing in our cohort, this may have caused a negative shift
in survival rate.
In the current study, 45% of the patients had cancer of the mobile tongue, which corre-
sponds well to reports from previous studies [5–7]. The site and TNM classification are gener-
ally the most important prognostic factors for OCC [36]. In the present study, we found
significantly higher survival for patients with low T status and stage, whereas the anatomical
site of the tumor had no significant impact on survival. Number of recurrences or develop-
ment of second primaries were in line with previous studies [5, 24].
There were more T1-T2 tumors in the tongue than in other locations, which may be caused
by functions of the mobile tongue giving an earlier awareness of a tumor, along with the rela-
tive ease of self-inspection compared to other intraoral locations. The proportion of T4 tumors
was higher in the gingiva and alveolar mucosa than in the other locations, which may reflect
the short distance from the mucosa to the bone at these sites. Tumor involving the bone is clas-
sified as a T4 tumor irrespective of tumor size.
Stage I and II OCSCCs are often curable, thus early detection and treatment is of vital
importance. In Norway, a large proportion of adults have regular dental examinations, and
both dentists and dental hygienists are trained to examine the oral mucosa for malignant
lesions. Still, we found 44% of the tumors to be size T3 and T4 at time of diagnosis, which
could indicate a rapid growth of tumor. However, patients diagnosed with large tumors were
more often edentulous or in need of dental treatment at time of diagnosis, suggesting that
these patients did not seek dental care as frequently as those with smaller tumors. Older
patients had larger T status, perhaps also reflecting later awareness of illness. It may also sug-
gest that pain in the oral cavity, and symptoms such as changing diet and losing weight are
regarded differently in elderly patients.
Fig 1. Flowchart outlining how we identified 535 unique primary treatment-naïve oral cavity squamous cell
carsinomas in Norway in the time period 2005–2009.
https://doi.org/10.1371/journal.pone.0227738.g001
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Globally, men have higher risk of OCC than women, and we found a male: female ratio of
1.2. This ratio is slightly lower than reported from a Danish and a US study (1.5 and 1.8 respec-
tively) [13, 14], and slightly higher than reported in a Finnish study with 0.9 [5]. Tobacco and
alcohol consumption have become more similar for men and women over the last three
decades in Nordic countries compared to when the patients in our study were young [46]. The
percentage of drinkers has also decreased both in Europe and in the US by approximately 10%
since 2000 [47, 48].
Despite these changes in smoking and drinking habits, the incidence of OCC is rising. This
suggests that other etiological factors are involved. For cancers arising in the oropharyngeal
region, high-risk human papilloma virus (HPV) is considered to be an additional risk factor
[49–51]. However, there is little scientific evidence to consider HPV as a risk factor for OCC,
and the frequency of HPV positive SCC in the oral cavity is generally very low, with less than
four percent in a Brazilian cohort [17] and less than 10% in a previous study from our group
[16]. The use of Scandinavian snuff instead of cigarette smoking has increased tremendously
over the last two decades in Norway, whereas cigarette smoking has decreased [52]. Future
studies will reveal whether this influences the risk of OCC.
The choice of treatment was decided at MDT meetings for the vast majority of patients.
This is according to current recommendations [35], and was a positive finding, as these
patients were treated nine to 14 years ago when MDT meetings were less established than
today. Cancer in the oral cavity is normally managed by surgical removal of the primary
tumor, sometimes combined with neck dissection and/or RT, while chemotherapy is seldom
used [28–34]. The same standard of treatment was also found in our cohort.
Fig 2. Kaplan-Meier curves show five-year disease-specific survival by stage in 435 patients diagnosed with primary treatment-naïve oral cavity
squamous cell carcinoma in Norway in the years of 2005–2009.
https://doi.org/10.1371/journal.pone.0227738.g002
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There are limitations to our study. It was not possible to specify the amount of tobacco use
in pack-years or drinking units as this was a retrospective study. In as many as 35% of the
EHR, the information of either smoking or drinking habits or both, were missing. Calculations
must be evaluated with this perspective. The patient files stated present or past occupation, but
not level of education. Level of education is interesting as a measure of cancer incidence in dif-
ferent socioeconomic classes. For a future prospective study one may recommend a systematic
and accurate registration of socioeconomic status, smoking habits and alcohol consumption,
as well as treatment modalities.
The Eighth Edition of the TNM classification has been introduced since this study was initi-
ated, and in the new TNM classification tumor depth of invasion is included in the T classifica-
tion of OCC, and this will influence determination of stage as well as prognosis [4].
Conclusion
We present a study of a large cohort of 535 primary treatment-naïve OCSCC. Five-year DSS
for the whole cohort was near 52%, and included patients receiving curative as well as palliative
treatment. When extracting patients given treatment with curative intent, the five-year DSS
increased to 62%. There was no gender difference in survival even though men on average
were eight years younger than the women at the time of diagnosis. Patients with the smaller
tumors have better prognosis, and this emphasizes the importance of early detection.
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Objectives: The presence of and the causative role of high-risk human papilloma virus 
(HPV) is a subject of controversy in oral squamous cell carcinoma (OSCC). The 
disagreement can be related to the misclassification of OSCC as oropharyngeal squamous cell 
carcinoma (OPSCC) and/or lack of standard detection methods. This study aimed to examine 
the presence of transcriptionally active high-risk HPV in a homogenous Norwegian cohort of 
primary and second primary OSCC of the mobile tongue (OTSCC).  
Materials and Methods: Tissue microarrays containing formalin fixed and paraffin 
embedded cores of 146 OTSCC from the anterior 2/3 of the tongue (n=128 primary, and 
n=18 second primary) from a multicentric Norwegian cohort were examined for the presence 
of high-risk HPV by DNA- and RNA- in situ hybridization (ISH) assays and p16 
immunohistochemistry (IHC).  
Results: Transcriptionally active HPV (E6/E7 mRNA) was not identified in any of the 
OTSCC specimens. In parallel, no tumors were positive for HPV by DNA ISH. Although, 61 
(42%) OTSCC demonstrated p16 positivity with varying staining intensity and sub-cellular 
localization, only two cases demonstrated strong and uniform p16-staining (both cytoplasmic 
and nuclear) in > 70% of cancer cells.   
Conclusions: The absence of transcriptionally active high-risk HPV in this cohort of OTSCC 
indicates that high-risk HPV is an unlikely causative factor in the present material.  
Keywords: oral cancer, cancer of the head and neck, squamous cell carcinoma, tongue, 
human papillomavirus, human papillomavirus oncogene protein, immunohistochemistry, p16, 






The oral cavity is considered to be a separate anatomical location from the oropharynx. Here, 
squamous cell carcinoma (SCC) accounts for the majority of malignant tumors [1]. The five-
year overall survival for oral SCC (OSCC) is about 64% and is closely related to the tumor 
stage [2, 3]. In a recent systematic review, the mobile tongue is shown to be the most 
common site of oral cancer among the patients below 45 years of age [4]. This is of great 
concern since patients with oral tongue SCC (OTSCC) have a significantly more unfavorable 
prognosis than those at other oral cavity sites [5, 6].   
High-risk human papilloma virus (HPV) is the primary etiological factor in oropharyngeal 
squamous cell carcinoma (OPSCC) in the Western world [7]. Accordingly, high-risk HPV 
subtypes have been shown to be present in more than 70% of OPSCC [8, 9]. The HPV 
positive OPSCC is considered to be a biologically distinct entity and is associated with a 
higher survival rate as compared to the conventional HPV negative (tobacco-induced) 
OPSCC [10]. In 1983, Sÿrjanen proposed that HPV could be a possible etiological factor for 
a subgroup of OSCC [11]. Since then, several studies have focused on HPV detection in 
OSCC, however, with conflicting results [12, 13]. Firstly, misclassification of OPSCC as 
OSCC makes it difficult to analyze the results [14]. Secondly, lack of standard 
methodological approach for HPV testing can significantly lead to over- or underestimation 
of HPV positivity [12, 15, 16]. In a systematic literature review of approximately 4000 oral 
cavity cancer specimens, the weighted prevalence of Polymerase Chain Reaction (PCR)-
based HPV DNA detection was found to be 20.2 % [17]. However, the high sensitivity of 
DNA PCR analysis increases the risk of false positive results. Moreover, HPV DNA 
detection does not distinguish an active (driver) HPV infection from passenger/bystander 
infection [18, 19]. In recent years, the mRNA E6/E7 in situ hybridization (ISH) technique has 
become increasing popular and it allows direct visualization of viral transcripts in routinely 
processed tissues, thereby reflecting the active HPV infection [20]. To our knowledge, only a 
few studies using relatively limited numbers of OSCC have evaluated the presence of high-
risk HPV in OSCC by this technique [12, 21, 22]. Their results indicate that high-risk HPV 
prevalence is very low in OSCC and challenge the view that HPV is a possible etiological 
factor in OSCC. This underscores the importance of studies aimed at identifying active HPV 
infection in a large and homogenous OSCC cohort.   
The current work represents a sub-study of a joint initiative (Norwegian Oral Cancer 
(NOROC) multicenter study) between the four University hospitals in Norway treating 
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OSCC [23]. Here, 146 OTSCC diagnosed in Norway from 2005 until 2010 were included. 
The hypothesis of the current study was that high-risk HPV infection is uncommon in 
OTSCC in the Norwegian population. Here we compared three different and independent 





Material and methods 
 
OTSCC selection and extraction of clinical data   
The study was approved by the Northern Norwegian Regional Committee for Medical 
Research Ethics (REK Nord; 2013/1786 and 2015/1381). In this multicenter study, all OSCC 
cases diagnosed between January 1st , 2005 through December 31st , 2009 at the four 
Norwegian university hospitals treating head and neck cancer (Oslo, Bergen, Trondheim and 
Tromsø) were retrospectively identified.  Using ICD-10 codes (C02-C06) except for codes 
C05.1 and C05.2 (oropharyngeal sites, and cancer of the external upper or lower 
lip/vermilion), a total of 608 OSCC patients were identified from the electronic health record. 
Two hundreds and seventy-three OTSCC with clinical data were identified. Of the 273 
OTSCC, 146 (128 primary + 18 second primary) were included in the present study (for 
details of the exclusion criteria, see Figure 1). Unidentifiable clinical data were recorded in a 
web based Case Report Form (CRF). Relevant patient data, ICD-10 diagnosis, TNM 
classification, treatment received and minimum of five years follow-up (last follow-up date 
June 1st 2015) were registered. The patients were classified according to TNM 5th Edition 
2005 UICC [24].  
Tissue microarray generation 
Tissue microarrays were constructed from formalin-fixed, paraffin-embedded (FFPE) tissue 
blocks in a fully automated tissue microarray machine (TMA Master II, 3DHISTECH). Two 
to four tissue cores (both invasive front and more superficial parts of the tumors) with a 
diameter of 2 mm were arrayed on the recipient paraffin blocks. The stained TMA-sections 
were scanned (Pannoramic® MIDI scanner, Thermo Fisher Scientific) and evaluated using the 
CaseViewerTM software (3dhistech.com). For scanned images with inadequate focus, the 
original glass slides were examined by a Leitz Aristoplan microscope.  
p16 immunohistochemistry (IHC) and scoring 
IHC was performed on TMAs on a Ventana Benchmark Ultra automated immunostainer 
(Ventana Medical Systems, VMS, Tucson AZ, USA), using a mouse monoclonal antibody 
clone E6H4 (CINtec® p16 Histology, VMS #805-4713). Bound antibody was detected by the 
biotin-free ultraView Universal DAB Detection Kit (VMS #760-500). A known p16- 
expressing OPSCC was used as a positive control. Sections incubated with phosphate buffer 
saline (instead of primary antibody) and with isotype-matched control (Mouse IgG2a, Sigma-
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Aldrich, St. Louis, MO, # M9144) were used as negative controls. For details, see Appendix 
A, supplementary 1 (S1). Blinded for the clinicopathological data, the p16 stained TMA-
sections were scored by TMS, DS, PJ and HL. p16 expression was evaluated as follows: 
score 0: no expression, score 1: positive staining  in < 70% of the tumor cells, score 2: 
positive staining, either nuclear or cytoplasmic in >70% of the tumor cells score 3: Strong 
and uniform p16-staining (both cytoplasmic and nuclear) in > 70% of cancer cells [25].  
HPV DNA ISH and scoring 
Automated in situ hybridisations were carried out on TMAs on a Discovery XT (VMS) 
instrument using Research ISH UltraMap XT procedure and Ventana products (INFORM HPV 
III Family 16 Probe (B), #800-4295; ). For details, see Appendix A, supplementary 2 (S2). 
Each TMA slide contained HeLa cells as positive staining controls. Additionally, sections of a 
known HPV positive OPSCC were also used as positive controls. A no probe control containing 
only RiboHybe and RiboWash served as a negative control.  
Blinded for the clinicopathological data, the HPV DNA ISH results were scored by TMS and 
DS. The in situ results were interpreted following the manufacturer’s guidelines (Interpretation 
Guide for Ventana INFORM HPV Probes ISH). Any blue nuclear dots in the tumor cells were 
regarded as positive staining and all of the samples were classified binary as either positive or 
negative.  
HPV RNA ISH  
Automated RNA in situ hybridisations were carried out on a Discovery Ultra (Ventana 
Medical Systems, Tucson, AZ, USA) using the fully automated RNAscope VS HRP assay 
(#323200 Advanced Cell Diagnostics Inc, Hayward,  CA, USA). Standard protocols were 
used for the deparaffinization followed by heat pretreatement using Discovery CC1 and 
mRNA sample prep protease treatment. For details, see Appendix A supplementary 3 (S3). 
The RNA quality was controlled in some ramdomly selected specimens using a probe for the 
common housekeeping gene PPIB (#313909 ACD). Background signal was investigated with 
a negative control probe for the bacterial gene DapB (#312039 ACD). Both probes were 
incubated on full FFPE sections and evaluated according to the manufactures instructions. 
Sections of FFPE pellets of HeLa cells were used as positive controls. 
Blinded for the clinicopathological data, the HPV RNA ISH results were scored by TMS and 
DS. A positive HPV test result was defined as punctate staining that localised in the 
cytoplasm and/or nucleus of malignant cells. The RNA ISH staining was scored according to 
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Advanced CELL diagnostics guidelines, as described in the Appendix A Supplementary 4 
(S4). 
Statistical analysis 
Descriptive statistics (range, mean, median and frequencies), where applicable, were 
calculated for continuous and categorical variables using the Statistical Package for the Social 






The present study adheres to the REMARK criteria [26]. Out of 146 OTSCC, cases with 
missing tissue cores or containing few/no malignant cells in the array were excluded from the 
analysis. Following these criteria, two primary cases were excluded from the analysis of p16 
and DNA ISH, and three primary cases were omitted from the analysis of the RNA ISH.  
The clinicopathological variables for 128 primary OTSCC are summarized in Table 1. In 
brief, primary OTSCC occurred in 77 males (60.2%) and in 51 females (39.8%). At the time 
of diagnosis, the median age for the cohort was 65.5 years (range: 25-90 years). The second 
primary OTSCC occurred in 10 males (55.6%) and 8 females (44.4%). The median age was 
72.0 years (range: 42-91 years). Fifteen tumors (83.3%) were cT1/cT2, two were cT3/cT4 
(11.1%) while T-classification was missing for one case.  
p16 immunohistochemistry  
Sixty one (42%) OTSCC showed p16 positivity with varying staining intensity and sub-
cellular localization (Figure 2). Among the positives, only 2 (1%) OTSCC (both primary) 
demonstrated strong and uniform p16 staining, fulfilling the criteria for score 3 (Figure 2A).  
For details on distribution of p16 staining in OTSCC, see Table 2. 
HPV DNA ISH  
Based on the evaluation criteria described above, all tumors tested negative for HPV DNA 
(Figure 3A), including the two cases with p16 score 3. The positive controls, a known HPV 
positive OPSCC (Figure 3B) and HeLa cells (Figure 3C) showed positive staining. The no 
probe control was negative (Figure 3D). 
HPV RNA ISH  
No staining or less than one dot to every ten cells was observed in all of the OTSCC 
investigated (Figure 4A). The positive control, HeLa cells, was positive (Figure 4B) and the 
RNA controls with PPIB probes were positive (Figure 4C and D). The bacterial gene dapB 






The pathogenic role of HPV in OPSCC has been well established however, its role in OSCC 
carcinogenesis is a subject of a controversy. Although several tests are available for HPV 
detection, there is no consensus on the test method(s) for routine diagnostics of HPV-related 
oropharyngeal squamous cell carcinomas/head and neck carcinomas [16, 19]. Different 
methods have different detection targets including HPV DNA, RNA, viral oncoproteins like 
E6/E7, cellular proteins (e.g. p16 protein) or HPV-specific serum antibodies. Careful 
selection of the detection technique and viral target is extremely important to obtain reliable 
and clinically meaningful data. However, the commonly used assays such as p16 IHC and 
PCR have limitations. For example, p16 overexpression may be caused by molecular 
mechanisms independent of the presence of high-risk HPV. DNA or RNA extraction 
procedures in PCR techniques destroy the tumor tissue context of importance for 
morphological correlation [20]. Furthermore, the detection of HPV DNA (either PCR-based 
or by ISH) can not discern an incidental virus from a persistant viral oncogene expression 
[15, 16]. In contrast, RNA ISH probes complementary to E6/E7 mRNA permit direct 
visualization of viral transcripts in routinely processed tissues [16, 20]. Unfortunately, only a 
handful of studies have used this approach to examine the HPV infection in OSCC. The 
current study consisted of a homogenous and a relatively large number of OTSCC specimens 
(both primary and second primary). Use of three different test methods enabled us to examine 
the presence of HPV DNA, its transcriptional active form (E6/E7 mRNA) and the HPV-
surrogate marker, p16.  
All of the OTSCC specimens in the current Norwegian cohort were negative for E6/E7 
mRNA and HPV DNA. This is in line with the observations reported by Lewis et al., where 
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all of the 45 OSCC examined were negative for HPV E6/E7 RNA [12]. Similarly, only one of 
107 OSCC contained transcriptionally active HPV in the study by Bishop et al., [22]. Due to 
the absence of HPV E6/E7 RNA positive carcinomas, we could not characterize their 
biological or clinical significance. The present HPV DNA results is in agreement with Jaber 
et al., [27]. Lewis et al., identified only one HPV DNA positive OSCC out of 45 in their 
study [12]. In contrast, a recent systematic review and meta-analysis reported a higher 
prevalence of HPV DNA positivity in South and Central America and Asia, as compared to 
that in North America and Europe [28].  
In line with the DNA/RNA ISH results, only two OTSCC were p16 positive (score 3). 
However, both of the p16 positive OTSCC were negative for HPV DNA and RNA ISH. This 
suggests that the p16 expression in those cases might be related to non-HPV mechanisms and 
supports the view that p16 is not a reliable surrogate marker for HPV in OTSCC [22, 29]. 
One of the two OTSCC with p16 score 3 staining was a basaloid carcinoma (non-
keratinizating). This is an interesting observation since p16 positive OPSCC usually are non-
keratinizing. However, another non-keratinizing carcinoma included in the present study, was 
p16 negative.  
A general increase in the incidence of OTSCC has been reported globaly with a shifting trend 
towards female and/or younger patients with OTSCC [30]. In the present study, such a trend 
was not obvious in Norway in the period 2005 - 2010. Here, the majority of the patients were 
males and 66% of the patients were 60 years or older. The current study benefitted from the 
use of a homogenous cohort of OSCC only including carcinomas from the anterior 2/3rd of 
the tongue. As the Norwegian population is homogeneous regarding ethnic origin, lifestyle 
and OSCC-related risk habits, the carcinomas can be considered similar with respect to 
etiology and biology, thereby minimizing the potential biases. 
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Additionally, to minimize the the possible bias caused by tumor heterogeneity, tissue cores 
representing  both the invasive front and the more superficial parts of each tumor were 
included in the TMA block. From the majority of the OTSCC, four tissue cores were 
prepared. From the rest of the tumors, two tissue cores were made. Four cores should achieve 
a high degree of concordance when comparing results from whole sections with those of 
TMA cores [31]. A high concordance using triplicate TMA cores [32] and even when 
including only two cores is reported [33]. 
Conclusion 
 
None of the 146 OTSCC (128 primary and 18 second primary) diagnosed from 2005 until 
2010 were found to be positive for high-risk HPV. In parallel, only two OTSCC were p16 
(score 3) positive. Our results suggest that high-risk HPV is an unlikely causative factor in 
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Table 1. Clinicopathological variables in 128 patients with primary oral tongue 
squamous cell carcinoma.  
   
    Patients (n=128) (%) 
Gender   
 Male 77 (60.2) 
 Female 51 (39.8) 
Age at diagnosis, years   
 0-59 43 (33.6) 
 ≥ 60 85 (66.4) 
Smoking history   
 Never smoker 30 (23.4) 
 Former smoker 28 (21.9) 
 Current smoker 56 (43.8) 
 Unknown 14 (10.9) 
Alcohol consumption   
 Never drinker 12 (9.4) 
 Seldom (≤1 times weekly) 26 (20.3) 
 Moderately/heavy drinking (>1times weekly or daily) 39 (30.5) 
 Unknown 51 (39.9) 
Tumor differentiation   
 Well 23 (17.9) 
 Moderately  88 (68.8) 
 Poor 12(9.4) 
 Unknown 5 (3.9) 
cT status   
 cT1/cT2 101 (78.9) 
 cT3/cT4 25 (19.5) 
 Unknown 2  (1.6) 
cN status   
 N0 93 (72.7) 
 N+ 31 (24.3) 












p16 IHC staining  Number (%) Primary OTSCC Second primary 
OTSCC 
Score 0:   
no expression  
83 (58) 72 11 
Score 1:  
positive staining  in < 70% of 
the tumor cells 
47 (33) 42 5 
Score 2:  
positive staining, either 
nuclear or cytoplasmic in 
>70% of the tumor cells  
12 (8) 10 2 
Score 3: 
Strong and uniform p16-
staining (both cytoplasmic 
and nuclear) in > 70% of 
cancer cells 
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Appendix A. Supplementary data 
 
S1: p16 IHC 
For the detection of p16 protein in TMA sections, IHC was performed on a Ventana Benchmark Ultra 
automated immunostainer (Ventana Medical Systems, VMS, Tucson AZ, USA), using a mouse 
monoclonal antibody clone E6H4 (CINtec® p16 Histology, VMS #805-4713) and the biotin-free 
ultraView Universal DAB Detection Kit (VMS #760-500). Briefly, the tissue sections were 
deparaffinised followed by heat epitope retrieval with Cell Conditioning 1 for 36 minutes at 96 ˚C 
(mild CC1, VMS #950-124) and quenching of endogenous peroxidase with 3 % hydrogen peroxide 
for 4 minutes. The slides where incubated with the p16 antibody or an isotype-matched control 
(Mouse IgG2a, Sigma-Aldrich, St. Louis, MO, # M9144) at the same concentration of 1 µg/ml for 16 
minutes at 36 ˚C. Bound antibody was detected by an HRP-multimer labeled secondary antibody 
cocktail recognizing mouse and rabbit immunoglobulins for 8 min and visualized with 3,3’-
diaminobenzidine tetrahydrochloride for 8 minutes before enhancement with copper sulfate for 4 
minutes. A known p16- expressing head and neck squamous cell carcinoma was used as positive 
control. In addition to the isotype-matched control, sections incubated with phosphate buffer saline 
(instead of primary antibody) was included as a negative control. 
 
S2: DNA in situ hybridization for HPV  
Automated in situ hybridisations were performed on a Discovery XT (VMS) using the following 
Research ISH UltraMap XT procedure and Ventana products. Sections (4µm) were deparaffinised, 
followed by heat treatment for 16 minutes at 95 °C using a citrate-based acidic buffer (RiboCC, #760-
107) and a protease treatment (Protease 3, #760-2020) for 4 minutes at 37 °C. 200µL Dinitrophenol- 
(DNP-) labelled probe (INFORM HPV III Family 16 Probe (B), #800-4295) that captures HPV 
genotypes 16, 18, 31, 33, 35, 45, 52, 56, 58 and 66 was diluted with 75 µL RiboHybe hybridisation 
buffer (#760-104) and 25 µL RiboWash (#760-105) and a total of 300 µL was added manually on 
each slide. Denaturation of the probe was performed for 8 minutes at 95 °C followed by a 2 hrs long 
hybridisation at 52 °C. After hybridisation, three stringency washes ensued with 2 x SSC (RiboWash, 
#760-105) for 8 min each, at hybridisation temperature.  Sections were blocked for 4 minutes with 
Discovery Antibody Block (#760-4204) before bound probe was detected using a rabbit antibody 
detecting DNP (#780-4335) for 20 min, followed by an alkaline phosphatase-conjugated anti-rabbit 
antibody (UltraMap anti-Rb AP, #760-4314) for 16 minutes. Chromogenic signal detection was done 
by BCIP/NBT for 1 hr (ChromoMap Blue Kit, #760-161). Slides were counterstained manually with 
0.1 % Nuclear Fast Red (Gurr, London) in a 5 % aqueous Aluminium sulphate (Sigma-Aldrich) 
solution for 2 min, washed, dehydrated and coverslips were applied using a xylene-based mounting 
medium (HistoKit, Assistant). 
Each TMA slide contained HeLa cells as positive staining control. Additionally, sections of a known 
HPV positive OPSCC were also used as positive controls.  A no probe control containing RiboHybe 
and RiboWash only served as a negative control.  
S3: RNA in situ hybridization for HPV  
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HPV E6/E7 mRNA was examined using 5 µm FFPE TMA along with sections of FFPE pellets of 
human HeLa cells as positive control. The automated RNA in situ hybridisations were carried out on a 
Discovery Ultra (Ventana Medical Systems, Tucson, AZ, USA) using fully automated RNAscope VS 
HRP assay (#323200 Advanced Cell Diagnostics Inc, Hayward,  CA, USA). Standard procedures 
were used for the deparaffinization followed by heat pretreatement at 100 °C for 32 minutes using 
Discovery CC1 and mRNA sample prep protease treatment at 37 °C for 16 minutes. Endogenous 
peroxidase was blocked with DAB inhibitor (#760-224 Ventana medical systems) for 4 minutes. The 
FFPE TMA slides were incubated with the HPV HR18 cocktail probe for detection of the HPV 
genotypes: 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, & 82 (#312599 ACD) and 
hybridized at 43 °C for 2 hours. After the hybridization, the signals were amplified with AMP 5 for 1 
hour and detected with the mRNA DAB kit (#760-224 Ventana medical systems). The sections were 
counterstained with Mayers Hematoxylin for 8 minutes. 
To assess the RNA quality in the tissue prior to the HPV E6/E7 mRNA assay we used a positive 
probe for the common housekeeping gene PPIB (#313909 ACD) and to assess for background signal 
we used a negative control probe for the bacterial gene DapB (#312039 ACD). Both probes were 
incubated on FFPE full sections and evaluated according to the manufactures instructions. 
 
S4: Scoring guideline HPV RNA ISH  
Semi-quantitative scoring guideline utilizing the estimated number of punctate dots present within 
each cell boundary (Advanced Cell Diagnostics 2018). 
The staining was categorized according to the following table:  
Score 0: No staining or less than 1 dot for every 10 cells (40X magnification)  
Score 1:  1–3 dots/cell (visible at 20–40X magnification)  
Score 2:  4–10 dots/cell. No or very few dot clusters (visible at 20–40X magnification) 
 Score 3: <10 dots/cell. Less than 10% positive cells have dot clusters (visible at 20X magnification)  












Figure legends:  
Figure 1. Flowchart illustrating the selection procedure for OTSCC used in the the present study. 
OSCC = oral squamous cell carcinoma, OTSCC = oral tongue squamous cell carcinoma, RT = 
radiation therapy, TMA = tissue microarray 
Figure 2: p16 immunohistochemistry in OTSCC. 
2A = Strong and uniform p16-staining (both cytoplasmic and nuclear) in > 70% of OTSCC cells, 
score 3. 2B = cytoplasmic p16 staining in >70% of the OTSCC cells, score 2, 2C= weak cytoplasmic 
staining in OTSCC cells, score 1, and 2D = p16 negative OTSCC cells, score 0. 
Figure 3: Representative figures for high-risk HPV DNA in situ hybridization in oral tongue 
squamous cell carcinoma (OTSCC) 
3A = HPV DNA negative OTSCC. 3B = HPV DNA positive OPSCC (positive control). 3C= HPV 
DNA positive HeLa-cells (positive control). 3D = negative no probe control (in situ without probe) in 
HeLa-cells. 
OPSCC = oropharyngeal squamous cell carcinoma 
Figure 4: Representative figures for high -risk HPV RNA in situ hybridization in oral tongue 
squamous cell carcinoma (OTSCC) 
4A = No staining or less than one dot to every ten cells in a HPV mRNA negative OTSCC 4B = HPV 
mRNA positive HeLa cells. 4C and D = Two different OTSCC with PPIB probes were positive (RNA 
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The majority of oral cavity arises in the oral tongue.  The aim of this study was to evaluate 
the prognostic impact of the newest classification of tumor size (T), where of depth of 
invasion (DOI) now supplements dimension, in oral tongue squamous cell carcinoma 
(OTSCC). We also assessed the prognostic value of tumor budding (TB) and DOI as separate 
variables, as well as a combination of TB/DOI score.  
Methods  
Patients diagnosed with primary oral tongue squamous cell were evaluated retrospectively. 
Spearman correlation with bivariate model including bootstrapping was used to identify 
correlation between parameters. Survival data were compared with clinical and 
histopathological data to evaluate their prognostic value using Log rank and Cox regression. 
All results were considered significant if p≤0.05.  
Results 
One-hundred and fifty patients had available material for microscopic evaluation on 
Hematoxylin and Eosin-stained slides. The newest T classification shifted more tumors to a 
higher level compared to previous models. High TB-score was associated with higher degree 
of lymph node metastases, as 22.5% of the patients with tumors with low score had lymph 
node metastases, compared with 42.8% in the group with a high score. In univariate 
analyses age groups, T-classification, lymph node status, tumor budding in 2-tier and 3-tier-
scoring models, DOI in 3 tier scoring model, and the combined TB/DOI score were all 
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significant.  In multivariate analyses the newest T-classification together with TB in a 3-tier 
score were independent prognosticators.  
Conclusion 
The new T classification shifted more patients to a higher stage, and also significantly 
influenced the prognosis. This indicates that DOI is an important contributor in the new T 
classification. Degree of TB was associated with lymph node metastases, and can be of 
important information for the clinicians as a supplement the decision of treatment. 
Introduction 
Oral cavity cancer is the most common subtype of head and neck cancer [1], and 
squamous cell carcinomas (SCC) account for about 90% of these [2, 3]. The majority of oral 
cavity cancers arise in the mobile, anterior two-thirds of the tongue called the oral tongue 
[2].  Recent studies report rising incidence of oral tongue (OT)SCC, especially in younger 
patients [4-6].  
Patients with OTSCC have a high morbidity and poor prognosis even when tumors are 
small [7]. For low-stage tumors (T1-T2N0M0), as much as 20% of patients may develop neck 
metastasis and recurrence within 2 years [8, 9]. In Europe the five-year relative survival for 
oral cancer is around 50% [10]. Surgical removal of the tumor is the preferred choice of 
treatment for OTSCC in most institutions when the tumor is regarded resectable. In addition, 
neck dissection is performed when positive lymph nodes are detected clinically. For patients 
with clinically negative lymph node status, there is no established biomarker or method to 
predict whether they will benefit from neck dissection. Thereby, a neck dissection in these 
patients might result in overtreatment of patients.  Postoperative radiation therapy is 
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recommended when the histopathological examination reveals short tumor margins and/or 
a positive lymph node status. Chemotherapy is mostly used for patients for palliative 
treatment [11, 12].  
Squamous cell carcinomas are classified according to the tumor’s greatest dimension 
and depth of invasion (T), regional lymph node metastases (N), and organ metastasis (M), 
according to the TNM system [2, 3]. The TNM classification is the most established predictor 
of patient survival in OTSCC, but it gives limited information about the aggressiveness of the 
tumor. The latest edition of the TNM classification (TNM8) has been in use since 2017. In this 
edition the depth of tumor invasion (DOI) supplements tumor greatest dimension when 
determining the T classification, in an attempt to increase its prognostic value [2, 13]. Prior 
to the TNM8 classification, only greatest dimension was included in the evaluation of T, and 
DOI was proposed as a separate prognostic variable [14]. Some report that the new T criteria 
in TNM8 lead to a shift to higher T-status compared with previous TNM editions, those who 
remains in a lower T-status have better survival outcomes when DOI is included [15].   
Other histopathological characteristics than DOI have also been evaluated for 
prognostic value, such as tumor budding (TB). TB  is defined as invading clusters of four or 
fewer tumor cells at the invasive front, and has been associated in many studies with lymph 
node metastasis, relapse, and accordingly poor prognosis [16-22]. In many studies, TB has 
been proposed to be a useful and significant prognostic marker that can be evaluated on 
hematoxylin and eosin (H&E)-stained sections, at low cost and with fair reproducibility [18, 
23-25]. The International Tumor Budding Consensus Conference has made a scoring system 
for TB and recommends implementation of this marker in the classification of colorectal 
cancer [17]. Some propose that this is applicable also in OTSCC, and suggest that TB should 
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be included in the routine histopathological report [21, 22]. An additional prognostic factor, 
a combined score for TB and the score of DOI,  was suggested for early stages of OTSCC 
before the DOI was implemented into the TNM8, and that these in a combination could be 
used as a prognostic model [14, 26].  
The aim of this study was to evaluate the prognostic impact of the T classification 
after implementation of DOI as described in TNM8, in a large cohort of OTSCC. We also 
assessed the prognostic value of TB-scores and DOI as separate variables, as well as in 
combination as a TB/DOI score.   
Methods   
Identification of patients 
In Norway, management of oral cavity cancer is centralized to the university hospitals 
of Rikshospitalet (Oslo), Haukeland (Bergen), St. Olavs (Trondheim) and North Norway 
(Tromsø). The Norwegian oral cancer (NOROC) study is a retrospective study that includes 
the majority of patients diagnosed with oral cavity SCC in Norway from  January 1st  2005 
through  December 31st 2009 [27]. The patients diagnosed during this period were classified 
according to the fifth edition of the Union for International Cancer Control TNM 
Classification of Malignant Tumors [13]. Patients were identified by searching for the 
relevant ICD-10 codes in the electronic health record, and by searching the hospital’s 
pathology archives for cancers with topographic SNOMED coding T51 and T53, which were 
subsequently matched with the relevant ICD-10 codes recorded in the electronic health 
records. In this sub-study, the relevant ICD-10 code was C02, which refers to cancers in the 
mobile tongue. Patients with cancers other than SCC were excluded, as well as patients with 
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second primaries or previous cancer treatment, and patients from whom formalin fixed, 
paraffin embedded tumor tissue was lacking. 
Extracting clinical data 
Relevant patient data including age, gender, ICD-10 diagnosis, TNM classification, 
treatment, and follow-up were registered as previously described [27]. Cause of death was 
acquired from Norwegian Cause of Death Registry. Patients were divided into ten-year 
interval groups (51-60 years, 61-70 years, and 71-80 years) based on age at time of 
diagnosis. Patients younger than 50 years and older than 80 years were pooled in younger 
(≤50 years) and older (≥81 years) age groups. Survival was measured from the date of 
diagnosis until death or last day of follow-up, which was June 1st 2015 ensuring a minimum 
of five years of follow-up for surviving patients.  
Histological samples and categorical grouping 
 TB and DOI were scored on H&E-stained sections by calibrated and experienced 
pathologists (HL, ESN, TMS, DC, HH, LUH and SES). No special stains were provided. The 
scoring was done independently or by pairs of pathologists who were blinded for the 
patients` clinical outcomes. Biopsies or resections that were too fragmented, too shallow, 
too superficial, or with technical artefacts that rendered the histological evaluation 
impossible, were excluded; thus the number of cases with information of TB and DOI varies.  
The TB was assessed after scanning 10 separate fields along the invasive front before 
counting number of buds in the single  field (20x objective) with the highest density 
(hotspot) [17]. TB was categorized  into a two-tier (2-tier)  system where 0 through 4 buds 
were called low-Bd and ≥ 5 buds high-Bd, according to the work of Wang et al. and Xie et al. 
[28, 29] (Fig 1) Also, the three-tier (3-tier) system recommended by the International Tumor 
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Budding Consensus Conference was applied, where  0 through 4 buds is denoted  Bd1, 5 
through 9 buds as Bd2, and 10 and more buds as Bd3 [17].  
DOI was measured in millimeters, and categorically divided into a DOI 2-tier system 
with cutoff ≥4mm according to Almangush et al. [23] as well as into a 3-tier system according 
to TNM8: ≤5 mm, 5.1-10.0 mm, and >10 mm [2].  
The combined score of low or high number of buds and DOI was assigned according 
to Almangush et al. [14, 26]. In short, tumors with < 5 buds and thickness < 4 mm were given 
TB/DOI-score 0. Tumors with either < 5 buds and tumor thickness ≥4 mm, or ≥5 buds and 
thickness < 4 mm are given TB/DOI-score 1, whereas tumors with ≥5 buds and thickness ≥4 
mm are given TB/DOI-score 2.  
Ethics 
The study was approved by the Institutional Review Board of the Northern 
Norwegian Regional Committee for Medical Research Ethics (REK Nord) (Protocol number 
REK Nord; 2013/1786 and 2015/1381), applicable to all four hospitals. A patient information-
consent letter was sent to the patients still alive at the start of the retrospective study, giving 
them the opportunity to opt-out of the study.  
Statistical analyses 
Descriptive statistics with frequencies were used to describe the cohort. Spearman 
correlation with bivariate model including bootstrapping was used to identify correlation 
between parameters. Univariate survival analyses were conducted using the Log-rank test. 
Cox regression with bootstrapping was applied for calculating survival analyses, 95% 
confidence intervals and hazard ratio. Collinearity was evaluated with linear regression. 
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Multivariate survival analyses were conducted using forward-stepwise Cox regression. All 
results were considered significant if p≤0.05. Statistical analyses were performed with IBM 
Statistical Package for the Social Sciences (SPSS) statistics, version 26.  
Results 
Clinical characteristics 
Altogether 239 patients with primary, treatment-naïve OTSCC were identified, and 
200 (84%) of these were included in the study as they received treatment with curative 
intent. For the remaining 39 patients, palliative treatment was recorded for 16 (6.7%), and 
information was missing for 23 (9.6%); these patients were excluded. During the five-year 
follow-up time, 37 (18.5%) patients developed local recurrence and 23 (12%) patients 
developed a second primary head and neck cancer.  H&E-stained tumor sections were 
available for 150 (75%) of the cases, of which 127 (84.7%) were resections, 18 (12%) were 
biopsies, and 5 (3.3%) lacked information. 
When reclassifying T-status from the older TNM (T old) to the TNM8 edition (T 8 ed), 
31 tumors shifted from T1 to T2, 17 from T1 to T3, and 10 from T2 to T3 (Table 1). Only two 
tumors shifted to a lower T status.  
Correlation analyses 
Correlation analyses were first performed on the whole cohort for the variables TB, 
DOI, T old, T 8 ed, and lymph node status (N). TB score (both 2-tier and 3-tier) correlated 
with lymph node status (Table 2), where 42.8% of tumors with a high TB-score had 
metastasized to lymph nodes, compared with 22.5% of the tumors with low TB-score. For 
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patients with low-stage disease (T1-T2N0M0), none of the analyzed variables were 
associated with TB-score.  
DOI (2-tier and 3-tier) and the combined TB/DOI score were significantly correlated 
with T old (tumor dimension) and lymph node status (N) (Table 3), whereas TB/DOI-score 
was only significantly associated with lymph node status (N).  
For low-stage disease, only DOI 3 tier was associated with tumor dimension (p<0.001, 
CI: 0.234-0.605, r=0.431).  
Univariate survival analyses 
In contrast to T-status according to the old TNM edition, the T-status in line with the 
TNM8 edition was significantly associated with DSS for the whole cohort as shown in Table 4. 
TB was significantly associated with 5-year DSS using both the 2-tier and 3-tier system.  
DOI was a significant predictor of 5-year DSS only when assessed by the 3-tier scale. 
Furthermore, the combination of TB and DOI was significantly associated with 5-year DSS. 
Separate survival analyses for the low-stage disease patients showed similar results as 
analyses of the whole cohort, except that TB was not a significant prognosticator in this sub-
group (Table 5).  
Multivariate survival analyses 
All variables with statistically significant results in the univariate survival, were 
potentially eligible for multivariate analyses. However, T 8 ed and DOI were highly collinear, 
and also TB 2-tier and TB 3-tier. Therefore, for the whole cohort, the histopathological 
variables implemented in the multivariate survival analyses were T 8 ed, TB 3-tier, and the 
combined TB/DOI-score. T 8 ed and TB 3-tier were independent prognosticators of 5-year 
10 
 
DSS (p=0.007 and 0.037 respectively). For the low-stage disease group, only T 8 ed and the 
combined TB/DOI-score were included in the equation, and none of them were significant 
independent prognostic factors. 
Discussion  
In this study the prognostic value of the T-status according to the TNM8 edition, 
where DOI is included, has been evaluated. Also, the prognostic value of TB, DOI, and 
combined TB/DOI scores has been assessed in a large cohort of primary treatment-naïve 
OTSCC. There are recent studies that support a prognostic value of these variables in OSCC 
and validation in a large, homogenous cohort can facilitate clinical implementation of the 
markers.  
The TNM classification system of a cancer does not always provide adequate 
information for treatment stratification and prognostic outcome. A consequence of this is 
the risk of overtreatment or undertreatment. Therefore, it is important to find a reliable and 
reproducible method to distinguish between aggressive OTSCC needing more extensive 
treatment, such as neck dissection surgery and with postoperative radiotherapy, compared 
with less aggressive OTSCC, where the patients can be spared from the burden of the latter 
treatment modalities. Here, the use of simple prognostic markers or parameters that were 
easily assessed on H&E-stained histological sections from tumor biopsies or resection 
specimens was an ideal approach. In this way there was no need for expensive equipment, 
reagents, or extra laboratory procedures, and this is in accordance with other studies [14, 
19, 21, 22, 24, 26].  
The DOI 3-tier showed a significant positive correlation with T old and N-status, 
supporting the introduction of tumor DOI to the T-status. When we re-classified the T-status 
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according to TNM8 where DOI is included, there was a shift towards a higher number of T2 
and T3 tumors, which is in line with a previous study [15]. The newest T-classification was a 
significant prognosticator for 5-year DSS, in contrast to T according to the old classification 
that only included dimension of the tumor.  
Several studies have investigated TB in low-stage OTSCC (T1-T2N0M0), where TB has 
been correlated with lymph node metastasis and poor prognosis [28, 29]. In some studies, a 
low TB count correlated well with longer survival, and TB has been suggested to be a 
valuable prognostic marker for OTSCC that should be implemented in treatment decision-
making [17]. However, there are also studies that have not found TB to be of significant 
prognostic value [24], showing the need for further studies in large and homogenous 
cohorts. We found that TB was an independent prognostic factor when assessing the whole 
patient cohort, but it did not reach statistical significance when analyzing the low-stage and 
high-stage disease groups separately. Interestingly, degree of budding was associated with 
lymph node metastases. This could be of clinical importance for patients where the clinicians 
have restrained from neck dissection. If the pathology report states a high degree of budding 
this might indicate a higher chance of lymph node metastases, implying that a tighter follow 
up is warranted. This could include new radiological imaging for evaluation of lymph nodes 
at short intervals [30] , or neck dissection when in doubt.  
Conclusion 
With the newest T-classification many tumors shifted toward a higher T-status compared 
with the older classification, and this influenced the prognostic value significantly.  This 
indicates that DOI is an important contributor in the new T classification. Degree of TB was 
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associated with lymph node metastases, and thereby suggests that TB can provide important 
information for the treatment decision. 
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Table 2 Spearman correlation between TB and T and DOI 
      
  T old  T 8 ed DOI 2-tier DOI 3-tier  N  
  n=126 n=132 n=130 n=130 n=139 
 
     
TB 2-tier 
p=0.919 p=0.566 p=0.403 p=0.397 p=0.013* 
CI: -0.152-0.188 CI: -0.108-0.212 CI: -0.094-0.221 CI: -0.103-0.238 CI: 0.033-0.392 
r=0.009 r=0.050 r=0.074 r=0.075 r=0.210 
      
TB 3-tier 
p=0.975 p=0.624 p=0.429 p=0.459 p=0.030* 
CI: -0.172-0.179 CI: -0.124-0.199 CI: -0.107-0.211 CI: -0.107-0.220 CI: -0.052-0.358 
r=0.003 r=0.043 r=0.070 r=0.066 r=0.185 
      
n= number of cases.     
p= significant ≤0.05     
CI= Confidence interval.     
r= spearman's Rho. 
 
      
 
 
Table 1 Number of cases with T1-T4 
according to the old staging system 
(T old) and reclassified according to 
the new staging system (T 8 ed).   
   
T old T 8 ed n 
1 1 43 
1 2 31 
1 3 17 
2 1 1 
2 2 17 
2 3 10 
3 2 1 
3 3 6 












Table 3 Spearman correlation between DOI, TB/DOI, and T and N 
   
  T old N0/N+ 
 n=124 n=131 
DOI p=0.015* 0.038* 
2-tier CI: 0.084-0.335 CI: 0.041-0.302 
 r=0.218 r=0.181 
   
 n=124 n=131 
DOI p<0.001* p=0.024* 
3-tier CI: 0.282-0.549 CI: 0.100-0.384 
 r=0.425 r=0.241 
   
 n=122 n=129 
TB/DOI score p=0.105 p=0.003* 
 CI: 0.002-0.297 CI: 0.104-0.419 
 r=0.147 r=0.262 
   
n= number of cases.  
p= significant ≤0.05  
CI= Confidence interval.  












Table 4 Characteristics of the patients (n=150) with OTSCC treated in curative intent, 
including number of cases, percent of patients with disease-specific survival (DSS) with p-
value (p), 95% confidence interval (CI), and hazard ratio (HR)  
 
   
 
Characteristic   No. of cases 5-year DSS % p (CI) HR 
    
0.702 (-0.612-0.609) 1.105 Gender Male 92 70.7 
  Female 58 69.0 
Age (year) group ≤ 50 29 79.3 
0.015 (0.66-0.600) 1.382 
 51-60 29 65.5 
 61-70 44 70.5 
 71-80 31 67.7 
  ≥81 17 64.7 
T old  
classification 
T1 91 70.3 
0.806 (-0.546-0.472) 1.063 
 T2 28 75.0 
 T3 8 75.0. 
 T4 2 50.0 
  T unknown 21   
T 8 ed  
classification 
pT1 48 87.5 
0.006 (0.117-0.961) 1.734  pT2 53 64.2 
 pT3 34 64.7 
  pT unknown 15   
N N0 108 82.4 
0.001 (0.951-2.139) 4.639  N+ 40 37.5 
  Unknown 2   
TB 2-tier Low (Bd1) 112 76.8 





  Unknown 9   
TB 3-tier Bd1 <5 112 76.8 




 Bd3 ≥ 10 11 27.3 
  Unknown 9   
DOI 2-tier < 4 mm 29 86.2 
0.090 (-0.103-2.434) 2.172  ≥4 mm 103 68.0 
  Unknown 18   
DOI 3-tier < 5 mm 47 87.2 




 ≥10 mm 33 66.7 





0.013 (0.165-1.202) 1.889 
 TB/DOI-1 84 65.8 
 TB/DOI-2 21 52.6 
  Unknown 20   
* Almangush et al 





Table 5 Low-stage and high-stage disease evaluated separately. Percentage of 5-year 
DSS and p-value for each group 
      
  Low-stage High-stage 
    
DSS 
% p   p 






 T2 90.9 45.5 
 T3  66.7 
 T4   50.0 








 pT2 73.3 35.3 
 pT3 
 58.6 
N N0   
÷ 
70.0 0.021 (0.187-2.273) 
2.862  N+ ÷ 30.6 






High (Bd2+Bd3) 66.7 
40.0 






 Bd2 ≥5 and<10 66.7 71.4 
 Bd3 ≥ 10 66.7 12.5 
DOI 2-tier < 4 mm 94.4 0.098 ((-0.047-3.821) 
4.415 
0.0 0.016 (-1.581--0.276) 
0.461  ≥4 mm 76.7 51.1 




















 TB/DOI-1 77.5 50.0 










Fig 1. Tumor budding. Case with low number of buds (marked with black arrows) shown in a, 
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We wanted to evaluate the prognostic value of common histopathological variables in a large cohort 
of patients with cancer in the mobile tongue as such information can be important for treatment 
stratification of the individual patient, especially for patients with low-stage disease. In addition we 
wanted to investigate whether an alternative scoring model with fewer options would compromise 
the prognostic value. 150 patients with oral tongue squamous cell carcinomas that were treated in 
curative intent and with available HE-stained tumor sections were included. We reclassified all 
tumors and performed univariate and multivariate survival analyses of histopathological and clinical 
variables.  For the complete cohort, lymph node status, grade of differentiation, perineural 
infiltration, and lymphocytic infiltration were independent prognosticators. In the low-stage disease 
group independent prognostic factors were tumor size, grade of differentiation, and lymphocytic 
infiltrate. For patients with low stage disease, a histo-score combining the scores for tumor 
differentiation and lymphocytic infiltrate identified a group of patients with particularly low survival, 
as patients with moderately or poorly differentiated tumors and little lymphocytic infiltrate had a 
less favorable 5-year survival outcome than patients in the high-stage disease group. This study 
shows that a histo-score combining tumor differentiation and lymphocytic infiltration should be 
given special consideration in treatment planning. Our results also illustrate that many variables can 
be scored with fewer options than previously suggested to increase their reproducibility, and still 
maintain their prognostic value. 
 
Keywords: Oral squamous cell carcinoma, low-stage, differentiation, lymphocyte infiltrate, histo-







Conflict of interest 
Elisabeth Sivy Nginamau has declared that she has been a consultant for MSD Norway  
Availability of data and material: 
Statistics file with generated data is provided  
Code availability: 
Not applicable 
Authors’ contributions:  
Inger-Heidi Bjerkli has been essential for building the database, conducting analyses, and writing the 
paper. Elin Hadler-Olsen and Lars Uhlin-Hansen have designed the research study, and contributed in 
scoring histopathological variables, critically evaluating results, and writing the paper. Elisabeth Sivy 
Nginamau, Helene Laurvik, Tine M. Søland and Daniela Elena Costea have performed scoring of 
histopathological variables, and contributed to the scientific content of the paper.  Sonja E. Steigen 
has designed the research study, and contributed in scoring histopathological variables, conducting 
analyses, critically evaluating results, and writing the paper. All authors have read and commented 
on the final draft of the paper.  
Ethics approval: 
The study was approved by the Northern Norwegian Regional Committee for Medical Research 
Ethics (Protocol numbers REK Nord; 2013/1786 and 2015/1381). 





About half of all malignant tumors in the oral cavity arise in the mobile, anterior two-thirds of 
the tongue, and more than 90% of them are squamous cell carcinomas (SCC) [1]. The aggressiveness 
of oral cavity tongue (OT)SCC varies markedly, even for small tumors without lymph node metastases 
[2]. The search for morphological tumor traits that reliably predict the prognosis for the individual 
patient has been going on for decades [3-5]. Such prognostic markers could help clinicians select the 
optimal treatment for individual patients that could increase the chances of being cured of the 
disease, and at the same time minimize the side effects from overtreatment. The TNM system 
classifies tumors based on their size and depth of invasion (T), neck node involvement (N), and 
distant metastasis (M). Along with the International Union against cancer (UICC) staging, these 
factors are today the best survival prognosticators for cancers in the oral cavity [6]. On group level, 
patients with low-stage disease (stage I-II; T1-2, N0M0) have an estimated higher survival rate 
compared with patients with high-stage disease (stage III-IV) [7, 8]. However, there is a need to find 
markers that can differentiate between aggressive and more indolent tumors for individual patients 
within the same stage.  
Various aspects of a tumor’s morphology and growth pattern can be evaluated on 
hematoxylin and eosin (HE) stained tumor sections. Several of these characteristics have been 
proposed as prognostic markers in oral cancer [4, 9, 10]. However, despite some reports of 
prognostic usefulness, none of these markers has been implemented in clinical practice, mostly due 
to lack of coherence between studies. There are several putative explanations for the lack of 
consistency between prognostic studies. Many are based on small patient cohorts, and do not 
control for parameters known to affect prognosis, such as intraoral location and stage [11-14]. This 
biases the actual prognostic value of the markers in question. Furthermore, the evaluation of 
histopathological criteria is subjective, and different pathologists may interpret the same criterion 
differently [15, 16]. In a recent study, we found poor inter- and intra-observer agreement when 
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evaluating a selection of proposed histopathological prognostic markers in oral SCC, even though the 
observers had mutual training sessions and were experienced pathologists [17]. Improved agreement 
was obtained by reducing the number of scoring alternatives for each parameter. This suggests that 
fewer options for each parameter might increase the robustness of histopathological prognostic 
markers, provided that the reduction of scoring alternatives does not compromise the prognostic 
value. In the current study, we evaluated the prognostic value of a number of proposed 
histopathological variables as they were originally proposed, as well as with a reduced number of 
scoring alternatives, in a large, homogenous cohort of OTSCC. Our results show that some 
histopathological markers, individually and in combination, can add significant prognostic 
information for OTSCC. Our study further highlights the importance of controlling for known risk 
factors such as tumor size and lymph node metastasis when evaluating putative prognostic markers. 
 
MATERIALS AND METHODS 
Cohort of patients 
The Norwegian Oral Cancer (NOROC) Study is a retrospective study that includes patients 
diagnosed with oral cavity SCC in Norway from January 1st 2005 through December 31st 2009.The 
NOROC study includes patients with strict oral cavity SCC [8].  In the present study, the relevant ICD-
10 codes were C02, which refer to cancers in the mobile tongue. Of the original NOROC cohort, 273 
patients (45%) had OTSCC. From them, we included only the primary, treatment-naïve patients who 
were treated in curative intent and from whom we had HE-stained sections from biopsies or 
resections available, altogether 150 patients.  
Extracting clinical and histopathological data  
Experienced head and neck surgeons retrieved clinical parameters from the electronic health 
records as previously described [8]. Of the 150 patients that underwent surgery, 72 patients had neck 
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surgery, and for them the N-status was based on histopathological evaluation. For the patients who 
did not have neck surgery, the N-status was based on clinical/radiological evaluation.  
Senior pathologists re-evaluated the histopathological characteristics of the tumors, including WHO 
degree of differentiation, keratinization, nuclear polymorphism, perineural infiltration, lymphocyte 
infiltrate, and worst pattern of invasion [3, 4]. For several of these, a fairly elaborate grading system 
was originally suggested. In this study we have also applied alternative versions, as described in our 
previous paper [17] and summarized in Table 1. The pathologists were blinded for the patients’ 
clinical information and outcome. 
We calculated survival from the date of diagnosis until the date of death or last day of follow-
up, which was June 1st 2015. At that time, all patients were followed up for a minimum of 5 years or 
until death. Cause of death was acquired from the Norwegian Cause of Death Registry. 
The study was approved by the Northern Norwegian Regional Committee for Medical 
Research Ethics (Protocol numbers REK Nord; 2013/1786 and 2015/1381). Patients still alive were 
informed about the project and had the opportunity to opt-out.  
Statistical analysis 
Descriptive analyses and univariate survival analyses using Log Rank (Mantel Cox) giving 
Kaplan-Meier survival curves were performed. Variables significant in univariate calculations were 
tested for collinearity before entering them into multivariable equations.  Multivariate survival 
analyses were performed using Cox regression model. Associations were investigated using Chi-
square. All statistical analyses were performed using SPSS version 26. All survival analyzes were 






One hundred and fifty patients with OTSCC were eligible for histopathological reclassification 
and included in the study. Of the tumor material available, 127 were resection specimens, 18 
biopsies, and 5 unknown.  Seventy-seven patients  had low-stage disease (Stage I and II according to 
TNM 8th edition), 63 had high-stage (Stage III and IV) [6], and for 10 cases the information for stage  
was missing.  
Supplementary table 1 presents the scores for each variable for the whole cohort and after 
separation into low-stage and high-stage disease. Table 2 presents gender, age, TNM-status and 
stage, as well as calculation of five-year disease-specific survival (DSS).   
 
Survival  
The 5-year DSS was 64.8% for the whole group, and 82.8% and 44.6% for the low- and high-
stage group, respectively. 
Univariate analyses 
In Table 3 Five-year DSS from univariate analyses are listed for each variable, both with 
original and alternative versions of grading. For the whole cohort, the following variables were 
significantly associated with five-year DSS: degree of differentiation (1.0 and 1.1), keratinization of 
the whole tumor (3.0 and 3.1), keratinization at tumor front (4.0 and 4.1), perineural infiltration (7.0 
and 7.1), lymphocytic infiltrate (8.0, 8.1, and 8.2), and worst pattern of infiltration (9.2).  
For patients with low-stage disease, differentiation of the whole tumor (1.0 and 1.1), nuclear 
polymorphism whole tumor (5.0 and 5.1), nuclear polymorphism at tumor front (6.1), and 
lymphocytic infiltrate (8.0, 8.1, and 8.2), were significantly associated with DSS. For patients with 
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high-stage disease, differentiation of whole tumor (1.1), and perineural infiltration (7.0), were the 
only significant prognosticators of DSS.  
Separate calculations were also performed for resection specimens only (biopsies excluded) 
with results similar to those for all tumors (resections and biopsies), and it is presented in 
Supplementary table 2. 
 
Multivariate analyses 
We performed multivariate analysis of the histopathological variables that were significant in 
univariate calculations, with separate analyses for original and alternative grading of the variables. 
Additionally, T and lymph node status was included in the equation for the whole cohort, and T for 
the low-stage disease group. For the whole cohort this included differentiation, keratinization, 
perineural infiltration, and lymphocytic infiltration for both original and alternative scoring gradings, 
and WPOI was additionally included in the alternative version. Keratinization of the whole tumor and 
keratinization of the tumor front were collinear, and only keratinization of the whole tumor (3.0/3.1) 
was included in multivariate analyses. For patients with low-stage disease differentiation, nuclear 
polymorphism and lymphocytic infiltration were included. Nuclear polymorphism of the whole tumor 
and in the tumor front were collinear, and only polymorphism of whole tumor (5.0/5.1) was included 
in the multivariate analyses. Independent prognosticators for the complete patient cohort were 
lymph node status (N, p<0.001), differentiation of whole tumor (1.1, p=0.022), perineural infiltration 
(7.0, p=0.025), and lymphocytic infiltration (8.2, p=0.048). In the low-stage group, T (p=0.003), 
differentiation of whole tumor (1.1, p= 0.022), and lymphocytic infiltrate (8.2, p=0.003), were all 







For the low-stage group, we created a combined score, called histo-score, based on tumor 
differentiation and lymphocytic infiltrate (Figure 1). The histo-score was calculated by summarizing 
the individual score of differentiation and lymphocyte infiltration (Supplementary table 3). Using the 
original grading, the lowest score was 2 and the highest was 6. There was a highly significant 
difference in survival between the groups (p<001), Figure 2. Of the 48 patients with score 2, 3 or 4, 
only two patients died of the disease within 5 years (DSS = 95.8%). Of the 14 patients with a score of 
5 or 6, eight patients died within 5 years (DSS 42.9%). The combined histo-score based on the 
alternative grading differentiation 1.1 and lymphocytic infiltration 8.2, showed the same significant 
prognostic power (p<0.001).  
There were no common denominators for the patients with low-stage disease and low versus 
high histo-score who died with respect to age, gender, T-stage, keratinization, or worst pattern of 
infiltration. Additionally we explored whether there was a difference between different treatment 
options (with or without neck dissection, with or without postsurgical radiotherapy), but we could 




Reliable, prognostic markers that can supplement tumor staging are lacking for oral cavity 
cancer. As tumors of the same stage can have different degree of aggressiveness, there is a need to 
find additional markers to assist the treatment planning and to predict the outcome of individual 
patients. Oral cancer is most prevalent in developing countries [18]. Thus, markers that do not 
require expensive equipment or reagents, such as histopathological traits that can be assessed on HE 
stained sections are especially valuable. In the present study, we have evaluated the prognostic 
power of a number of histopathological variables suggested for oral cancer, where results from 
previous studies are contradictory [19, 20]. We have tested them in a large, homogenous cohort of 
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patients with OTSCC, in which clinical and histopathological parameters are well controlled. Our 
hypothesis was that the lack of consistency of prognostic value in previous studies can be partly 
explained by small cohorts of patients and the inclusion of tumors from various intraoral locations. 
Furthermore, scoring of histopathological parameters is subjective, as reflected by the poor inter- 
and intra-rater agreement [17]. Several of the histological variables have been proposed with three 
to six options for scoring, sometimes with subtle differences between each alternative. Grouping 
categories and thereby reducing the number of scoring alternatives can make the scoring easier and 
more reproducible [17]. Therefore, we also tested the prognostic power of the variables as they were 
originally proposed, as well as with broader and fewer categories.   
As expected, the well-established prognostic markers tumor size and lymph node metastases 
were independent predictors of survival. Additionally, we found that tumor differentiation was an 
independent prognosticator of survival both for the whole cohort and for patients with low-stage 
disease. WHO lists differentiation as a prognostic marker for oral cavity cancer, and degree of 
differentiation is usually described in pathology reports [21]. However, due to many studies reporting 
low prognostic value of differentiation for oral SCC, clinicians rarely give it much emphasis during 
treatment planning [22, 23]. Our results indicate that this marker has significant prognostic power.  
A revised grading for lymphocytic infiltration where the categories for marked and moderate 
infiltration were combined, was also an independent prognostic marker for low-stage disease and for 
the whole patient cohort. Grouping categories generates larger groups for statistical analyses, and 
this can affect the significance level. However, the cutoff for dichotomizing the original three-tier 
variable was important. The variable only had independent prognostic power when separating the 
tumors with low lymphocytic infiltration from those with moderate and abundant infiltration. This 
suggests that lymphocyte infiltration is tightly related to the biology of the tumor, and that the 
tumors with little infiltration may take a more aggressive course. This is in line with previous studies 
showing that a rich lymphocyte infiltration is associated with favorable prognosis [24-26].   
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By incorporating degree of diffentiation and lymphocytic infiltration in a combined histo-
score, we were able to define a subgroup of patients with low-stage disease that had a much lower 
survival rate than the rest of the low-stage disease patients. Interestingly, the survival in this 
subgroup was even less favorable than patients with high-stage disease (42.9 versus 46.6%). This 
indicates that patients with poorly differentiated tumors with a weak lymphocytic response should 
be regarded as high-risk patients who need special attention, even if the tumors are small and 
without lymph node metastases.  
Perineural infiltration was a significant prognostic marker for the whole cohort and for 
patients with high-stage disease, but not for low-stage disease. One could assume that nerve bundles 
are more abundant in deeper parts of the oral mucosa, and tumors probably need to invade deeper 
than in T1 and T2 tumors for this to be a relevant marker. This illustrates the importance of 
evaluating prognostic markers in homogenous groups of tumors and controlling for known risk 
factors.  
We found that alternative grading (fewer options) of histopathological variables only altered 
their prognostic value only to a minor extent. A previous study comparing inter- and intra-rater 
agreement showed significantly better agreement when using an alternative grading with fewer 
options, compared to the more elaborate original grading [17]. This supports the use of variables 
with fewer options as they improve the reproducibility of the scoring without reducing the 
prognostic power of the variables. A simplification of scoring models has been introduced for many 
cancers. The reproducibility for uterine endometrial endometrioid carcinoma was found to be higher 
with  a binary tumor grading system [27]. In the latest WHO-classification of tumors in the GI tract, 
the adenocarcinomas are stratified into a two-tiered grading system; low-grade and high-grade, 
where grading is based on the least differentiated component [28].   
The present study is retrospective, and this approach gives a larger risk of variation in how 
clinical variables are reported in the electronic health records compared with prospective studies. 
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When subgrouping, some groups became small, which increases the risk of underpowered statistical 
analyses and thereby of underestimating the prognostic power of some variables. Our cohort 
included some tumors from which we had only biopsy samples for histopathological evaluation, 
which makes evaluation less certain. Therefore, we performed separate statistical analyses excluding 
the grading of biopsies (supplementary tables), but this did not alter the results significantly.   
 
CONCLUSION 
Our study on a large, homogenous tumor cohort of OTSCC shows that a histo-score 
combining tumor differentiation and lymphocytic infiltration identified a subgroup among the low-
stage disease patients that had lower DSS than the average patients with high-stage disease. This 
subgroup should be given special consideration in treatment planning. Our results also illustrate that 
many variables can be scored with fewer options than previously suggested to increase their 
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Figure 1 Tumor differentiation and lymphocyte infiltration. Well, moderate and poorly differentiated 
tumor in a-c. Marked, moderate and little lymphocyte infiltration in d-f. 
 
Figure 2 Kaplan-Meier curve showing the results after combining the variables of differentiation (1.0), 
and lymphocytic infiltrate (8.0). Scoring alternatives are shown in table 5. Patients with low score (2-
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*according to Bryne et al. (1998). 
**according to Brandwein-Gensler et al. (2005). Type 1 pushing borders; Type 2 finger-like growth pattern; Type 3 large 








Table 2. Clinicopathological characteristics related to five- 
year disease specific survival (DSS). Number and percent of 
patients in each group, and in addition percentage of 
patients with five-year DSS 
      
Variable   n % DSS % p *(DSS) 
      
Gender 
Male  92 61.3 70.7 
0.702 
Female 58 38.7 69.0 
 
 
    
Age (year) 
group 
≤ 50 29 19.3 79.3 
0.015 
51-60 29 19.3 65.5 
61-70 44 29.3 70.5 
71-80 31 20.7 67.7 
≥ 81 17 11.3 64.7 
 
 
    
pT 8th Edition 
pT1 48 35.6 87.5 
0.006 pT2 53 39.3 64.2 
pT3 34 25.2 64.7 
      
N** 
N0 108 72.0 82.4 
0.001 N+ 40 26.7 37.5 
Nx/Unknown 2 1.3  
      
Stage 
Low stage 77 55.0 82.8 
<0.001 High stage 63 42.0 44.6 
Nx/Unknown 10 6.7  
 
    
 
* Significant at 0.05 level 
** Combination of cN and pN. If neck dissection was 













Table 3. Variables (both original and alternative grading) and five-year disease-specific 
survival in univariate calculations for the whole cohort, and for low-stage disease and high-
stage disease separately. The percentage of patients surviving according to different grading 
is specified under DSS%.   
        
  
Whole cohort (n=150) Low-stage (n=78) High-stage (n=63)  
Variables   All   All    All 







94.7/84.6/40.0 0.002 (63)* 75.0/47.7/0 0.055 (55) 
 












































































8.1 87.5/60.0 0.021* 100/77.1 0.050* 62.5/43.5 0.409  
8.2 72.9/50.0 0.007* 91.5/56.3 0.001* 45.5/47.6 0.821 
9.0 WPOI 100/70.6/82.








9.1 73.7/65.3 0.461  83.3/84.0 0.999 50,0/45.7 0.908  
9.2 79.2/58.3 0.022* 93.1/75.8 0.061 50.0/44.4 0.902 
        










Figure 1 Tumor differentiation and lymphocyte infiltration. Well, moderate and poorly 
















Figure 2 Kaplan-Meier curve showing survival of patients with low-stage disease stratified 
































Supplementary table S1. Histopathological information for the whole cohort (n=150), 
the low-stage (n=77) and the high-stage group (n=63) 
  Whole tumor Low-stage High-stage 
Variable   n % n % n % 
Differentiation whole 
tumor 
Well 34 22.7 26 33.8 5 7.9 
Moderate 100 6.7 45 58.4 48 76.2 
Poorly 14 9.3 5 6.5 9 14.3 
Missing/Not evaluable 2 1.3 1 1.3 1 1.6 
        
Differentiation worst 
pattern 
Well 10 6.7 9 11.7 1 1.6 
Moderate 62 41.3 36 46.8 21 33.3 
Poorly 73 48.7 31 40.3 39 61.9 
Missing/Not evaluable 5 3.3 1 1.3 2 3.2 
        
Keratinization whole 
tumor 
High 33 22 23 29.9 8 12.7 
Moderate 60 40 29 37.7 30 47.6 
Minimal 29 19.3 12 15.6 13 20.6 
None 23 15.3 10 13.0 10 15.9 
Missing/Not evaluable 5 3.3 3 3.9 2 3.3 
    
    
Keratinization tumor 
front* 
High 0 0 0 0 0 0 
Moderate 15 10 14 18.7 1 1.6 
Minimal 41 27.3 23 29.9 17 27.0 
None 85 56.7 38 49.4 41 65.1 
Missing/Not evaluable 9 6 2 2.6 4 6.3 
        
Nuclear polymorphism 
whole tumor 
Little/none 31 20.7 23 29.9 7 11.1 
Moderate 51 34 26 33.8 19 30.2 
Abundant 35 23.3 15 19.5 18 28.6 
Extreme 29 19.3 11 14.3 17 27.9 
Missing/Not evaluable 4 2.7 2 2.6 2 3.2 
        
Nuclear polymorphism 
tumor front* 
Little/none 14 9.3 9 11.7 5 7.9 
Moderate 43 28.7 25 32.5 16 25.4 
Abundant 36 24 21 27.3 11 17.5 
Extreme 48 32 20 26.0 27 42.9 
Missing/Not evaluable 9 6 2 2.6 4 6.3 
        
Perineural infiltration 
None 106 70.7 60 77.9 42 66.7 
Invasive front 21 14 9 11.7 10 15.9 
Tumor center 7 4.7 2 2.6 5 7.9 
Missing/Not evaluable 16 10.7 6 7.8 6 9.5 
        
Lymfocytic infiltrate 
Marked 30 20 21 27.3 8 12.7 
Moderate 67 44.7 34 44.2 28 44.4 
Slight/none 46 30.7 21 27.3 24 38.1 
Missing/Not evaluable 7 4.7 1 1.3 3 4.8 
  
  
    
Worst pattern of invasion 
(WPOI) 
Type 1 3 2 2 2.6 1 1.6 
Type2 24 16 14 18.2 9 14.3 
Type 3 36 24 23 29.9 11 17.5 
Type 4 60 40 29 37.7 28 44.4 
Type 5 18 12 7 9.1 10 15.9 




Supplementary Table S2. Variables and categorization and disease-specific survival for the 
whole cohort and for low-stage and high-stage disease separately. Separate columns for 
resection specimens only (biopsies excluded) 
        
  
Whole cohort (n=150) Low-stage (n=77) High-stage (n=63)   
All Resections  All  Resections All Resections 
 p (n) p (n) p (n) p (n) p (n) p (n) 
1.0 Differentiation 
whole tumor 
<0.001 (126)* <0.001 (106)* 0.003 (62)* 0.002 (58)* 0.055 (55) 0.035 (47)* 
 
Alternative 1.1 <0.001* <0.001* 0.001* 0.008* 0.025 * 0.035 
2.0 Differentiation 
worst pattern 
0.074 (123) 0.124 (106) 0.266 (62) 0.387 (58) 0.646 (54) 0.929 (47) 
 
Alternative 2.1 0.061 0.081 0.134 0.219 0.676 (54) 0.929 
3.0 Keratinization 0.030 (123)* 0.028 (104)* 0.404 (60) 0.584 (56) 0.157 (54) 0.065 (46)  
Alternative 3.1 0.007 * 0.004* 0.203 0.270 0.078 0.020* 
4.0 Keratinization 
tumor front 
0.060 (119) 0.083 (106) 0.150 (61) 0.235 (58) 0.665 (52) 0.426 (47) 
 
Alternative 4.1 0.033*  0.028* 0.168 0.179 0.374 0.350 
5.0 Nuclear 
polymorphism 
0.176 (124) 0.423 (104) 0.005 (61)* 0.023 (57)* 0.767 (54) 0.514 (46) 
 




0.548 (119) 0.822 (106) 0.061 (61) 0.134 (58) 0.363 (52) 0.290 (47) 
 
Alternative 6.1 0.339  0.134 0.034* 0.050* 0.343 0.216 
7.0 Perineural 
infiltration 
0.003 (113)* 0.003 (101)* 0.263 (58) 0.241 (55) 0.046 (50)* 0.069 (45) 
 
Alternative 7.1 0.023* 0.010* 0.221 0.200 0.098 0.080 
8.0 Lymphocytic 
infiltration 
0.009 (122)* 0.029 (106)* 0.004 (62)* 0.012 (58)* 0.711 (54) 0.763 (47) 
 
Alternative 8.1 0.019* 0.024* 0.047* 0.048* 0.409 0.492  
Alternative 8.2 0.008* 0.035* 0.001* 0.006* 0.921 0.908 
9.0 WPOI 0.218 (119) 0.323 (105) 0.248 (63) 0.249 (58) 0.997 (52) 0.833 (46)  
Alternative 9.1 0.445  0.362 0.977 0.605 0.908 0.719  
Alternative 9.2 0.027* 0.050* 0.069 0.038* 0.902 0.734   
      
 
T (8th) 0.020 (113)* 0.005 (105)* 0.050 (63)* 0.019 (59)* 0.047 (50) 0.793 (46)  
cN0/pN0 <0.001 (128)* <0.001 (107)* Only N0 Only N0 0.016 (56)* 0.115 (47) 
        











Supplementary table S3. Histo-score for patients with low-stage disease. 
Combination of differentiation of whole tumor (1.0) and lymphocyte 
infiltration (8.0) 





Sum of score 
(number of 
patients/dead*) 
Well (1) Marked (1) 2 (5/0) 
Well (1) Moderate (2) 3 (10/1) 
Moderate (2) Marked (1) 3 (10/0) 
Well (1) Slight/none (3) 4 (4/0) 
Moderate (2) Moderate (2) 4 (19/1) 
Poor (3) Marked (1) 4 (0/0) 
Moderate (2) Slight/none (3) 5 (9/5) 
Poor (3) Moderate (2) 5 (2/1) 
Poor (3) Slight/none (3) 6 (3/2) 
 





I. Letter of approval from REK-Nord (2013) 
II. Letter of approval from REK-Nord (2015) 
III. Informal and consent letter to the patients 
IV. Letter with extension of time-period REK-Nord (2019) 
V. Case Report Form 
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Prosjektleders prosjektomtale
Antall personer som får munnhulekreft har økt de senere år. Kirurgi er førstevalg ved behandling og blir
som regel kombinert med stråleterapi og eventuelt kjemoterapi. Ved små svulster uten holdepunkt for
spredning prøver man å begrense kirurgien og mengden stråling, for å unngå overbehandling og plagsomme
bivirkninger. Behandlingsstrategien ved munnhulekreft baseres i hovedsak på TNM-klassifisering
(tumorstørrelse, metastasering til lymfeknuter eller andre organer). Generelt har pasienter med små svulster
uten metastase (T1N0M0) best prognose, men det er store individuelle forskjeller i respons på
behandling.Side 4 av 8Det finnes i dag ingen sikre markører som kan brukes til å forutsi hvilke tumorer som
antas å ha et mer aggressivt forløp og hvilke som vil oppføre seg mer fredlig. Vi vil i denne studien
undersøke markørmolekyler som kan være et supplement til TNM-klassifiseringen når man skal behandling
av pasienten slik at den blir med individualisert.
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INFORMASJON OM DELTAKELSE I FORSKNINGSPROSJEKTET 
NOROC, -EN NASJONAL STUDIE OM MUNNHULEKREFT 
Vi vil herved informere deg om dette forskningsprosjektet som omhandler pasienter som har blitt 
behandlet for kreft i munnhulen. Formålet med studien er å kartlegge molekyler i kreftcellene som kan 
benyttes til å gi fremtidige pasienter en best mulig behandling. I utgangspunktet vil alle pasienter som ble 
behandlet for munnhulekreft i Norge i perioden 2005-2009 bli innlemmet i studien. Universitetet i Tromsø 
er ansvarlig for gjennomføringen, men leger ved alle universitetssykehusene i landet er med som 
samarbeidspartnere.  
HVA INNEBÆRER PROSJEKTET? 
Når pasienter blir operert for kreft, blir kreftsvulsten undersøkt ved avdeling for patologi. Etter at 
diagnosen er stilt, vil deler av kreftsvulsten rutinemessig bli arkivert i en såkalt diagnostisk biobank ved 
sykehuset. Dette kreftvevet kan senere eventuelt bli benyttet til videre undersøkelser. I prosjektet vil vi 
benytte kreftvev fra alle pasienter som ble behandlet for munnhulekreft i Norge i perioden 2005-2009 til å 
studere forekomst av molekyler som har betydning for prognosen. For at man skal kunne gjøre det, er det 
også nødvendig å registrere opplysninger som er relevant for kreftsykdommen. Opplysningene hentes fra 
sykejournalen til den enkelte pasient av en overlege som er ansatt ved sykehuset.  
HAR PROSJEKTET ULEMPER FOR DEG? 
Det skal ikke tas noen nye prøver av deg og du trenger ikke svare på noen spørsmål. Det er kun 
opplysninger som allerede finnes i sykejournalen som vil bli benyttet. Alle opplysningene vil bli behandlet 
uten navn og fødselsnummer eller andre direkte gjenkjennende opplysninger. Forskerne som deltar i 
prosjektet vil derfor ikke kunne gjenkjenne pasientene som er involvert i studien. Det vil være en kode 
som knytter deg til dine opplysninger gjennom en navneliste. Navnelisten oppbevares nedlåst i et 
arkivskap. Informasjonen som registreres om deg skal kun brukes slik som beskrevet i formålet med 
studien. Du har rett til innsyn i hvilke opplysninger som er registrert om deg og rett til å få korrigert 
eventuelle feil i de opplysningene som er registrert. 
Prosjektleder Lars Uhlin-Hansen har ansvar for den daglige driften av forskningsprosjektet og at 
opplysninger om deg blir behandlet på en sikker måte.  Informasjonen om deg vil bli slettet senest fem år 
etter prosjektslutt. 
MULIGHET FOR Å RESERVERE SEG 
Dersom du ikke ønsker at opplysninger fra din pasientjournal skal benyttes, eller at du ikke ønsker at det 
skal utføres undersøkelser på svulstvevet som ble fjernet i forbindelse med operasjonen, kan du reservere 
deg ved å kontakte professor Lars Uhlin-Hansen, Klinisk patologi, Universitetssykehuset Nord-Norge, 9038 
Tromsø.  Telefon 77627207, e-post: lars.uhlin.hansen@unn.no. Dette kan du gjøre uten å oppgi noen 
grunn og det vil selvfølgelig ikke få konsekvenser for din eventuelle videre behandling.  
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     Male 
     Female 
2. Year of birth [ integer ]
3. Date of diagnosis (dd.mm.yyyy) [ date ]
4. County
     Østfold 
     Akershus 
     Oslo 
     Hedmark 
     Oppland 
     Buskerud 
     Vestfold 
     Telemark 
     Aust-Agder 
     Vest-Agder 
     Rogaland 
     Hordaland 
     Sogn og Fjordane 
     Møre og Romsdal 
     Sør-Trøndelag 
     Nord-Trøndelag 
     Nordland 
     Troms 
     Finnmark 
     Svalbard 
Page 1/2
CRF version: 2020-02-19
Date (yyyy-mm-dd): 20 _  _  -  _  _  -  _  _   Patient ID / Initials: _  _  _  _  _  _  _  _  _  _   /  _  _  _
Oralcancer register: ID
Signatures CRF reporter / Researcher Principal Investigator
Date (yyyy-mm-dd): 20 _  _  -  _  _  -  _  _   20 _  _  -  _  _  -  _  _   
Place / Affiliation: _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _         _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _
Name: _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _         _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _
Signature: _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _         _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _
(I hereby confirm that information provided in this form is a correct, accurate and
complete representation of collected data.)
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CRF version: 2020-02-19
Date (yyyy-mm-dd): 20 _  _  -  _  _  -  _  _   Patient ID / Initials: _  _  _  _  _  _  _  _  _  _   /  _  _  _
Oralcancer register: Basic patient data
300-1Basic patient data
1. Patient alive?
     Yes 
     No 
2. Ev. time of death (dd.mm.yyyy) [ date ]
3. Level of education:
     Missing 
     No education 
     Finished primary school 
     Finished further school/high school 
     University degree 
4. If information about profession, please specify: [ text ]
5. Comorbidity:
     Missing 
     Heart and Coronary disease 
     COPD/Serious lung disease 
     Diabetic 
     Rheumatism 
     Transplanted 
     Previous cancer 
     Other 
     None 
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Oralcancer register: Basic patient data
6. If previous cancer; please specify [ text ]
7. If other, please specify: [ text ]
8. Family history of cancer; 1.degree relatives, parent and/or
siblings:
     Missing 
     Never 
     Others with head and neck cancer 
     Others with other types of cancer 
9. If others with other types of cancer please specify: [ text ]
10. Medication:
     Missing 
     None 
     Steroides 
     Immunosuppressiva 
     Antidiabetic insulin 
     Bisphosphonates 
     Others 
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Oralcancer register: Basic patient data
11. If others, specify: [ text ]
LIFESTYLE
12. Smoking:
     Missing 
     Never 
     Current 
     Former 
13. If current, specify cigarettes/d [ integer ]
14. If former smoker; if possible please specify when stopped;
     Stopped 0-1 year 
     Stopped 1-9 year 
     Stopped >=20 years 
     Stopped 10-19 years 
15. Specify smoking if not clear above/Scandinavian snuff/use
of illegal drugs if possible:
[ text ]
16. Alcohol consumption
     Missing 
     Never 
     Current 
     Seldom 
     Moderately 
     Heavy 
     Former alcoholic abuse 
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Oralcancer register: Basic patient data
17. If current alcohol consumption, please specify: Beer intake
(units/week)
[ integer ]
(please specify: one unit equals 1 normal beer, 1 glass of wine, 1
liquor/spiritus >= 40%)
18. If current alcohol consumption, please specify: Wine
intake (units/week)
[ integer ]
(please specify: one unit equals 1 normal beer, 1 glass of wine, 1
liquor/spiritus >= 40%)
19. If current alcohol consumption, please specify:
Liquor/spiritus >= 40% (units/week)
[ integer ]
20. Height cm: [ decimal 1 ]
21. Weight kg: [ decimal 1 ]
22. Dental status (Good: needs no dental treatment before
radiation) :
     Missing 
     Good 
     Needs treatment 
     Edentulous(toothless) 
23. Comments; please specify: [ text ]
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Oralcancer register: Basic patient data
Signatures CRF reporter / Researcher Principal Investigator
Date (yyyy-mm-dd): 20 _  _  -  _  _  -  _  _   20 _  _  -  _  _  -  _  _   
Place / Affiliation: _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _         _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _
Name: _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _         _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _
Signature: _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _         _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _
(I hereby confirm that information provided in this form is a correct, accurate and
complete representation of collected data.)
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Oralcancer register: DIAGNOSE ORAL CAVITY TUMOR SITE (UICC)
300-1DIAGNOSE ORAL CAVITY TUMOR SITE (UICC)
1. Neoplasma malignum partis alterius et non specificatae
linguae (tongue):
     CO2 
     CO2.0 
     CO2.1 
     C02.3 
     C02.8 
     C02.9 
2. Neoplasma malignum gingivae (alveolus and gingiva):
     CO3 
     CO3.0 
     CO3.1 
     CO3.9 
3. Neoplasma malignum basis cavi oris (floor of mouth):
     CO4 
     CO4.0 
     CO4.1 
     CO4.8 
     CO4.9 
4. Neoplasma malignum palati (hard palate):
     CO5 
     CO5.0 
     CO5.8 
     CO5.9 
5. Neoplasma malignum partis alterius et non specificatae
oris (cheek mucosa, bucco-alveolar sulci, retromolar
areas):
     CO6 
     CO6.0 
     CO6.1 
     CO6.2 
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Oralcancer register: DIAGNOSE ORAL CAVITY TUMOR SITE (UICC)
     CO6.8 
     CO6.9 
6. Others/not classified: [ text ]
7. Tumor stage TNM done?
     Yes 
     No 
     Only biopsi 
cTNM
8. T
     T1 
     T2 
     T3 
     T4 
     T4a 
     T4b 
     Missing 
9. N
     Nx 
     N0 
     N1 
     N2 
     N2a 
     N2b 
     N2c 
     N3 
     Missing 
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Oralcancer register: DIAGNOSE ORAL CAVITY TUMOR SITE (UICC)
10. M
     Mx 
     M0 
     M1 
     Missing 
11. Recidive: ( previous (primary)( could be diagnosed before
01.01.2005) ( lesion occurring at a distance less than 2 cm
from the index tumor and within 3 yrs) :
     Yes 
     No 
     Not relevant 
12. Second primary: ( lesion at a distance greater than 2 cm,
synchronous: less than 6 months. Metachronous: greater
than 6 months. Lesion at the same site or less than 2 cm
more than 3 years):
     Yes 
     No 
     Not relevant 
Signatures CRF reporter / Researcher Principal Investigator
Date (yyyy-mm-dd): 20 _  _  -  _  _  -  _  _   20 _  _  -  _  _  -  _  _   
Place / Affiliation: _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _         _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _
Name: _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _         _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _
Signature: _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _         _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _
(I hereby confirm that information provided in this form is a correct, accurate and
complete representation of collected data.)
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Oralcancer register: PATHOLOGICAL INFORMATION
300-1PATHOLOGICAL INFORMATION
(to be submitted preferently by pathologist)
1. Speciment
     Biopsy 
     Resection 
2. Tumor differentiation histology :
     Missing 
     Squamous cell carcinoma 
     Verrucous carcinoma 
     Others 
3. If others, please specify [ text ]
4. Differentiation, WHO classification, whole tumor
     Well 
     Moderate 
     Poor 
5. Differentiation, WHO classification, worst pattern
     Well 
     Moderate 
     Poor 
6. Degree of keratinization, whole tumor:
     Highly keratinized (>50 % of tumor areal) 
     Moderately keratinized (20-50% of tumor areal) 
     Minimal keratinisation (5-20% of tumor areal) 
     No keratinisation (0-5 % of tumor areal) 
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Oralcancer register: PATHOLOGICAL INFORMATION
7. Nuclear polymorphism, whole tumor:
     Little nuclear polymorphism (in less than 25% of the cells) 
     Moderately abundant nuclear polymorphism (in 25-50% of the
cells) 
     Abundant nuclear polymorphism (in 50-75% of the cells) 
     Extreme nuclear polymorphism (in 75-100% of cells) 
8. Worst pattern of invasion (WPOI) (Brandwein-Gensler
2005, 2012, POI 1-4 based on Bryne et al 1998)
     Pushing, well delineated infiltrating borders 
     Infiltrating, solid cords, bands and/or strands 
     Small grous of cords of infiltrating cells (n>15 cells) 
     Marked and widespread celleular dissociation in small groups
and/or in single cells (n<15 cells) 
     Tumor satellites of any size with 1 mm or greater distance of
intervening normal tissue (not fibrosis) at the tumor host interface 
     Missing/ not evaluable 
9. Tumor budding known?
     Yes 
     Missing/not evaluable 
10. Tumor budding: (Detached cluster of fewer than 5 cells at
the invasive front of a tumor)
[ integer ]
(Number of 'budded' groups in a 20X microscopic field)
11. Degree of keratinization, within the lowest differentiated
parts of the most invasive 2-3 cell layers at the advancing
front of tumors (Bryne et al 1998):
     Highly keratinized (>50 % of the cells) 
     Moderately keratinized (20-50% of the cells) 
     Minimal keratinisation (5-20% of the cells) 
     No keratinisation (0-5 % of the cells) 
     Missing/ not evaluable 
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Oralcancer register: PATHOLOGICAL INFORMATION
12. Nuclear polymorphism, within the lowest differentiated
parts of the most invasive 2-3 cell layers at the advancing
front of tumors (Bryne et al 1998):
     Little nuclear polymorphism (In less than 25% of the cells) 
     Moderately abundant nuclear polymorphism (In 25-50% of the
cells) 
     Abundant nuclear polymorphism (In 50-75% of the cells) 
     Extreme nuclear polymorphism (In 75-100% of the cells) 
     Missing/ not evaluable 
13. HPV status (p16 status, from the pathology reports):
     Missing 
     Positive 
     Negative 
14. Status of surgical margins exist
     Yes 
     Missing 
15. Status of surgical margins (closest distance between
tumor and surgical resection) mm
[ decimal 1 ]
16. Tumor thickness exist
     Yes 
     Missing/ not evaluable 
17. Tumor thickness mm, whole tumor (ad modum Woolgar
1995, figure 1, TA)
[ decimal 1 ]
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Oralcancer register: PATHOLOGICAL INFORMATION
18. Depth of invasion exist
     Yes 
     Missing/ not evaluable 
19. Depth of invasion (ad modum Woolgar 1995, figure 1, TR) [ decimal 1 ]
20. Tumor largest diameter
     Macroscopic 
     Microscopic in one slide (på ett snitt/oftest tverrsnitt) 
     Microscopic estimate( ved uttak av hele tumor) 
     Missing/not evaluable 
21. Tumor largest diameter mm [ decimal 1 ]
22. Infiltration
     Missing/ not evaluable 
     Subepithelial tissue(submucosa/lamina propria) 
     Muscle 
     Bone 
23. Lymfocytic infiltrate
     Marked 
     Moderate 
     Slight/none 
     Missing/ not evaluable 
24. Perineural infiltration
     None 
     Nerves at invasive front 
     Nerves in tumor center 
     Missing/ not evaluable 
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Oralcancer register: PATHOLOGICAL INFORMATION
25. Vascular infiltration: (Presence of aggregates of tumor
cells within endothelial-lined channels)
     Not present 
     Present 
pTNM
26. T
     T1 
     T2 
     T3 
     T4 
     Missing 
27. N
     N0 
     N1 
     N2 
     N2a 
     N2b 
     N2c 
     N3 
     Missing 
28. M
     M0 
     M1 
     Missing 
29. Dysplasia in the surgical margins(reseksjonsrender)
     No 
     Low grade (grad 1-2) 
     High grade (grad 3) 
     Missing/not evaluable 
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Signatures CRF reporter / Researcher Principal Investigator
Date (yyyy-mm-dd): 20 _  _  -  _  _  -  _  _   20 _  _  -  _  _  -  _  _   
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300-1TREATMENT
1. Treatment was discussed (before/under treatment) in
multidisciplinary teams MDT (MDT with members from
two or more departments or functional areas)
     Missing 
     Yes 
     No 
2. Please specify departments: [ text ]
3. Time for referral exist
     Yes 
     No 
4. Date for refferal if it exist: (dd.mm.yyyy) [ date ]
5. Time from primary referral to treatment (weeks) [ integer ]
6. Referred from
     General practitioner 
     Specialist 
     Missing 
7. Operation performed
     Curative 
     Palliative 
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8. Access:
     Missing 
     Oral 
     Mandibular split 
     Lip split 
     Lip split over 
     Lip split under 
9. Type of surgery:
     Soft tissue resection 
     with marginal mandible resection 
     with segmental mandible resection 
     with maxilla resection 
     elective tracheostomy 
     Other 
10. If other, describe: [ text ]
11. Neck surgery:
     Missing 
     No neck surgery 
     Elective neck 1,2,3 (N0 neck) 
     Selective neck 1,2,3 (N+ neck, supraomohyoidal hgd) 
     Modified radical neck (saves one or more of v.j.i
/n.accessory/m.scm) 
     Radical neck 
12. Postoperative complication (first 30 days):
     None 
     Haemathoma/bleeding (needed secondary surgery) 
     Infection 
     Necrosis of area 
     Incomplete healing 
     Postoperative cardiac complications 
     Postoperative pneumoni 
     Postoperative emboli/tromboemboli 
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     Death 
     Other 
     Missing 
13. If postoperative emboli/tromboemboli
     Pulmonary 
     Extremeties 
     Cerebral 
14. If death peri-/postoperative: [ text ]
15. If other, describe: [ text ]
16. Type of reconstruction:
     Missing 
     None 
     Nasolabial 
     Pedickel flap 
     Distant flap 
     Free flap 
     Split skin 
     Primary closure 
     Other 
17. Adjuvant radiation
     Missing 
     Primary (no surgery done) 
     Pre-operative 
     Post-operative 
     Conventional 
     IMRT 
     None 
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18. Dosage Gy exist
     Yes 
     No 
19. Dosage Gy [ integer ]
20. Fractions per week [ integer ]
21. Target
     Unilateral 
     Bilateral 
     Neck region 1,2,3, 
     Whole neck 
     Primary site 
     Other 
22. If other, describe [ text ]
23. Chemotherapy
     Missing 
     Yes 
     No 
24. If yes
     Concomitant 
     Neo-adjuvant 
     Adjuvant 
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25. Type of cytostatica [ text ]
26. Dosage cytostatica given [ text ]
27. Naxogin
     Yes 
     No 
28. Withdrawal from treatment, and why [ text ]
Signatures CRF reporter / Researcher Principal Investigator
Date (yyyy-mm-dd): 20 _  _  -  _  _  -  _  _   20 _  _  -  _  _  -  _  _   
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(I hereby confirm that information provided in this form is a correct, accurate and
complete representation of collected data.)
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300-1FOLLOW UP
Time for follow up until 01.06.2015
1. Follow up (months) : [ integer ]
2. Has continued smoking
     Yes 
     No 
     Non smoker 
     Missing 
3. Dental rehabilitation
     Yes 
     No 
     Missing 
4. Local recurrence/Recidive: (lesion occurring at a distance
less than 2 cm from the index tumor and within 3 yrs)
     Yes 
     No 
5. Eventual time of recidive local recurrence (dd.mm.yyyy) [ date ]
6. Recidive regional metastases
     Yes 
     No 
7. Recidive distant metastases
     Yes 
     No 
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8. Eventual time of recidive distant metastases (dd.mm.yyyy) [ date ]
9. If metastasis
     Lung 
     Bone 
     Liver 
     Brain 
10. Treatment of recidiv [ text ]
11. Persistent/Residual disease: (no disease control within 6
months after treatment)
     Yes 
     No 
12. Eventual time of local recurrence/recidive (dd.mm.yyyy) [ date ]
13. Second primary: (lesion at a distance greater than 2 cm,
synchronous: less than 6 months. Metachronous: greater
than 6 months. Lesion at the same site or less than 2 cm
more than 3 yrs)
     Yes 
     No 
14. Treatment of second primary [ text ]
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15. Long term complications
     Damage to accessory nerve/shoulder-syndrome 
     Necrosis of soft tissue 
     Osteoradionecrosis 
     Serious dental problem 
     Long term nasogastric tube 
     Long time PEG 
     Long time tracheostomy 
     Severe trismus 
     Serious speech problem 
     Hyperbar 0² 
     Xerostomi 
     Others 
     None 
16. If others, please describe [ text ]
Signatures CRF reporter / Researcher Principal Investigator
Date (yyyy-mm-dd): 20 _  _  -  _  _  -  _  _   20 _  _  -  _  _  -  _  _   
Place / Affiliation: _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _         _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _
Name: _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _         _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _
Signature: _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _         _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _
(I hereby confirm that information provided in this form is a correct, accurate and
complete representation of collected data.)
Page 3/3
Noroc 




REGISTRERING AV PATOLOGIPARAMETRE  - WebCRF  
 
Squamous cell carcinoma, differentiation, WHO 
Well differentiated Moderately differentiated Poorly differentiated 
Cells are large and slightly fusiform, 
nuclei shows a moderate degree of 
pleomorphism, few mitoses are 
seen. Lamelled keratin masses 
(keratin pearls) characteristic 
feature. 
Nuclear pleomorphism more 
distinct. Higher mitotic activity, 
including abnormal mitoses. 
Keratinization is less prominent. 
Dominated by immature cells, 
numerous typical and atypical 
mitoses, high nucleus/cytoplasmic 
ratio. Keratin pearl formation not 
seen, though individual cell 














Alle mål er i millimeter, kan også bruke desimal 
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Histologic variable Marked Moderate Slight/none 
Lymphocytic 
infiltrate at interface Continous band Large patches Little or none 
Noroc 
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